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INTRODUCTION 
Historically, new health interventions have been developed primarily to address the 
needs of the wealthy in the developed world. Where drugs, vaccines, diagnostic tests 
and other interventions happened to address diseases prevalent in the developing 
world, they would eventually trickle down, and in some cases be adopted and 
implemented through national health systems. Such new interventions were relatively 
rare, often separated by years or decades for a single disease area (e.g. malaria) or 
delivery strategy (e.g. routine immunization programs). 
Since 2000, the Global Fund to Fight Aids, TB and Malaria and GAVI Alliance have 
committed over US$20 billion to implementing existing interventions in developing 
countries. Partially as a result, countries have considered and will consider 
implementation of many new interventions. Multiple new malaria medicines and rapid 
diagnostic tests are now available and bednets have been improved over 
approximately the past decade. Challenges may be even greater for immunizations 
programs as countries consider four or more new vaccines for implementation, all 
becoming available to the poorest countries over approximately a five year period.  
It is likely that there will be even more interventions to address public health problems 
of the developing world in the future. An estimated $3.2 billion was spent on research 
and development for new interventions for the developing world in 2009 alone, up 
8.2% from 2008.  
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Given this environment, this thesis considers two questions: 
1) Have there been, and do there continue to be, delays accessing (i.e. implementing) 
new health interventions through national health systems in developing countries? 
When will they begin to prevent disease and save lives? 
2) If so, are the causes of delays predictable and what additional can be done to 
address the causes and accelerate access? 
METHODS 
Chapter two addresses the first question and proposes a new strategy to address the 
major aspects of the second question. It uses literature review, statistical analysis and 
descriptive analyses of temporal patterns.  
Frost and Reich (2008) propose an “access framework” which appears to capture the 
major themes identified in the literature and analysis. The framework suggests that 
access is the product of activities to address the availability, affordability, and adoption 
of new interventions, as well as the architecture (i.e. coordination) facilitating these 
activities. The chapter also uses descriptive and statistical methods to analyze the time 
from regulatory approval to the beginning of implementation of four vaccines and 
three malaria interventions. It further analyzes implementation by considering the 
impact of specific milestones reflecting coordination, availability, affordability, and 
adoption. It concludes by applying the results of the literature, descriptive analysis, 
and statistical analysis to propose modifications to Frost and Reich’s framework.  
Six chapters of the thesis go on to consider aspects of the transition of health 
interventions from research and development to implementation, in light of the 
modified framework. Many of the chapters draw upon the experience of, or research 
related to, RTS,S/AS01 (RTS,S). It is the most advance malaria vaccine, anticipated to 
complete its phase III trial by 2015. The vaccine is being developed by GlaxoSmithKline 
and the PATH Malaria Vaccine Initiative, in partnership with the Swiss Tropical and 
Public Health Institute and many other organizations. The final chapter synthesizes the 
findings of the previous chapters, suggests considerations for those who wish to 
operationalize the framework, and proposes future research questions. 
RESULTS 
The analyses suggest that there have been delays implementing new health 
interventions. Generally, a decade after each studied vaccine or malaria intervention 
was approved by regulators, less than 30% of developing countries, and in most cases 
less than 15%, had begun to implement it. The pace of implementing new health 
interventions in developing countries has not changed significantly since the 1980’s. 
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In order to accelerate implementation, activities must begin earlier, during research 
and development, which build the foundation for later access activities. The modified 
access framework (Figure 1) proposes architecture (i.e. coordination), availability, 
affordability, and adoption activities which should be considered for each intervention 
prior to regulatory approval. Individual chapters report on research into or analyses of 
concrete strategies and examples of activities to be undertaken during research and 
development:  
 Chapter 3. Aligning new interventions with developing country health systems: 
Target product profiles, presentation, and clinical trial design; 
 Chapter 4. Roles of international organizations and implementation of the new 
health interventions in developing counties: The RTS,S/AS01 malaria vaccine; 
 Chapter 5. Adoption of new health products in low and middle income settings: 
How product development partnerships can support country decision making; 
 Chapter 6. Country planning for health interventions under development: 
Lesson from the malaria vaccine decision-making framework and implications 
for other new interventions; 
 Chapter 7. Modeling the public health impact of malaria vaccines for 
developers and policy-makers; and 
 Chapter 8. Simulated impact of RTS,S/AS01 vaccination programs in the context 
of changing malaria transmission. 
LIMITATIONS & DISCUSSION THEMES FROM ACROSS THE CHAPTERS 
LIMITATION THEMES 
A number of limitations arose in multiple chapters. The perspective of the analysis was 
primarily that of not-for profit organizations and governments. There is no ideal means 
of measuring access, so the analysis used the beginning of implementation through 
national health systems as the proxy. However, the analysis does not consider how 
long it took from beginning implementation to reach nation-wide use, nor the equity 
of coverage within countries. Given this, it is likely that the analysis of timelines tend 
to understate the delays. There are reasons to assume that the experience for malaria 
and immunization interventions has been faster than that seen for other 
interventions, again suggesting that delays may have been longer than found. Finally, 
while many of the chapters describe evaluation approaches, it is too early to 
determine if the access strategies have accelerated the transition of malaria vaccines, 
or the other health interventions considered.  
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FIGURE 1. PROPOSED ACCESS FRAMEWORK INCORPORATING R&D AND 
IMPLEMENTATION PERIODS. 
Legend:  The area in grey reflects Frost and Reich’s (2008) original access framework. Other areas are 
new to the framework. Actions that take place during the R&D period are described in the space above 
the black strip, “Regulatory Approval, while actions carried out in the decision and implementation 
period are described in the space below. Area in grey is reproduced under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License. 
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DISCUSSION THEMES 
Accelerating access requires bridging between many complex activities, commitments 
of many years and deep collaboration between access and research and development 
specialists. Access activities must be carefully paced with scientific progress. An 
intervention can fail at any time, for example if a safety concern arises or efficacy is 
not shown in a pivotal clinical trial. Collaborators need to be careful not to 
overpromise.  
Since interventions may always fail, the proposed strategy requires investments of 
time and resources be made at risk. This is particularly important to consider when 
weighing requests to staff in developing countries that have responsibilities for 
implementing proven, existing health interventions.  
It may be clear which organization is best placed to fill the coordination role. However 
there is no reason to assume it should be a specific type of not-for profit organization. 
Universities, institutes, product-development partnerships, the World Health 
Organization (WHO) and others from the Northern and Southern hemispheres could 
be best positioned. Regardless of who fills the role, particular consideration should be 
given to WHO and its important role in the strategies in many of the chapters.  
OPERATIONALIZING THE FRAMEWORK 
Those seeking to operationalize the framework may want to give particular 
consideration to the follow issues: 
 Agree who fills the coordinating role; 
 Recruit the appropriate skill sets to complement research and development 
specialists; 
 Tailor the strategy to the intervention and wider disease context;  
 Consider developing activities by working backwards from the vision of desired 
impact and anticipated access strategies;  
 Set expectations for a long-term view and process, breaking major challenges 
into more manageable, concrete steps; 
 Agree explicitly on a mandate to undertake such activities with funders; and 
 Determine the appropriate level and type of collaboration with WHO. 
FUTURE RESEARCH 
The thesis proposes a number of potential future research activities. Similar analyses 
could be undertaken from other perspectives, such as regulators, pharmaceutical 
companies, private health providers, or others. Further historical analyses could be 
undertaken of a wider sample of existing interventions.  
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The proposed strategy and activities in this thesis could be evaluated in the future. 
One could compare against other approaches taken for interventions currently in 
research and development. Activities reported in this thesis undertaken for malaria 
vaccines could be more fully evaluated after approximately 2016. In addition to asking 
if the correct activities were undertaken, important questions may be which activities 
occurred too early and which occurred too late relative to research and development 
progress.  
 
PLANNING FOR NEW HEALTH INTERVENTIONS   
Introduction 8 
CHAPTER 1. INTRODUCTION 
BACKGROUND 
The past decade has seen a striking increase in new interventions promising to 
decrease public health problems in developing countries. Just taking the fields of 
vaccination and malaria, the list includes: pneumococcal conjugate (PCV), rotavirus 
(RV), Japanese encephalitis (JE), meningococcal A conjugate (MenA), and human 
papillomavirus (HPV) vaccines; long-lasting insecticide-treated bednets (LLINs); rapid 
diagnostics tests (RDTs) for malaria; and artemisinin-based combination therapies 
(ACTs) for treating malaria. This growth in new interventions is partially a result of 
increased funding for research and development (R&D) into interventions needed in 
the developing world. An estimated $3.2 billion was spent on R&D in 2009, up 8.2% 
from the previous year, suggesting the number of new interventions will only increase 
in the future [1]. 
Prior to the upswing described above, the world saw relatively few new interventions 
available to the developing world. Measles vaccine was added to the expanded 
programme on immunization (EPI) in the 1980s, hepatitis B in the 1990s and 
Haemophilus influenza type B (Hib) around 2000. Today, seven vaccines are receiving 
additional focus from policy and funding bodies; the five newer vaccines noted above 
(PCV, RV, JE, MenA, and HPV) and two older vaccines (rubella and typhoid). But it 
remains unclear if the availability of more vaccines and the additional focus will lead to 
these vaccines being adopted and impacting public health any more rapidly than 
hepatitis B or Hib.  
The situation is similar for malaria. While bednets have been around for decades, the 
inclusion of insecticide, impregnating with long-lasting insecticide, and distribution for 
large-scale public health uses are more recent innovations. There are now multiple 
rapid diagnostics tests available for malaria. In terms of drugs, chloroquine was the 
treatment of choice for decades, followed by sulfadoxine and pyrimethamine 
(Fansidar) in the 1980s and 1990’s. Over the past 10 years ACTs have become the 
treatment of choice in many parts of the world. Multiple types of ACTs are now on the 
market and more are anticipated.  
A product is a manufactured, public health tool overseen by some form of regulatory-
like body. An intervention is a means of addressing a public health problem. Generally 
it may or may not involve a product (e.g. behavior change interventions do not 
necessarily), however for this thesis, an intervention means a product plus the 
strategies for its use.  
The growing investments in R&D noted above reflect initiatives by international health 
and funding bodies to address the divergence in health between developed and 
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developing countries. Commercial realities have dictated that traditionally, new health 
interventions were developed to address the needs of developed countries where 
private investments were most likely to be recouped. In some cases, such as with 
hepatitis B vaccine, recognition grew that some interventions could have comparable 
or greater public health impact if they could be implemented in developing countries. 
This led to interventions “trickling down” to developing countries over decades.  
The past 10-15 years has seen as a shift away from interventions only trickling down to 
developing countries. The Millennium Development Goals, as well as new initiatives 
like the Bill and Melinda Gates Foundation (Gates Foundation), Global Fund to Fight 
Aids, Tuberculosis, and Malaria (GFATM), and the GAVI Alliance (GAVI), partially grew 
out of recognition of the divergence in health, and access to health interventions. 
Universities, national institutes of health, research institutions, product development 
partnerships (PDPs) between for-profit and not-for-profit partners, the World Health 
Organization (WHO), and others, are creating interventions intended for use in the 
developed world from early R&D. The Gates Foundation and others provide critical 
“push” funding, investing to stimulate and accelerate R&D of new health 
interventions. While the GFATM and GAVI are examples of “pull” funding, providing a 
more predictable and lucrative market for successful producers on behalf of 
developing countries.   
Much of the investments to date have gone to infectious diseases. In terms of 
disability-adjusted life years (DALYs), Africa bears two to three times the disease 
burden of other parts of the world, particularly because of the relatively large number 
of infants and children dying from pneumonia, diarrhea and malaria, and the influence 
of those deaths on DALY calculations (Figure 2). However, there is an as yet 
unanswered question of funds needed for similar investments targeting non-
communicable, or chronic, diseases. Non-communicable diseases account for 
approximately 60% of world-wide deaths annually (Table 1).  
Health care systems in the developing world which deliver interventions are 
characterized by a number of attributes. For example, populations are afflicted with 
large and diverse disease burdens. Yet diagnostic capabilities are limited, leading to 
challenges deciding on priorities and perceptions of a zero-sum game between 
diseases or interventions. There is limited infrastructure, often for power as well as 
delivery of supplies. Health facilities are often staffed by minimally trained workers 
with infrequent or irregular oversight. And budgets are very limited relative to the 
mandates given to the health systems.  
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FIGURE 2. DALYS LOST BY WHO REGION (2004). 
 
Legend 
Reproduced from WHO; Available at:  
http://www.who.int/gho/mortality_burden_disease/regions/dalys/en/index.html; Accessed: 1 Aug, 
2011. DALY calculations assume 3% discounting and age weighting.  YLL means “Years of life lost.” YLD 
means “Years lost due to disability”.  
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TABLE 1. ESTIMATED CAUSES OF DEATH WORLDWIDE (1000S), 2004.  
  
World Population (000) 6 436 826   
TOTAL Deaths  58 772 100.0% 
I. Communicable diseases, maternal and perinatal conditions and 
nutritional deficiencies 
 17 971 30.6 
Infectious and parasitic diseases 9 519 16.2 
Tuberculosis 1 464 2.5 
HIV/AIDS 2 040 3.5 
Diarrheal diseases 2 163 3.7 
Hepatitis B 105 0.2 
Malaria 889 1.5 
Other infectious & parasitic diseases 2 858 4.9 
Respiratory infections 4 259 7.2 
Maternal conditions 527 0.9 
Perinatal conditions 3 180 5.4 
Nutritional deficiencies 487 0.8 
II. Non-communicable conditions 35 017 59.6 
Malignant neoplasms 7 424 12.6 
Other neoplasms 163 0.3 
Diabetes mellitus 1 141 1.9 
Nutritional/endocrine disorders 303 0.5 
Neuropsychiatric disorders 1 263 2.1 
Sense organ disorders 4 0.0 
Cardiovascular diseases 17 073 29.0 
Ischaemic heart disease 7 198 12.2 
Cerebrovascular disease 5 712 9.7 
Other cardiovascular diseases 4 162 7.1 
Respiratory diseases 4 036 6.9 
Digestive diseases 2 045 3.5 
Diseases of the genitourinary system 928 1.6 
Skin diseases 68 0.1 
Musculoskeletal diseases 127 0.2 
Congenital abnormalities 440 0.7 
Oral diseases 3 0.0 
III. Injuries  5 784 9.8 
Unintentional injuries 3 906 6.6 
Intentional injuries 1 642 2.8 
Source: Modified from WHO; http://apps.who.int/ghodata/?vid=100001; Accessed 1 August, 2011. 
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TRANSITIONING INTERVENTIONS FROM R&D TO IMPLEMENTATION 
This thesis is based upon a hypothesis that there have been re-occurring delays in 
implementing interventions, but that causes of delays can be foreseen and addressed 
by working in advance. The progression of an intervention can be broken down 
broadly into processes of:  Development – Decision – Implementation (Figure 3). These 
may be more complex and time-consuming (e.g. the level of regulatory scrutiny) for a 
novel, or “first in class” intervention like a malaria vaccine, as compared to a generic or 
follow-on intervention such as a new type of antimalarial treatment.  
FIGURE 3. NEW INTERVENTIONS: FROM R&D TO IMPLEMENTATION (ILLUSTRATIVE). 
 
Legend 
*Drugs, Vaccines Diagnostics, Reproductive health supplies. **WHOPES: WHO Pesticide Evaluation 
Scheme. 
 
An unfortunate shared lesson from the immunization and malaria fields, and public 
health more generally over the past decade plus, is that moving health interventions 
from development to implementation and ultimately making them accessible to those 
most in need, is a slow, challenging process. It is a process which is unlikely to get 
quicker or easier as the number of new interventions increases, without research into 
appropriate, concerted changes.  
This thesis focuses on what can be done to make a change from past experience. It 
focuses on what can be done during the development to decision process, in order to 
accelerate the decision to implementation process which ultimately leads to those 
needing a preventive, therapeutic or diagnostic interventions having access to it.  
Development 
• Pre-clinical 
• Safety & 
efficacy/ 
Phases 1-3 
• Regulatory 
approval 
Decision-Making at 
International & National Levels 
• WHO evaluation for UN 
purchase and public health use 
• Pre-Qualification* 
• WHOPES**: Insecticides 
• Policy/National adoption 
• Financing 
•  
Implementation & 
Scaling Up 
• Procurement 
• Health system 
strengthening 
• Staff training 
• Product distribution 
• Demand generation 
• Delivery 
Phase 4 trials/Community & system effectiveness studies 
Manufacturing 
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Most of the papers in this thesis use a lens of malaria and vaccines, or malaria vaccines 
specifically (For the status of malaria vaccines under development see: WHO; Table of 
Malaria Vaccine Projects Globally; Available at: 
http://www.who.int/vaccine_research/links/Rainbow/en/index.html; Accessed 
September 12, 2011). Malaria has been a focus of new intervention investment given 
its significant contribution to mortality in African children, and that preventive, 
therapeutic and diagnostic interventions are all thought to be part of a long-term 
solution. There has also been extensive focus on developing new vaccines as a critical 
preventive strategy globally, particularly for diarrhea and pneumonia for children, as 
well as malaria.  
This thesis considers implications of its findings for other vaccines and malaria 
interventions, as well as health interventions more broadly, and proposes a series of 
concrete strategies that organizations involved in developing and supporting use of 
new interventions can take to accelerate their transition from development to use. It 
considers issues from the perspective of a not-for-profit organization (e.g. 
government, multi-lateral, and/or non-governmental organization) interested in new 
health interventions. 
ACCESS FRAMEWORK 
In 2008 Frost and Reich [2] released a book entitled “Access: How do good health 
technologies get to poor people in poor countries?” This book was a valuable 
landmark for those working on new interventions. It consists of six case studies of past 
interventions from various public health fields, and a synthesis of the implications. It 
proposes an “Access Framework” (see chapter 2) focusing on architecture (i.e. 
coordination), availability, affordability and adoption as the essential elements of 
planning for access to new interventions.  
Frost and Reich’s work, built upon a diverse evidence base of interventions, provides 
the foundation for the conceptual framework used in this thesis. However, this thesis 
extends and seeks to share new insights beyond what the book entails. Among the 
major distinctions:  
 The access framework in the book, similar to the existing literature, focuses 
primarily on what happens after an intervention is available. The intervention 
development period is included systematically in the six case studies, however 
largely as a descriptive chronology. In contrast, this thesis focuses primarily on 
actions during the development and decision processes which can accelerate 
decisions on use and implementation.  
 The book presents the concepts of availability, affordability, and adoption as 
parallel, vertical streams without emphasis on the lateral interplay between 
PLANNING FOR NEW HEALTH INTERVENTIONS   
Introduction 14 
these elements. This thesis highlights important ways each of these three 
concepts are intertwined with the other two.  
 This thesis argues that activities need coordination during the intervention 
development process and during the decision into implementation process. 
 The book covers a relatively wide set of points during the intervention life-
cycle, leading it to be, by necessity, more general, while the thesis centering on 
the development and decision processes can be more concrete and specific in 
proposed strategies. 
OBJECTIVES  
 Propose key elements of strategies during the intervention development 
period to shorten the time to accessibility for health interventions anticipated 
for use in the developing world 
 Detail a practical strategy to shorten the time from availability of a malaria 
vaccine to use in public health programs in Africa 
SPECIFIC OBJECTIVES 
 Analyze the time from development to accessibility for recent public health 
interventions intended for the developing world, and identify major reasons for 
delays. 
 Identify strategies for ensuring that public health interventions, and 
particularly malaria vaccines, are tailored to meet the needs of developing 
world health systems. 
 Improve the means for international organizations to establish and provide 
guidance to developing countries on use of new health interventions. 
 Review the support PDPs are providing to national decision-making processes. 
 Analyze the data and processes required by countries to take a decision on use 
of a malaria vaccine, and determine when the data is needed and the 
processes should take place relative to vaccine availability. 
 Estimate the impact of a pre-erythrocytic malaria vaccine in the context of 
changing transmission, and ways that such data can be tailored to meet the 
needs of key policy-makers.  
 Detail a model interface allowing estimates of malaria vaccine impact to be 
tailored for vaccine developers and policy makers. 
 Synthesize the key strategies needed to shorten the time from development to 
accessibility for new interventions. 
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CHAPTER 2. DEVELOPMENT OF AND ACCESS TO HEALTH INTERVENTIONS BY 
DEVELOPING COUNTRIES: EVIDENCE OF DELAYS AND STRATEGY FOR 
ACCELERATION 
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ABSTRACT 
BACKGROUND 
Billions of dollars are invested each year in research and development (R&D) of new 
health interventions intended for the developing world. However, it is unclear how 
quickly resulting interventions will be accessible. Activities that could be undertaken 
during the R&D process to accelerate access to interventions by developing countries 
following regulatory approval have not been extensively researched. Existing 
frameworks suggest that access depends chiefly on coordinated action, availability, 
affordability, and adoption-supporting activities. We undertook the first 
comprehensive analysis of these activities in the R&D period in order to identify 
strategies that may accelerate access. 
METHODS AND FINDINGS 
WHO databases, supplemented by data from John’s Hopkins University, were used to 
determine the number of years from first regulatory approval to implementation for a 
number of tracer interventions:  hepatitis B (HepB), Haemophilus influenzae type b 
(Hib), rotavirus (RV), and pneumococcal conjugate (PC) vaccines, as well as three 
malaria interventions: insecticide treated nets (ITNs); rapid diagnostic tests (RDTs); 
and artemisinin-based combination therapies (ACTs). The data were stratified by year 
of regulatory approval and country income. One to two milestones representing 
access activities consistent with coordinated action, availability, affordability, and 
adoption-supporting activities were identified for each intervention. Descriptive 
analyses of temporal associations, available literature, and statistical analyses 
supported the importance of these activities for access. Five years after regulatory 
approval, no low-income countries (LICs) had implemented any of the vaccines, 
increasing to an average of each vaccine being used by only 4% of LICs after 10 years. 
Each malaria intervention was used by an average of 7% of LICs after five years and 
37% after 10 years. Hib, RV, PC, and ITNs, all had similar adoption rates to HepB, while 
this rate was slower than for ACTs and faster than for RDTs. Activities addressing 
coordinated action, affordability, and supporting adoption seemed to be most 
associated with implementation, although only adoption-supporting activities had a 
significant effect in all statistical analyses. A new access framework is proposed, 
building upon existing concepts and the present analysis of delays.  
CONCLUSIONS 
Our analysis suggests that unless intervention development is done differently, the 
billions spent on R&D of new health interventions will culminate in a delay of more 
than 10 years before most developing countries begin large scale access. Carefully 
paced activities integrated within the R&D process, and tailored to the intervention 
and its public health context, should contribute to new interventions realizing their 
goal of saving lives as rapidly as possible.    
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INTRODUCTION 
The GAVI Alliance (GAVI) and the Global Fund to Fight AIDS, TB and Malaria (GFATM) 
were established in 2000 and 2002, respectively. Since then, they have committed 
more than USD 20 billion to address the divergence in health status and access to 
health interventions between developed and developing countries (DCs). In parallel, 
the past decade has seen unprecedented investments in research and development 
(R&D) for new health interventions for use in developing countries. Approximately 
USD 3.2 billion was invested in 2009 alone, an increase of 8.2% from 2008 [1]. Product 
R&D partnerships (PDPs) have grown in number, developing drugs, rapid diagnostic 
tests, vaccines and other interventions for developing countries [3]. Interventions 
arising from these R&D investments could then be implemented with support from 
GAVI, GFATM and other financing mechanisms. 
Although many potential interventions will fail during R&D or regulatory review, it is 
reasonable to assume that many will be approved by regulators and become available 
for use. It is unclear, however, how quickly these new health interventions will be 
made accessible to those in need in developing countries, and hence deliver on 
promises to save lives and improve health. Here, access is the result of a set of 
coordinated activities needed to ensure that interventions will ultimately have an 
equitable public health impact [4]. Unfortunately, there is no optimal, widely available 
indicator of access when using this definition. Implementation of interventions, after 
policies adopting them into national health systems, is a reasonable proxy and widely 
discussed in the literature. 
Determining if there have been access delays begins by understanding the factors that 
facilitate policy decisions on use, and subsequent implementation of interventions in 
DCs. It also requires a process to ensure that interventions are suitable for low 
resource health systems and users. This paper evaluates access to new health 
interventions in DCs. The analysis compares, for a number of tracer interventions, 
activities during the R&D period, prior to approval by a stringent regulatory authority, 
with the decision and implementation period that followed. The specific issues of 
access to new interventions for specific segments of populations in developed 
countries, for example the poorest or most remote populations, are beyond the scope 
of this paper. 
Literature focusing on the R&D period tends to emphasize clinical trials and regulatory 
processes [5–9]. There is a relatively small body of literature that identifies factors 
facilitating policy decisions and implementation that should be considered during the 
R&D period of health interventions (Table 2). However, none of these papers offer 
comprehensive strategies intended to facilitate overall  access. PDPs also identify 
activities undertaken during the R&D period to support implementation and access, 
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broadly consistent with the considerations noted in the literature, but without 
prioritizing them or suggesting which are most critical for which interventions [4].   
TABLE 2. CONSIDERATIONS AFFECTING ACCESS TO NEW INTERVENTIONS – A 
LITERATURE REVIEW. 
 Relevance to 
access 
Considerations 
Prior to 
regulatory 
approval 
Availability & 
Affordability 
Design of interventions specifically for the needs of 
DCs  [10–16] 
 Adoption Clinical studies to address questions unique to DCs 
[6,17–21] 
  Requirements for international policy 
recommendations [22,23] 
  Preparing for country decision-making processes 
[24] 
After 
regulatory 
approval 
Coordinated 
action  
Coordination between stakeholders [25] 
 Availability Alignment of intervention with the unique needs of 
developing country health systems [25–29] 
  Forecasting and manufacturing plans incorporating 
DCs, [25,30] 
  Adapted procurement mechanisms [25,30] 
 Affordability Affordability, financing, & cost-effectiveness [25–33] 
 Adoption Research aligned with policy-maker needs, including 
burden of disease addressed by an intervention 
[26,28–31,33] 
  Importance of international technical consensus and 
recommendations, including influence of 
neighboring countries [28,30,34] 
  Strengthened national processes, acceptability, 
and/or governance [27,30,35–37] 
Legend: Pubmed and Web of Science® databases were searched for full names or abbreviations of 
hepatitis B, Haemophilus influenzae type B, pneumococcal conjugate, rotavirus, insecticide-treated net, 
rapid diagnostic test, or artemisinin-based combination therapies AND (malaria or vaccin*) AND 
(develop* OR decision* OR policy* OR adopt* OR implement*)  
 
Understandably, papers tend to consider access factors and challenges arising after 
regulatory approval of new vaccines and malaria interventions rather than before 
(Table 2). Qualitative  [25–30,33,35,37–39] and quantitative approaches [31,32,36] are 
used to look at single or closely-related interventions (e.g. vaccines against enteric 
pathogens). For ITNs and intermittent preventive treatment for malaria in infants 
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(IPTi), comprehensive strategies for operational and implementation research were 
considered [40,41].  
The current literature largely takes for granted that interventions have a fixed set of 
characteristics, such as the target population, size of dose, packaging, and storage 
requirements, and attempts to determine how to take advantage of those 
characteristics in developing countries. It does not typically consider how and why 
those characteristics originated, nor if there are lessons to inform the R&D process and 
design of future interventions.  
Obrist et al. (2007) propose a comprehensive access framework focusing on consumer 
decisions, livelihood, and the assets of poor populations with regard to health 
interventions [42]. They review five concepts that determine access to health 
interventions: availability, accessibility, affordability, adequacy, and acceptability.  
Mahoney et al. (2007)  [38] and Frost & Reich (2008) [2] propose access frameworks 
that acknowledge the role of decisions made during the R&D period on eventual 
implementation. Mahoney et al. (2007) identifies four criteria for access to new 
vaccines: availability; affordability; acceptability; and adoptability, but provides little 
insight into how actions in the R&D period are translated into policy decisions and 
implementation later. PDPs generally agree on a similar set of access criteria, and see 
them as relevant to any intervention during the R&D phase [2,4]. 
Frost & Reich (2008) analyze the history of access to six health interventions in the 
developing world: praziquantel; hepatitis B vaccine; malaria rapid diagnostic tests; 
Norplant; vaccine vial monitors; female condoms [2]. They propose that access 
depends on activities related to four key factors: architecture, availability, 
affordability, and adoption. Architecture encompasses the organizational structures 
and relationships that coordinate activities addressing availability, affordability and 
adoption (Figure 4). They also provide a historical overview of the R&D phase of each 
intervention. However, while they note that intervention developer choices are 
important for later policy decisions on use and implementation, their analyses and 
framework focus on access through the lens of implementation, without 
systematically considering the impact of decisions made during the R&D period.  
Each concept Mahoney et al. (2007) and Obrist et al. (2007) use in their access 
frameworks is consistent with the ones identified by Frost & Reich. For example, 
Obrist’s et al. concept of acceptability is consistent with Frost and Reich’s “end-user 
adoption and appropriate use.” The one exception, which is not relevant to national 
implementation of an intervention and therefore this analysis, is Obrist et al.’s 
adequacy concept, matching health service organization with individual client 
expectations.  
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FIGURE 4. FROST AND REICH’S (2008) ACCESS FRAMEWORK.  
 
Legend   
The figure presents access as depending on a coordinating architecture that ensures that availability, 
affordability and adoption considerations are addressed for an intervention.  
Architecture: Organizational structures and relationship established with the purpose of coordinating 
and steering the availability, affordability, and adoption activities. 
Availability: Logistics of making, ordering, shipping, storing, distributing, and delivering a new health 
technology to ensure it reaches the hands (or mouths) of the end-user. 
Affordability: Ensuring that health technologies and related services are not too costly for the people 
who need them. 
Adoption: Gaining acceptance and creating demand for a new health technology from global 
organizations, government actors, providers and dispensers, and individual patients.  
 
The concept of “acceptability” is inherent in “End-User Adoption and Appropriate Use” but was made 
explicit in the graphic above to illustrate this framework’s consistency with the work of other authors. 
Reproduced under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License [2]. 
 
The literature cited above suggests that once regulators approve an intervention, 
access is contingent on efforts to address availability, affordability, adoption, and the 
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relevant coordinating architecture. However, each of these elements is strongly 
influenced by, or directly follows from, decisions made during the R&D period. 
Therefore, by anticipating access activities during the R&D stages, delays between 
regulatory approval and implementation should be decreased.  
This paper systematically explores access activities during the R&D period and it aims 
to investigate analytically the delays between the R&D phase and the implementation 
of new interventions in DCs. To do so we extended the Frost and Reich (2008) 
framework in order to propose a new approach to developing health interventions. 
The analysis focuses on the role of not-for profit, multilateral organizations (e.g. World 
Health Organization (WHO)) and governments, while discussing the role of for-profit 
and other collaborators.  
METHODS 
EVIDENCE OF DELAYS 
MILESTONES 
Selected interventions were assessed to determine the number of years between 
initial approval by a stringent regulatory body and the beginning of each country’s 
implementation through its national health system. Similar but more limited analyses 
have been applied to interventions previously [25,43,44].  
The year of approval by a stringent regulatory authority was intended to reflect the 
earliest indication of when it would be possible and ethical to consider 
implementation on a large scale outside of a controlled trial. This is especially critical 
for vaccines and drugs because of the issues of safety and quality. Some interventions, 
such as ITNs, while generally not overseen by regulatory authorities have mechanisms 
in place for reviewing safety and more recently quality. In these cases, efficacy is often 
evaluated through the establishment of a scientific consensus between experts on the 
basis of existing trial experience. 
Milestones consistent with architecture, availability, affordability and adoption were 
drawn from the literature above. The year of establishment of an organization or a 
process focused on supporting development or use of the intervention was considered 
an indicator of coordinating architecture. Availability was reflected by the year a new 
version of the intervention, intentionally designed to meet the needs of DCs, was 
approved. A major global financing commitment by an international organization was 
considered an indicator of affordability. Recommendations to use the intervention 
reflected support for adoption from international organizations. The timing of initial 
and global recommendations by the World Health Organization (WHO) was 
documented for each intervention. The year of implementation was determined 
according to available country reports, as described below.   
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Countries were categorized as low- (LIC), lower-middle- (LMIC), upper-middle- (UMIC), 
and high-income (HIC) according to the World Bank stratification, corresponding 
respectively to 2009 gross national income per capita of $995 or less, $996 - $3,945, 
$3,946 - $12,195, and $12,196 or more (http://data.worldbank.org/about/country-
classifications/country-and-lending-groups, Accessed March 31, 2011). 
VACCINES 
Four vaccines were selected for inclusion in the study based on their public health 
importance, diversity in year of availability, similar ages of target populations and 
comparable delivery strategies. The diseases they target — hepatitis, pneumonia, 
meningitis, and diarrhea— are among the world’s leading causes of mortality and 
morbidity, especially in developing countries. Hepatitis B (HepB) and Haemophilus 
influenza type b (Hib) vaccines have been available for decades while pneumococcal 
conjugate (PC) and rotavirus (RV) vaccines are among the newest.  
The regulatory approval of the first RV vaccine was a unique case. Licensed in 1998, it 
was removed from the market in 1999 due to concerns about intussusception (a 
potentially life threatening telescoping of the intestine within itself). A new RV vaccine 
was licensed in 2004. This analysis considered 2004 to be the year of the RV vaccine’s 
first regulatory approval. To account for the period in 1998-99 when a RV vaccine was 
licensed and sold, one year was added to the time to policy recommendation.  
WHO collects reports from 193 countries each year in order to assess vaccine 
implementation 
(http://www.who.int/immunization_monitoring/data/data_subject/en/index.html, 
Accessed March 14, 2011) (Table 3). These data were used to generate tables showing 
the first year of vaccine use and the number of years until coverage matched that of 
the third dose of diphtheria-tetanus-whole cell pertussis vaccines (DTP3), which is 
given to the same infant population at the same times as the other vaccines in this 
analysis. WHO’s data cover the years 1989-2009 for HepB, 1991-2009 for Hib, and 
2008-09 for PC and RV. Data for other years and for missing dates in the WHO data 
were taken from the Vaccine Information Management System (VIMS), a database 
maintained at the International Vaccine Access Center, Johns Hopkins University 
(http://www.jhsph.edu/ivac/vims.html, Accessed March 23, 2011). VIMS provided 
information on the year of application to GAVI for financial support by eligible 
countries. It also provided product presentation and formulation of Hib in most 
countries, used in this study to consider if the speed of implementation changed when 
the presentation of the vaccine was better aligned with the needs of DCs.  
Each vaccine was improved to better align with the needs of DCs which is reflected in 
the availability milestone. HepB and Hib antigens were combined with the widely 
implemented DTP vaccines to create new “four-in-one” or “five-in-one” vaccines. New 
versions of PC vaccines included additional serotypes prevalent in the developing 
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world and smaller packaging. New RV vaccines required two doses instead of the 
traditional three and decreased the size of packaging. GAVI’s commitment to each 
vaccine was used to determine the year of financing commitment, reflected in the 
affordability milestone. 
TABLE 3. CHARACTERISTICS OF COUNTRIES INCLUDED IN THE ANALYSIS AND SUMMARY 
OF RESPONSES. 
 Included 
in sample 
High 
income 
Upper 
middle 
income 
Lower 
middle 
income 
Low 
income 
No 
income 
category 
Intervention 
implemented 
Not 
imple-
mented 
Did not 
respond 
Hepatitis B 
vaccine 
193 50 46 54 40 3 180 13 0 
Haemophilus 
influenzae 
type B 
vaccine 
193 50 46 54 40 3 163 30 0 
Rotavirus 
vaccine 
193 50 46 54 40 3 30 163 0 
Pneumococc
al vaccine 
190 50 46 54 40 0 61 132 0 
Insecticide-
treated 
mosquito net 
104 4 21 39 40 0 89 0 15 
Rapid 
diagnostic 
test 
104 4 21 39 40 0 40 6 58 
Artemisinin-
based 
combination 
therapy 
104 4 21 39 40 0 63 12 29 
MALARIA INTERVENTIONS  
Malaria is one of the major causes of mortality and morbidity in children, and 
preventive, therapeutic and diagnostic interventions are available. Insecticide-Treated 
Nets (ITNs) and more recently developed Long-Lasting Insecticidal Nets (LLINs) prevent 
malaria. In this paper, “ITN” is used for both ITNs and LLINs. Immuno-chromatographic 
rapid diagnostic tests (RDTs) allow diagnosis of malaria with minimal training and 
hence are crucial to optimize treatment strategies. Artemisinin-based combination 
therapies (ACTs) are the current standard for malaria treatment. 
In the absence of a formal regulatory structure, regulatory approval of ITNs was based 
on a WHO expert committee concluding they were safe for individuals, and therefore 
could be used outside clinical trials [45].  For RDTs, regulatory approval was considered 
to be the point at which the first RDT became available in the developed world where 
there are strong quality assurance systems.    
WHO provided data on country implementation in 104 malaria-endemic countries, 
taken from the 2010 survey of countries by the Global Malaria Program as part of the 
annual World Malaria Report [46] (Table 3). The survey asked about year of 
PLANNING FOR NEW HEALTH INTERVENTIONS   
Accelerating access to public health interventions  24 
implementation of WHO-recommended malaria policies. Responses to “ITNs 
distributed to all age groups” or “ITNs distributed free of charge” were deemed 
reflective of implementation. Responses to “RDTs used in communities,” and “ACT is 
free of charge for under 5 years olds in the public sector” or “ACT is free to all,” were 
considered to be reflective of RDT and ACT implementation, respectively. Non-
response to the specific questions about use of the interventions, while other 
questions in the survey were answered, was classified as not implementing the 
intervention. Fourteen percent of countries did not respond for the ITN questions, 
56% for RDTs, and 28% for ACTs. The earliest date was used in cases where different 
dates were given for each policy or if parts of countries (e.g. mainland Tanzania versus 
Zanzibar) reported different dates.  
Approvals of new versions of the interventions aligned with the needs of developing 
countries were considered indicators of the availability milestone. ITNs were replaced 
by LLINs, and an ACT specifically formulated and packaged for use in infants was 
developed after the initial tablet formulation. No major improvements in RDTs were 
identified over the course of their deployment.  For malaria control, the GFATM is by 
far the most important donor, and its implementation date used to determine the year 
of financing supporting affordability. 
STATISTICAL ANALYSIS  
The year of country implementation of each intervention was extracted from the 
relevant databases into Microsoft Excel, and back-validated against the original 
databases for accuracy. Cox proportional hazard models were used to compare the 
rates of adoption of interventions between countries, as functions of the intervention 
and income group of the country. The analysis for each country started with the year 
when the intervention became available. The data were treated as right-censored 
where the country had not introduced the intervention by 2011.  In this analysis the 
adoption rate corresponds to the hazard in a conventional survival analysis.  Plots of 
the cumulative baseline hazard over time were used to assess time trends in the 
underlying rate of adoption, allowing for the covariates of income level and milestones 
described previously (i.e. a coordinating organization, an improved intervention, 
funding commitments by GAVI or GFATM, and WHO initial and/or global 
recommendations).    
These analyses were carried out using the PHREG procedure in SAS (SAS Institute Inc., 
Cary, NC, USA, version 9.2 for Windows). 
ANALYTIC FRAMEWORK 
The literature findings described previously were used to extend Frost and Reich’s 
access framework [2] retrospectively, to start from the R&D period, prior to regulatory 
approval. By complementing the original framework with activities that occur in 
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parallel to, are critical to, and are informed-by access-related activities, a more 
complete framework was developed. 
RESULTS 
EVIDENCE OF DELAYS 
The implementation of all interventions is presented in Table 4 for LICs and LMICs 
after 5, 10 and 15 years. Generally, a decade after each studied vaccine or malaria 
intervention was approved by regulators, less than 30% of countries, and in most cases 
less than 15%, had begun to implement it.  
On average, an intervention was beginning to be implemented in 3% of low-income 
countries after five years and 20% after 10 years. However, the speed of 
implementation was greater for malaria interventions, each of which was 
implemented by an average of 37% of countries at 10 years compared with only 4% for 
vaccines. No LIC implemented any of the new vaccines in the first five years.  
On average, an intervention was beginning to be implemented in 6% of lower middle 
income countries after five years and 24% after 10 years. On average, malaria 
interventions were beginning to be implemented by 35% of countries after 10 years 
compared with 12% for vaccines. Figure 5 shows the cumulative implementation of 
interventions, by year and for all income groups. 
TABLE 4. PERCENTAGE OF LICS AND LMICS IMPLEMENTING INTERVENTIONS AFTER 5, 
10, AND 15 YEARS. 
 5 years 10 years 15 years 
 LIC LMIC LIC LMIC LIC LMIC 
Hepatitis B 0% 6% 3% 24% 10% 41% 
Haemophilus 
influenzae type B 
0% 0% 3% 0% 15% 26% 
Rotavirus 0% 15% -- -- -- -- 
Pneumococcal 0% 0% 5% 13% -- -- 
Insecticide-treated 
mosquito nets 
3% 5% 30% 33% 95% 72% 
Rapid diagnostic test 0% 3% 10% 15% -- -- 
Artemisinin-based 
combination therapy 
18% 15% 70% 56% -- -- 
Average Vaccines 0% 5% 4% 12% -- -- 
Average Malaria 7% 8% 37% 35% -- -- 
Average All 3% 6% 20% 24% -- -- 
Legend 
LIC = Low income countries; LMIC = Lower middle income countries 
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FIGURE 5. PROPORTION OF IMPLEMENTING COUNTRIES OVER TIME IN EACH INCOME 
CATEGORY, STRATIFIED BY INTERVENTION.  
Legend  
Figure 5 presents the proportion of countries implementing each intervention by year since regulatory 
approval.  
Panel A = High income countries; B = Upper middle income countries; C = Lower middle income 
countries; D = Low income countries.  
Color code: Hepatitis B vaccine = Blue; Haemophilus influenzae type b vaccine = Dark red; Rotavirus 
vaccine  = Green; Pneumococcal vaccine = Purple; Artemisinin-based combination therapy = Light red; 
Insecticide-treated mosquito net = Orange; Rapid diagnostic test = Black.    
Solid lines indicate the arbitrary thresholds of 50% or 90% of countries implementing each intervention. 
 
Table 5 shows the average time elapsed between regulatory approvals and beginning 
implementation for HepB, Hib, and ITNs, three interventions which nearly all countries 
have begun to implement.  The average was 12.2 years across all malaria-endemic 
countries to begin implementing ITNs, and 14.6 years for Hib and 16.7 years for HepB 
across all countries. Beginning implementation in LICs took an average of 12.2 years 
for ITNs, 18.8 years for Hib vaccine and 21.2 years for HepB vaccine as compared to 
15.0, 9.0 and 13.2 years in HICs. 
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TABLE 5. AVERAGE NUMBER OF YEARS (RANGE) TO IMPLEMENTATION FOR 
INTERVENTIONS APPROACHING UNIVERSAL ADOPTION, 2011. 
 High 
income 
Upper 
middle 
income 
Lower 
middle 
income 
Low 
income 
All countries 
Hepatitis B 13.3 
(1-25) 
16.9 
(6-24) 
16.0 
(1-26) 
21.2 
(8-27) 
16.7 
(1-27) 
Haemophilus 
influenzae type B 
9.0 
(3-17) 
14.3 
(8-23) 
17.5 
(11-22) 
18.8 
(10-22) 
14.6 
(3-23) 
Insecticide-treated 
mosquito net 
15.0 
(14-16) 
12.9 
(4-18) 
11.7 
(1-18) 
12.2 
(5-16) 
12.2 
(1-18) 
 
For HepB and Hib vaccines it was possible to estimate the average time it took for 
coverage to match DTP3 levels. After combination vaccines became available in 1997, 
which allowed the antigens to be administered in a single injection with DTP, countries 
tended to require approximately one year less to reach full implementation than they 
did prior to a combined vaccine.  
There were significant statistical differences in adoption rates between interventions 
relative to hepatitis B vaccine in high income countries (likelihood ratio statistic (LRS): 
30.6; 6 degrees of freedom (d.f.); P<0.001, adjusted for effects of income level and of 
the different milestones) (Table 6). The fastest intervention to be adopted was ACTs, 
with a rate 1.85 times that of HepB (95% CI 1.07-3.19) (Table 7). The slowest adoption 
was of RDTs with a rate of 0.80 (95% CI 0.55-1.14; P=0.2164). Hib, RV, and PC all had 
similar adoption rates to HepB, intermediate between ACTs and RDTs.   
There was also a highly significant difference between level of income of countries in 
the rate of adoption (LRS 27.2; 3 d.f.; P<0.0001), this difference being almost entirely 
accounted for by the difference between high income countries and the others. There 
was very little difference in adoption rates between the different categories of middle 
income countries, or between middle and low income countries (Table 6); each of 
these categories was associated with adoption rates only just over half that of high 
income countries. 
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TABLE 6. RELATIVE ADOPTION RATES BY INTERVENTION AND COUNTRY INCOME (FROM 
COX PROPORTIONAL HAZARD MODEL). 
  Adoption rate  95% confidence interval 
Haemophilus influenzae type B 
vaccine 
0.83 (0.62-1.11) 
Rotavirus vaccine 0.76 (0.38-1.54) 
Pneumococcal vaccine 0.95 (0.57-1.57) 
Insecticide-treated mosquito nets 0.97 (0.69-1.36) 
Rapid diagnostic test 0.56 (0.34-0.92) 
Artemisinin-based combination 
therapy 
1.85 (1.07-3.19) 
Low income 0.51 (0.40-0.64) 
Lower middle income 0.56 (0.44-0.70) 
Upper middle income 0.52 (0.41-0.67) 
Legend  
Adoption rates are calculated relative to the rate of adoption of HepB vaccine in high income countries 
in the absence of any of the facilitating milestones. All likelihood ratio statistics (interventions 
having 6 degrees of freedom and income groups having 3) testing these effects were highly 
significant, with P<0.001. 
ACCESS MILESTONES  
Table 7 summarizes milestones for each intervention. Figure 6 presents the cumulative 
implementation of each intervention by countries, stratified by income group. The 
figure also indicates when each milestone from Table 7 was reached relative to initial 
regulatory approval.  
Twenty-seven years after the HepB vaccine was first approved, nearly all countries had 
implemented it for routine infant use. A few HICs in Europe recommend it instead for 
adolescents or high-risk individuals. It has taken more than 20 years for 90% of LICs to 
use Hib. The lowest coverage of Hib (76% of countries) was in the LMICs, many of 
which are too wealthy to receive financing from GAVI. The average time from GAVI 
application to implementation was approximately 1.5 years for HepB and 1.2 years for 
Hib 
For rotavirus vaccines, 15-20% of HICs, UMICs, and LMICs countries had implemented 
it after five years, an equality across these income levels of countries that did not 
occur for other vaccines. This speed of implementation was only seen in HICs for the 
PC vaccine. 15% of LMICs were using RV vaccines after five years, while it took 11 
years for PC to reach that level. However, no LICs had implemented RV vaccines as of 
early 2011, a situation that was similar to that seen with HepB, Hib, and PC vaccines 
where LIC early adopters did not begin implementation until almost 10 years after the 
vaccines were available. For PC, there was a three to five year delay between use in 
UMICs relative to HICs, and a six-year delay so far for LMIC and LICs.   
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TABLE 7. ACCESS MILESTONES FOR EACH INTERVENTION. 
 
1) 
Regulatory 
approval 
2) 
Coordinating 
group 
(Architecture) 
3) 
Improved 
intervention 
(Availability) 
4) 
Financing 
commitment 
(Affordability) 
5) 
Initial WHO 
recommendation 
(Adoption) 
6) 
Global WHO 
recommendation 
(Adoption) 
HepB 1982 1986 1996 2000 n/a 1992 
Hib 1988 1998 1997 2000 1998 2006 
RV 2004 2003 2008 2007 2007 2009 
PC 2000 2003 2009 2007 n/a 2007 
ITN 1991 1998 2001 2002 1995 2007 
RDT 1995 2003 n/a 2002 2006 2010 
ACT 1999 1999 2009 2002 2002 2006 
Legend  
Data sources below relate to the column number for each intervention. All websites were accessed on 
April 14, 2011. 
Hepatitis B vaccine:  1)  [47]; 2) [48]; 3) Personal communication, Marie-Claude Dubois, April 11, 
2011 ; 4) GAVI:  
http://www.gavialliance.org/vision/programme_support/new_vaccines/hepatitis/index.php;5) 
n/a;  6) [49]. 
Haemophilus influenzae type b vaccine: 1) [22]; 2) [50];  3)  Personal communication, Marie-
Claude Dubois, April 11, 2011 ; 4)  GAVI: 
http://www.gavialliance.org/vision/programme_support/new_vaccines/index.php; 5-6) [22]. 
Rotavirus vaccine : 1) [22]; 2) GAVI: 
http://www.gavialliance.org/performance/commitments/rotavirus/index.php; 3) European 
Medicines Agency: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000639/hu
man_med_001043.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124; 4-
6) [22]. 
Pneumococcal vaccine: 1) [22]; 2) GAVI: 
http://www.gavialliance.org/vision/programme_support/new_vaccines/adips/index.php;  3) 
GlaxoSmithKline: 
http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10039.htm; 4) GAVI: 
http://www.gavialliance.org/vision/programme_support/new_vaccines/adips/index.php; 5) n/a; 
6) [22].     
Insecticide-treated net: 1) [45]; 2) Roll Back Malaria Partnership: 
http://www.rollbackmalaria.org/rbmmandate.html; 3) [51]; 4) GFATM: 
http://www.theglobalfund.org/en/whoweare/?lang=en; 5) [52]; 6)[53]. 
Rapid diagnostic test: 1) National Institute for Allergy & Infectious Diseases: 
www.niaid.nih.gov/labsandresources/techdev/Pages/paraSight.aspx; 2) [2,54], Page 103; 3)  n/a; 
4) GFATM: http://www.theglobalfund.org/en/whoweare/?lang=en; 5) [55]; 6) [54].   
Artemisinin-based combination therapy: 1) [56]; 2) Medicines for Malaria Venture (MMV): 
http://www.mmv.org/about-us/faqs; 3) MMV: http://www.mmv.org/achievements-
challenges/achievements/coartem-d?page=0; 4) GFATM: 
http://www.theglobalfund.org/en/whoweare/?lang=en; 5) [56]; 6) [57].  
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FIGURE 6. IMPLEMENTATION OF EACH INTERVENTION BY COUNTRIES, STRATIFIED BY 
INCOME GROUP, INCLUDING MILESTONES.  
 
Legend 
Panels A-G present the proportion of countries implementing each intervention by year since the year 
of regulatory approval. Panel A= Hepatitis B vaccine; B= Haemophilus influenzae type b vaccine; C= 
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Rotavirus vaccine; D= Pneumococcal vaccine; E= Insecticide-treated mosquito net; F= Rapid diagnostic 
test; and G= Artemisinin-based combination therapy.  
For vaccines, countries are stratified according to World Bank income groups: High = Blue dotted line; 
Upper middle = Red short dashed line; Lower middle = Green long dashed line; Lower = Purple line.  
Malaria-endemic countries are stratified by low income versus all other endemic countries. LICs = Purple 
line; Other endemic countries = Red dash and dot line.   
Year of regulatory approval (year 0) is provided in the bottom left hand corner of each panel. Ar 
indicates establishment of a group providing coordination (i.e. architecture). II indicates availability of 
an improved intervention better aligned with the needs of developing countries. Fi indicates year of a 
global financing commitment, such as through GAVI or GFATM. IR indicates year of initial WHO 
recommendation. GR indicates year of global WHO recommendation. 
A solid line indicates the arbitrary threshold of 50% of countries implementing each intervention. 
 
Malaria interventions were implemented more quickly in LICs relative to wealthier 
endemic countries. It took approximately 16 years to reach global implementation of 
ITNs in LICs. Initially, RDTs were implemented faster in wealthier countries, but LICs 
surpassed them after 12 years. ACTs were implemented at approximately the same 
pace in LICs and other countries during the first seven years, after which LICs 
accelerated implementation. These differences are consistent with the differences in 
disease burden in these countries, with higher levels in the poorest countries. 
Patterns of temporal associations between access milestones, and between 
milestones and implementation, can be drawn from Figure 6. A coordinating 
architecture was put in place years before global WHO recommendations were made 
in all situations, and prior to initial WHO recommendations in all cases except for that 
of ITNs. Implementation of HepB, Hib, PC, ITNs, and ACTS did not accelerate until after 
a WHO recommendation, except in HICs. Global WHO recommendations for use of the 
malaria interventions did not come until 40% or more of LICs were already 
implementing the interventions, while for HepB, RV and PC, global recommendations 
came prior to any significant implementation in LICs. There was a sharp increase in 
coverage of HepB and Hib vaccines after GAVI’s advent and associated financing 
commitments. For ITNs, HepB, Hib and RV, financing commitments came after an 
initial recommendation, but before a global recommendation. RDT financing came 
before any recommendation, and for RV, PC and ACTs, a recommendation and 
financing came in the same year. Improved vaccines became available when only 
about 20% of LIC and LMICs had implemented each vaccine. Improved malaria 
interventions arrived after 30-70% of countries had implemented each type of 
intervention.  
Figure 7 shows the number of years from regulatory approval to initial and/or global 
WHO recommendation, and financing commitment, for each intervention. Five 
interventions had initial recommendations, which took on average 6.4 years. The 
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additional time for those five interventions to receive a global recommendation was 
an average of 6.2 years. For all seven interventions, the average time from regulatory 
approval to global recommendation was 11.4 years, with a range of 7-18 years. On 
average it took 8.7 years, with a range of 3-18 years, from regulatory approval to a 
financing commitment.  
FIGURE 7. TIME FROM REGULATORY APPROVAL TO WHO RECOMMENDATION AND 
FINANCING, BY INTERVENTION. 
 
Legend 
Dark blue bars indicate the number of years to an initial recommendation, when relevant, while light 
blue bars indicate the number of years to a global recommendation. Green bars indicate the number of 
years to a financing commitment. 
 
An initial proportional hazard model analyzed the relative rates associated with each 
of the milestones separately, adjusted for levels of income groups of countries and 
interventions. Initial WHO recommendation (relative uptake rate 1.87; 95% confidence 
interval (CI) 1.30-2.70)), coordinating group (relative uptake rate 2.12; CI 1.41-3.19), 
and financing commitment (relative uptake rate 1.89; CI 1.38-2.59) were all positively 
associated in this analysis, while global recommendation (relative uptake rate 0.51; CI 
0.38-0.69) was negatively associated. An improved intervention seemed to have little 
effect on the rate of implementation (relative uptake rate 0.94; CI 0.68-1.30). Since the 
timing of these steps was unlikely to be independent, a further analysis was conducted 
in which the effects were fitted simultaneously to adjust for possible confounding 
(Table 8). In this analysis the estimated effect sizes were similar to those in the 
unadjusted analysis, while the only statistically significant milestones were the positive 
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effect of initial WHO recommendation, and the association of global WHO 
recommendation with a slowing down of uptake. 
TABLE 8. EFFECTS OF ACCESS MILESTONES ON ADOPTION RATES (FROM COX 
PROPORTIONAL HAZARD MODEL). 
  Relative 
adoption rate 
95% confidence 
interval 
Likelihood ratio 
statistic 
P-
value 
Coordinating group 
(Architecture) 
1.37 (0.86-2.20) 1.7 0.2 
Improved 
intervention 
(Availability) 
0.95 (0.65-1.36) 0.1 0.8 
Financing 
commitment 
(Affordability) 
1.38 (0.98-1.94) 3.4 0.06 
Initial WHO 
recommendation 
(Adoption) 
2.00 (1.34-2.97) 11.7 <0.001 
Global WHO 
recommendation 
(Adoption) 
0.53 (0.37-0.76) 12.0 <0.001 
Legend 
Adoption rates are calculated relative to the rate of adoption of HepB vaccine in high income countries.  
 
Plots of the rate of adoption (cumulative baseline hazard from the Cox model) for 
analysis   including only high income countries (Figure 8A), suggested a more or less 
linear increase with time. This corresponds to a constant underlying rate of adoption, 
once the effects of the different milestones are allowed for. In contrast, the 
cumulative baseline hazard for low income countries (Figure 8B) increased with the 
time for which the intervention had been available, indicating a tendency for 
interventions to be more likely to be adopted the longer they were available, even 
allowing for the effects of the milestones.  
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FIGURE 8. EFFECT OF TIME SINCE REGULATORY APPROVAL ON RATE OF ADOPTION. 
 
Legend 
The vertical axis shows the rate of adoption of interventions according to the number of years since 
regulatory approval. All interventions are included, except where too few countries were relevant to the 
analysis, as noted below. The grey area indicates the 95% confidence region around the result.  A. High 
income countries only. Analysis includes all interventions except those against malaria. B. Low income 
countries only. Analysis includes all interventions except rotavirus vaccination. 
 
ANALYTIC FRAMEWORK 
On the basis of our findings, we developed a modified access framework (Figure 9). 
The new framework includes a coordinating architecture in the R&D period and in the 
decision and implementation period. The coordination role during the R&D period 
should advance activities related to availability, affordability and adoption, so that 
each comes to maturity as close to the date of regulatory approval as possible.  
Activities to address availability prior to regulatory approval seek to ensure that 
interventions completing R&D are suitable for the programmatic needs of DC health 
systems and users of health services. Another important consideration will be that 
sufficient supplies are available. Activities aimed at improving affordability include 
ensuring that future prices will not prohibit use in DCs and to plan for future financing 
to subsidize implementation. Affordability activities also seek to minimize the 
implementation costs to health systems (e.g. requirements for additional 
refrigeration.) Adoption activities relate to planning by international organizations to 
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identify and ensure that information needed for normative guidance on use and policy 
recommendations are developed at pace with, or as part of, clinical development. If an 
intervention is going to be used in the developed world, research questions specific to 
DCs need to be addressed as well. Adoption also encompasses working with countries 
and communities to anticipate and generate the data and processes they will need to 
make decisions about implementation and whether or not to accept an intervention 
once available.  
A number of other actions that directly inform, and that may be directly informed by, 
access activities are reflected in the framework although they are beyond the scope of 
this analysis. Regulatory oversight of clinical trials extends throughout R&D and 
evolves into regulatory monitoring and pharmacovigilance in the implementation 
period. Pre-clinical and clinical studies lead into phase four effectiveness studies and 
operational research, which may extend and refine how an intervention is used. These 
in turn inform country decisions and may impact access. Epidemiological studies of 
disease burden and economic and modeling studies may also directly inform decisions 
on use of a specific intervention or they may relate much more generically to a disease 
area. For example, a study on the direct and indirect costs of malaria to a health 
system may inform use of a specific intervention but also informs societal resource 
planning more generally. Therefore, such studies are reflected under the coordinating 
architecture of the framework, in both the R&D and implementation periods, but not 
presented here as necessarily following directly from that coordination. 
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FIGURE 9. PROPOSED ACCESS FRAMEWORK INCORPORATING R&D AND 
IMPLEMENTATION PERIODS. 
 
Legend 
The area in grey represents the original access framework as shown in Figure 4. Other areas are new to 
the framework. Actions that take place during the R&D period are described in the space above the 
black strip, “Regulatory Approval, while actions carried out in the decision and implementation period 
are described in the space below. Area in grey is reproduced under a Creative Commons Attribution-
Noncommercial-Share Alike 3.0 License [2]. 
DISCUSSION 
This paper describes the systematic delays observed in the period between regulatory 
approval and implementation of seven interventions, four vaccines and three malaria 
interventions. The interventions target diseases responsible for a substantial 
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proportion of the overall global burden of disease, particularly for children. According 
to WHO, each of these interventions should be used globally in all countries, or all 
malaria-endemic countries for the malaria interventions.  
Despite varied experiences, there have been consistent delays of 10 or more years 
until implementation in developing countries. The delays suggest that focusing efforts 
on supporting adoption and scaling-up of interventions only after regulatory approval 
is likely insufficient on its own. Organizations need to begin working systematically on 
access-related issues earlier on, during the R&D stages. Carefully paced activities 
during R&D would lead to action supporting decision-making processes shortly after 
regulatory approval. Activities during R&D may decrease the time and resources 
needed for ongoing efforts supporting implementation and scaling-up of interventions 
where appropriate.  
CHALLENGES AND LIMITATIONS TO THE ANALYSIS 
The analysis focuses on not-for-profit organizations, including academia, governments, 
multi-lateral organizations like WHO, product-development partnerships, public-
private partnerships, foundations, and others. It is concerned with implementation of 
interventions through national health systems as a way of reaching enough people to 
achieve an equitable public health impact, consistent with the definition of access. 
Future analyses would benefit from looking at the issue of delays from other 
perspectives, such as private for-profit organizations (e.g. manufacturers), regulators, 
and private sector health providers; these perspectives are consistent with other 
possible causes of delays, such as supply shortages. However, delays caused by such 
groups can be at least partially attributed to failure in the not-for-profit sector to 
anticipate and address access challenges. Thus, not including their perspectives does 
not undermine the basic findings of this paper. For example, a supply shortage may be 
caused in part by insufficient planning during the R&D period between the not-for-
profit sector and manufacturers on issues of availability and/or affordability for the 
developing world.  
The analysis did not consider country characteristics apart from income group, given 
that each of the interventions has been recommended for use globally. The analysis is 
also likely to be conservative, understating the delays, given that it focused on 
beginning of implementation, not the point at which nation-wide coverage was 
achieved. Coverage is already analyzed by WHO and others elsewhere [46,58].  
Data used in the analysis are imperfect.  However, we found no evidence of a 
systematic reporting gap or bias from any group of countries. Imperfect data were 
partially offset by including every country in the world. The only relatively small 
income group was HIC malaria-endemic countries, of which there are only four (Table 
3). It is important to recognize that countries can choose not to implement any 
intervention, or use it in a different fashion, which may not be captured in databases. 
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Selecting milestones required the authors to make judgment calls. For example, ITNs 
were deemed safe for use in 1991, which was considered the point of regulatory 
approval for this analysis. However, the first recommendation for use of ITN’s based 
upon demonstrated efficacy was made by WHO in 1995 [52].  International 
organizations did not develop a shared commitment to initiate large scale 
implementation of ITNs until 1997 and later.  
There is no reason to assume that the pattern of delays in the adoption of vaccines 
and malaria interventions is unique. It is possible that the delays for other 
interventions are longer than those for immunization and malaria, which enjoy a 
relatively high profile within public health arenas.  
ACCELERATING ACCESS 
High income countries generally introduce new interventions within a reasonably 
short period after they become available, and experience with the more recent RV and 
PC vaccines suggest the delays are becoming shorter. Middle and low income 
countries require years or decades longer to implement, with an increased pace of 
implementation happening only 15 to 20 years after regulatory approval. Vaccines 
continue to be implemented in developing countries at approximately the same pace 
as HepB in the 1980s and 1990s. ACTs have been implemented relatively quickly which 
would be expected given the crisis situation seen over the past decade as resistance 
grew to antimalarial treatments. Even so, one may question if implementation of ACTs 
was fast enough. ITNs are about on pace with HepB vaccine, while RDTs are being 
implemented significantly slower. 
From the literature and empirically, WHO’s initial recommendation had the strongest, 
and only statistically significant, effect on adoption. This may not be surprising as 
countries and financing bodies often follow WHO’s guidance. This suggests that those 
developing new interventions should work systematically to anticipate the research 
questions WHO and international organizations, including financing bodies, will need 
addressed to make policy decisions. It is noteworthy that countries often did not 
choose to wait for more comprehensive, global WHO recommendations, particularly 
when deciding to implement malaria interventions, suggesting that activities 
strengthening country decision-making may also accelerate implementation. 
Coordinating groups and financing appear to have important effects. Statistically the 
impact of an improved intervention, better aligned with developing country needs had 
limited impact. This suggests that many countries do choose to begin implementing 
interventions even if they are less than optimally designed. The analysis of Hep B and 
Hib combination vaccines suggested that improved interventions may have led to 
faster scaling up. And the literature and anecdotal reports from the field about the 
challenges implementing interventions not well-suited to developing countries suggest 
poor alignment is a re-occurring cause of delays. The literature and data analyzed in 
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this paper argue for the need to work more comprehensively during R&D, tailoring 
activities to each intervention which anticipate and can accelerate access. 
ANALYTIC FRAMEWORK 
This paper proposes a new framework for interventions in the R&D period to 
accelerate the process from regulatory approval to decision and implementation. The 
framework builds on and extends existing research on architecture, availability, 
affordability, and adoption to identify enabling activities that could occur earlier in the 
R&D process. Multiple activities happen during the R&D phase of an intervention. The 
major regulatory, clinical trial and epidemiological activities included in this framework 
complement activities specifically addressing future access in the form of country 
decisions and implementation. If the coordinating architecture is well integrated with 
clinical trials and related activities, there is greater potential for synergy. The 
coordinator must ensure that access activities neither outpace nor lag behind the 
accumulation scientific evidence. 
Activities relating to the four access factors in the framework can guide those working 
to develop interventions to accelerate the transition period between R&D to 
implementation. The activities are not in themselves prescriptive, nor do they attempt 
to overly simplify the R&D and implementation continuum. Activities during the R&D 
phase must be tailored to each intervention, and account for each partnership 
contributing to that intervention, the type of disease burden, and other contextual 
factors. The R&D process for a new intervention is lengthy and complex and requires a 
long-term and systematic approach to associated access activities. Coordination in the 
R&D, decision, and implementation periods may be by the same or different 
organizations, but the role of the coordinating body evolves from one period to the 
next. 
The new framework also assumes that no single activity will lead to implementation. 
The HepB vaccine was the subject of a strong, global WHO recommendation more 
than a decade before implementation accelerated. The Hib vaccine had assured 
financing years before it took off.  ITNs had a well-established architecture in the Roll 
Back Malaria Partnership from the late 1990s but implementation accelerated only 
years later and after the development of an improved intervention in the form of the 
LLIN. Moreover, the global recommendation for ITNs came only after most LICs had 
already adopted ITNs as part of its public health policy.  
Available interventions need to be tailored to fragile developing country health 
systems and their users, and scientific questions resolved to facilitate eventual 
implementation. Target product profiles, and subsequent formulation, clinical trial 
design or other R&D steps, need to explicitly consider the needs of health systems. For 
example, additional investments during the R&D phase to increase the heat stability of 
a vaccine could lead to a greater likelihood of reaching remote populations, while 
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minimizing the amount of vaccine wasted, facilitating more equitable use and saving 
money over the long term. Forecasting is also a key part of availability, aligning supply 
and demand. This is particularly important for pharmaceuticals, as supply planning, 
including decisions on production capacity and building a manufacturing facility, is 
completed years before regulatory approval [59].   
Affordability-related decisions during R&D seek to minimize future purchase and 
implementation costs. Decisions should seek to minimize the indirect costs and time 
requirements eventually borne by countries and health care workers. An example of a 
heat-stable vaccine is presented above. In addition, the interaction with international 
financing bodies needs to be initiated years before funds are required. Organizations 
like GAVI and the GFATM need to anticipate future financing requirements and raise 
funds accordingly. 
Anticipating adoption decisions at the global and country levels during R&D can 
increase the transparency and efficiency of normative and policy-making processes. 
One key element is the identification, prior to phase 3 trials, of the type of data that 
will be needed by various policy-making and financing organizations so that suitable 
studies can be designed  [22].   
RISK OF STARTING TOO EARLY 
There are risks to planning for access during the R&D phase. Interventions can always 
fail due to safety, efficacy or other concerns. One risk is the possibility of over-
promising to countries. A second is that time is finite, and for some organizations and 
countries, time spent on activities anticipating future intervention is time lost for 
implementing existing interventions. A third is the financial loss that may occur if an 
intervention eventually fails. These risks need to be balanced with the evidence of 
delays presented in this paper. The optimal strategy is not to wait until an intervention 
is available before planning for access-related issues. It is important to carefully select 
and pace access-related activities with the R&D process and scientific progress. Access 
activities should not get ahead of clinical and regulatory progress, but they should also 
not lag years behind as has happened thus far. Effective coordination can prepare for 
the availability of phase 3 trial data and regulatory approval, so that promising 
interventions move efficiently from R&D towards impact. 
CONCLUSION 
The analysis in this paper confirms that 5-10 years after a proven public health 
intervention becomes available, only a small fraction of countries in need in the 
developing world will have access to it. As a result, lives are being lost unnecessarily. 
The enormous investments in carrying out high-quality clinical trials and regulatory 
processes as fast as possible are at risk of being wasted. During this extended period, 
manufacturers may be left with idle capacity or may decide to exclude LMICs and LICs 
PLANNING FOR NEW HEALTH INTERVENTIONS   
Accelerating access to public health interventions  41 
entirely from their supply plans, in favor of more reliable markets in HICs. This paper 
proposes a new approach, challenging the international community to systematically 
address questions of access during the R&D period of new interventions, instead of 
waiting until regulators have given approval. All critical factors need to be identified 
early for potential new interventions, and the process of supporting their later 
implementation started as early as possible. 
Our approach has implications throughout the international public health community, 
including researchers, manufacturers, WHO, funders, countries, and others. It raises a 
challenge to each organization, asking them to identify ways they can contribute to 
new interventions during R&D, anticipating and beginning to address likely bottlenecks 
in advance.  Early foresight in the development process has the potential to 
significantly shorten the time elapsed before developing countries access new 
interventions, and as a consequence, reduce the unnecessary loss of life that is 
experienced today.  
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ABSTRACT 
A growing number of interventions are being created to address health problems of 
the developing world. However, most developing countries have fragile health systems 
and find it difficult to accommodate new interventions. Consequently, it is important 
that the design of these new interventions aligns with the needs of health systems and 
their users in developing countries. Establishing target product profiles (TPPs) is a 
critical, early step towards tailoring interventions to suit both of these constituencies. 
Specific analyses may be needed to identify and establish relevant TPP criteria such as 
optimal formulation, presentation and packaging. Clinical trials for a new intervention 
should be designed to address both TPP-specific questions and anticipated use of the 
intervention in target countries. Examples are provided from applied research on 
malaria vaccines that are applicable to other new public health interventions. 
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INTRODUCTION 
Health systems in developing countries (DCs) are more fragile than those in the 
developed world. Major challenges include inconsistent energy supply, limited health 
infrastructure, highly constrained financing and the large and diverse disease burdens 
borne by populations. Unless new interventions are specifically designed to facilitate 
integration into, and be acceptable to users of such systems, these challenges may be 
exacerbated.  
 
The world is seeing a welcome commitment to creating new means of addressing 
public health problems in DCs. The G-Finder report, which tracks funding for 
interventions that target neglected diseases, lists 31 diseases and 134 product areas 
for these diseases, including drugs, vaccines, microbicides, diagnostics, and vector 
control [60,60]. To avoid delays in use after approval by regulatory authorities, the 
specific needs of the developing world must be considered from the earliest stages of 
intervention development.   
 
Frost and Reich (2008), and others [2,4,38,42], suggest that access to health 
interventions involves multiple considerations following regulatory approval; 
particularly availability, affordability, decisions on adoption, and effective coordination 
(i.e., architecture) of all these considerations. Availability covers factors relating to 
manufacturing, storage and distribution. Affordability represents the cost to 
purchasers and end-users. Adoption requires a series of positive decisions to be made 
by governments, providers, and individuals. The authors provide insights into the 
many factors that ultimately influence access to health interventions, and the 
realization of a positive and equitable public health impact. 
 
All three considerations—availability, affordability, and adoption—are directly 
influenced by decisions taken and studies conducted by developers and collaborators 
well before regulatory approval. To achieve public health impact in the context of DC 
health systems, an available intervention must have characteristics that are acceptable 
to end users and facilitate implementation; for example, suitability for tropical 
climates and a low logistical burden. Affordability is not limited to initial purchase 
price; it also takes account of total delivery costs, including storage, transport, health 
worker time, and the quantity of unused or wasted product. Adoption partly depends 
upon providing data that responds to questions specific to DC health systems and 
populations.  
 
If issues of availability, affordability and the adoption are not considered during 
development, additional studies and investment may be needed after regulatory 
approval; expending time and money that might have been more efficiently used 
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during the development phase. The associated public health impact of delayed 
implementation—possibly years—can be even more significant. The GAVI Alliance 
(GAVI) invested approximately US$100 million to address supply constraints and 
outstanding research questions in support of implementing Haemophilus influenzae 
type B (Hib), pneumococcal, and rotavirus vaccines [61]. The Hib vaccine prevents one 
of the most important causes of pneumonia and meningitis in infants.  GAVI’s 
expenditure began after Hib was offered free to countries in the year 2000. Target 
countries were unfamiliar with the disease and did not have data on its burden, a 
situation which could have been foreseen and addressed while the vaccine was still in 
research and development (R&D). Consequently, very few countries adopted the 
vaccine, and few children were protected. GAVI had to make additional investments to 
strengthen the evidence base to inform the use of Hib, and to prevent a similar 
situation with pneumococcal and rotavirus vaccines.  
 
This paper presents an applied research strategy to foresee challenges and align 
interventions with DC health systems from the early stages of development. Published 
literature is used to complement Frost’s framework. Examples from a number of 
public health interventions and the work of the PATH Malaria Vaccine Initiative (MVI), 
a product-development partnership, demonstrate the application of this approach. 
The paper’s second section proposes a target product profile (TPP) template that 
should be utilized for public health interventions intended for the developing world.  
 
Since the ideal target for every attribute in a TPP may not be readily apparent, the 
third section of this paper provides an example of research efforts to determine the 
optimal formulation, presentation, storage and packaging of a malaria vaccine 
candidate intended for DCs. These attributes influence availability, affordability, and 
decisions on adoption. A similar approach informed the establishment of the TPP for 
the US$1.5 billion advance market commitment for pneumococcal vaccines [62].  
 
The paper’s fourth section considers research questions specific to the data 
requirements for adoption in DCs. Such requirements may not be explicitly stated in a 
TPP, but highlight the need for careful alignment of research studies with TPP targets 
and desired health impact. The fifth section of the paper discusses the implications of 
the previous sections, prior to the conclusion.  
TARGET PRODUCT PROFILES 
BACKGROUND 
There is no universal understanding of a TPP and its use. At its most generic, a TPP can 
be a list of the attributes of an intervention. A TPP can be a formal document used in 
discussions with regulators, as part of a summary of a drug development program 
leading to specific label claims [63–65]. It can also be used as a commercial tool, to 
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compare a product with a competitor’s and set pricing strategies [66]. Alternatively, a TPP 
can be used as a tool that transparently identifies the major characteristics of a public 
health intervention, thereby unifying those working on the intervention so as to 
achieve the intended health impact [16,67–69]. Several documents provide guidance 
on potential structures or categories when developing TPPs; however, most of these 
relate to experience from the developed world and are tailored to for-profit 
companies focused on market share [16,64,65,67–72]. 
 
TPPs are living documents evolving over time as research, analyses, and consultations 
clarify the ideal targets, and as interventions move from pre-clinical to the late 
development stage [71,72]. Within an organization or consortium there should be a 
formal mechanism for approving a TPP template; individual TPPs for specific classes of 
interventions, and a formal change control system for revisions to the template and to 
individual TPPs over time. One way to manage product evolution is to identify an 
acceptable range for each characteristic, and then to indicate where an individual 
intervention’s characteristics fall within that range as it enters late development. If its 
characteristics move outside the identified acceptable range, an assessment must be 
made to determine whether continued development is justified. 
 
CASE STUDY: TPP DEVELOPMENT 
MVI began a process in 2009-10 to formalize both the development of TPPs for the 
candidate malaria vaccines it was developing, and the role of TPPs in guiding the work 
of the organization. A multi-disciplinary team was led by experts on policy and access, 
accountable for envisioning the eventual implementation process for malaria vaccines. 
The team included members with clinical, regulatory, and commercial expertise. It 
adapted, with permission, a TPP format that was developed by the Bill and Melinda 
Gates Foundation (Gates Foundation). In parallel, the malaria eradication research 
agenda (malERA) initiative agreed upon a TPP template for vaccines that could 
contribute to malaria elimination and eradication by interrupting transmission, 
informed by MVI and the Gates Foundation templates [67]. Following iterative 
modifications to the Gates Foundation template, a final MVI TPP template was agreed 
upon by team members, and formally approved by MVI’s Portfolio Management 
Committee (PMC), which oversees development of the organisation’s vaccine 
candidates. MVI decided that the PMC would approve, and MVI’s external advisory 
body review, all TPPs and any significant changes to them. Approved TPPs were shared 
with collaborators and made publicly available. 
 
MVI’s TPP template was a table that identified a range of target characteristics, from 
desired to minimally acceptable, for each class of malaria vaccines, as well as the 
attributes of a specific product as it moved into late development (Figure 10). Targets 
were intended to be concrete, evidence-based, and/or measurable. Key components 
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of the TPP would be described on the vaccine package insert. Definitions and examples 
are provided in Table 9 and Table 10. 
FIGURE 10. TARGET PRODUCT PROFILE TEMPLATE. 
Product Class:   
Product Name:  To be completed once product approaches phase 2b 
Date of TPP Endorsement   
Dates of TPP Revisions   
 
 Desired 
  
Minimally 
Acceptable 
  
“Insert Product 
Name” Profile 
(Completed as 
product 
approaches 
Phase 2b) 
  Target Rationale Target Rationale Target Rationale 
Indication       
Expected Efficacy       
Target Population(s)       
Route of Administration       
Formulation & 
Presentation 
      
Dosage schedule       
Safety profile       
Co-administration       
Shelf-Life & Storage       
Manufacturability       
Price       
Product registration and 
WHO prequalification 
      
 
One distinguishing attribute of MVI’s TPP was that each target was accompanied by a 
rationale. The rationale could be based upon published studies, modeling or, at a 
minimum, the logic that justifies the chosen target. The rationale provided a critical 
means for others to understand the driving forces behind individual targets. This was 
particularly important because development activities can take many years, teams 
often evolve, and it can be challenging to ensure consistent assumptions among 
targets within a TPP.  
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MVI’s TPP included explicit consideration of affordability in the form of purchase price, 
or relative cost-effectiveness. It also included the preferred route of administration, 
formulation and presentation, dosage schedule, co-administration, shelf-life and 
storage, and manufacturability. These characteristics will eventually inform country 
adoption decisions [73].  
 
TABLE 9. TPP TEMPLATE DEFINITIONS: STRUCTURAL ELEMENTS. 
Structural 
elements 
Definitions 
Product Class: Category of product. Example (Ex): Blood-stage malaria vaccine 
Product Name:  How product will be known publicly. To be completed once 
product approaches phase 2b 
Date of TPP 
Endorsement 
Date TPP formally adopted by organization  
Date of TPP 
Revisions 
Means of tracking changes over time 
Desired target Optimal characteristics 
Minimally 
acceptable 
target 
Minimal characteristics that would allow product to continue 
development 
Product profile 
target 
Characteristics specific to a product in late development (e.g. 
phase 2b), which should fall between desired and minimal targets 
Rationale Identifies data and publications to justify each target, or at 
minimum the reasoning behind each target 
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TABLE 10. TPP TEMPLATE DEFINITIONS: CHARACTERISTIC CATEGORIES. 
Categories Definitions 
Indication Intended use against a measurable outcome. Ex: Prevention of 
uncomplicated malaria. 
Expected Efficacy Anticipated efficacy level for the indication, measured in a clinical 
trial. 
Target 
Population(s) 
Ages, parts of the world, and/or defining characteristics of those 
who could receive the intervention. Ex: Children under five years 
of age in malaria-endemic countries. 
Route of 
Administration 
Ex: Oral ; intra-muscular injection. 
Formulation & 
Presentation 
Formulation, Ex: liquid or lyophilized (a dried powder) which 
needs to be reconstituted (mixed with a liquid) before injection; 
presence of a preservative; and volume of each injection. 
Presentation, ex: size and type of vial; vial labelling.  
Dosage schedule How may doses, at what intervals. Ex: three doses at one month 
intervals 
Safety profile Anticipated or acceptable levels of adverse events; populations or 
individuals that should not receive the product, or receive it with 
caution. Ex: safety allows for use in the target population, or 
comparable to similar interventions used in the target population. 
Co-
administration 
Other interventions that can be administered at the same health 
visit. 
Shelf-Life & 
Storage 
Shelf-life relates to how long the product can be stored after it 
leaves the manufacturer, and storage indicates packaging 
requirements and temperature at which it needs to be 
maintained. 
Manufacturability Scalability of the production process to quantities anticipated for 
the developing world.  
Price  Absolute or cost-effectiveness relative to peer interventions. 
Product 
registration and 
WHO 
prequalification 
Rigour of the regulatory bodies anticipated to register the 
product, and expectations for pre-qualification. Ex: Licensure by 
WHO-evaluated fully-functional regulatory agency. Pre-qualified 
by WHO. 
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FORMULATION, PRESENTATION, SHELF-LIFE AND STORAGE 
BACKGROUND 
Once an intervention becomes available, the extent to which its final characteristics 
comply with the TPP will directly impact affordability and the adoption decisions. 
 
Some public-private collaborations, intervention developers and advocates seek to 
align product characteristics with the needs of DCs [16]. For example, a public-private 
partnership recently formulated and packaged an appropriately flavoured and easy to 
swallow dispersible artemisinin-based combination therapy (ACT) for the treatment of 
malaria in children [74]. Similarly, vaccines have been formulated to combine multiple 
antigens into single injections [75,76]. The number of doses in a vaccine vial can be 
optimized for DC immunization programs [77]. Novel pharmaceuticals can be 
evaluated under hot and humid storage conditions common in DCs [78,79]. Packaging 
can be minimized to reduce shipping and handling costs [80]. Research has considered 
the perceptions of malaria and vaccines, and the acceptability of malaria vaccines, to 
users of health services [81]. Each of the considerations above relates to one or more 
aspects of a TPP that responds to the preferences of the public health community and 
of DCs. If an intervention is modified in late development, or after licensure, this may 
cause delay and impose additional costs, i.e., additional/extended clinical trials, 
modifications to manufacturing systems, and requirements for health worker 
retraining.  
 
Systematic alignment of interventions with the needs of DCs builds upon an analytic 
foundation supported by clearly stated rationales and trade-off comparisons; 
particularly when there is collaboration with private sector partners. Most of the 
authors above do not report analyzing and/or quantifying the trade-offs. Alignment is 
also most likely when preferred characteristics are integrated into the TPP and product 
development plans early in the development process, which may be years before 
anticipated availability.  
 
One set of interrelated characteristics that lends itself to analysis is the optimal targets 
for formulation, presentation, and shelf-life and storage of malaria vaccines based on 
direct trade-offs between vaccine wastage and health system costs. For example, a 
multi-dose lyophilized vaccine or a multi-dose liquid vaccine formulated without a 
preservative cannot be reused from one immunization session to the next when 
unused doses remain in a vial; this leads to more vaccine wastage than a liquid multi-
dose vial with a preservative [82]. Presentation of a vaccine in a multi-dose vial is more 
space-efficient for transport and storage; consequently when a single-dose, lyophilized 
or few-dose, preservative-free vaccine is adopted in order to reduce wastage, this will 
inevitably generate greater logistics costs. Similarly, a vaccine with a short shelf-life 
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will often lead to increased wastage if health care workers have to destroy expired, 
unopened vials. A mandatory requirement for refrigerated storage and transport also 
increases costs, particularly if the packaging is not optimized for developing country 
distribution systems.      
 
CASE STUDY: PUBLIC SECTOR PREFERENCES FOR RTS,S/AS01(RTSS) MALARIA 
VACCINE FORMULATION, PRESENTATION, SHELF-LIFE AND STORAGE 
RTS,S, under development since the 1980s, has progressed over the last decade 
through a collaboration between the PATH Malaria Vaccine Initiative (MVI) and 
GlaxoSmithKline (GSK). Its phase III clinical trial began in 2009 [83]. If all goes well in 
phase III testing, WHO has indicated that a policy recommendation for RTS,S is 
possible as early as 2015, paving the way for implementation in countries through the 
Expanded Program on Immunization (EPI).  
 
The process of defining the targets for a number of specific vaccine characteristics 
evolved into a five-step process, which started in November 2006 and was completed 
in September 2007.  
STEP 1 – STRUCTURED DISCUSSIONS WITH A PUBLIC - PRIVATE SECTOR WORKING GROUP  
A working group from WHO, MVI and GSK was established in 2006, agreeing on a 
terms of reference to systematically analyze and/or quantify public sector preferences 
in order to: 
(1) Align RTS,S presentation and packaging with WHO/UNICEF procurement 
specifications and previous experience with other childhood vaccines used in EPI to: 
 Ensure that the packaging requires as little volume as possible, particularly in 
the cold chain and in dry storage.  
 Ensure that lyophilized product and adjuvant cannot be separated in shipping, 
storage, and handling at health centers. 
 Evaluate implications of pre-filled syringes versus vials. 
 Consider the implications of formulating RTS,S with other EPI antigens. 
 Ensure consistency with standard auto-disable syringe sizes and volumes. 
 Minimize medical waste implications.  
(2) Determine the factors governing the choice of preferred vial size(s). 
(3) Consider the use of preservatives in the vaccine. 
(4) Consider thermostability issues. 
(5) Consider implications of liquid vs. lyophilized formulations. 
(6) Consider health worker training and workload issues. 
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STEP 2 – QUANTITATIVE ANALYSIS USING THE VACCINE PRESENTATION ASSESSMENT TOOL 
(VPAT) 
An Excel-based Vaccine Presentation Assessment Tool (VPAT) was developed and 
refined over the course of the project to provide the working group with quantitative 
analyses of trade-offs among characteristics. It assessed the volumetric impact of 
alternative formulations and presentations of a vaccine, and associated commodities 
(syringes and safety boxes), with those for a typical immunization schedule in sub-
Saharan Africa. The tool used as its unit the Fully Immunized Target Group (FITG), 
which comprised a fully immunized child plus his/her mother’s tetanus toxoid 
immunization.  
 
In addition to this volumetric analysis, the tool incorporated sufficient cost data to 
perform a ‘break-even’ analysis. This analysis indicated which presentations were 
likely to have implementation costs comparable to, or cheaper than, a baseline 
presentation of the same vaccine in a single-dose vial. The tool used a goal-seeking 
algorithm to calculate the wastage rates at which the total cost per administered dose 
(vaccine purchase + vaccine storage + vaccine distribution + consumables purchase + 
consumables distribution) for each presentation was equal to the baseline 
presentation. The calculated break-even wastage rates for each possible presentation 
and vaccine purchase price point were then compared with wastage rates for similar 
presentations achieved in the field. If the calculated break-even wastage rate was 
higher than that typically achieved in the field, the presentation/price combination 
was considered to be potentially viable.  
STEP 3 –INCORPORATING DATA FROM AFRICAN EXPERTS AND WHO NORMATIVE MATERIALS 
A questionnaire on product profile options for RTS,S was developed in consultation 
with the working group. This questionnaire was administered at two regional 
immunization programme managers’ meetings held in Zimbabwe and Burkina Faso 
during March 2007 to determine the preferences of immunization experts in Africa. At 
each session a presentation on malaria vaccine development was given before the 
questionnaire was administered. The 71 respondents included 35 country staff and 36 
international agency staff from 31 malaria endemic African nations. Responses were 
consolidated and analyzed in Excel. 
 
The working group reviewed WHO materials relevant to the study analyses in parallel 
with the survey-related activities. Applicable recommendations and norms were 
synthesized according to the study’s topics and carefully referenced. 
STEP 4 - DISCUSSIONS BY PUBLIC SECTOR EXPERTS AND ENDORSEMENT BY WHO STAFF 
A complete report was drafted synthesizing the findings from the steps above and 
conclusions on formulation, presentation, shelf-life, storage, and packaging. It was 
discussed by a public sector expert group drawn from PATH and WHO. The report was 
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updated in response to the comments received and to take into account 
improvements in the break-even modeling arising from a parallel GAVI Alliance-
commissioned PATH study on pneumococcal conjugate vaccines [62]. The updated 
report was then reviewed and conclusions formally endorsed by senior immunization 
staff in WHO at a meeting in September 2007.  
STEP 5 – SHARING PUBLIC SECTOR RECOMMENDATIONS WITH THE MANUFACTURER 
The final project report set out the agreed-upon public sector priorities for the 
presentation, shelf-life, and storage of RTS,S [84]. This report was shared with GSK 
representatives in September 2007. The manufacturer considered its findings, along 
with other constraints, such as production challenges and process validation, in the 
determination of the final product profile for RTS,S.   
 
A complete list of conclusions endorsed at a meeting with WHO representatives is 
available in the final report, which includes the detailed methodologies associated 
with each step summarized in this paper. The conclusions related to vial size are 
presented in Table 11 to illustrate the complexity of aligning an intervention with the 
needs of developing countries. Factors contributing to the optimal vial size for RTS,S 
included price per dose, anticipated usage, vial dimensions, and estimates of likely 
wastage. The optimal vial size for RTS,S was found to be a two-dose vial if the price 
was above US$2.50/dose or a three-dose vial if the price was lower than US$2.50.  
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TABLE 11. PUBLIC SECTOR PREFERENCES FOR RTS,S VIAL SIZE. 
Vial size Public sector preference 
Mono-
dose 
vial 
A mono-dose RTS,S presentation is not recommended at any of the costs 
per purchased dose that were investigated. The advantage of the low 
opened-vial wastage rate associated with mono-dose vials is offset by the 
need to approximately double the volume of refrigerated storage required 
as compared with a basic schedule of vaccines. In addition, reconstituting 
mono-dose vials would have an excessive impact on health worker 
workload. 
2-dose 
vial 
The current 2-dose presentation appears to offer the best compromise 
between volume-per-dose, cost-per-dose, and wastage in routine 
immunization settings at a price point greater than around US2.50 per 
purchased dose. 
3-dose 
vial 
A 3-dose vial appears to offer the best compromise for routine use at a 
cost per purchased dose below the US$2.50 price point. 
5-dose 
vial 
A 5-dose vial looks unlikely to be viable at any price point unless it can be 
supplied in compact, purpose-made vials at a cost per administered dose 
that is competitive with 3-dose. 
10-dose 
vial 
A 10-dose presentation would be welcomed by countries but would only 
be economical at the lower price points (around US$1.00 per dose) as a 
supplementary presentation for use in larger urban and campaign settings, 
where opened-vial wastage levels can be assured to be around 10% or 
less.  
 
ANTICIPATING SUPPLEMENTAL RESEARCH QUESTIONS FOR THE 
DEVELOPING WORLD WHEN DESIGNING CLINICAL TRIALS 
BACKGROUND 
The targets in a TPP help to define the research questions that need to be addressed in 
trials and studies in order to be confident that an intervention meets expectations. 
The targets also assist in identifying data which may be sought by countries to inform 
adoption decisions.  Clinical trials are generally designed to address indication, efficacy 
and safety, although these may not be straightforward to define or evaluate in the DC 
context. Less apparent research questions may arise from characteristics in the TPP, 
which also require explicit consideration in trial designs.   
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There are many examples in the literature that highlight the important challenge of 
foreseeing research questions specific to DCs, which may not be as relevant in 
developed countries, and might, therefore, be overlooked [85]. A partially efficacious, 
preventive intervention may not be of interest to developed countries, but may be 
used in DCs where treatment is less accessible and the disease burden is higher [86]. 
Given the diverse disease load carried by many individuals in DCs, interventions may 
have indirect effects on unrelated pathogens [87]. The safety and efficacy of 
interventions in HIV positive individuals needs to be evaluated given its prevalence in 
Africa and the challenge of screening people [88–90]. Studies assessed whether the 
birth dose of Bacillus Calmette-Guerin (BCG) vaccination should be delayed in low 
birth-weight newborns [91]. Studies also evaluated the impact of breastfeeding on the 
efficacy of rotavirus vaccine [92].   
 
When designing TPPs and associated clinical trials in DCs, such considerations, should 
be foreseen in anticipation of adoption decisions by international and national policy-
makers. There is no formal requirement for policy-making bodies, particularly WHO, to 
inform or approve clinical development plans. However, it seems prudent to design 
pivotal studies that anticipate and address as many questions needed to establish 
policy as possible. Although it is desirable to be comprehensive during the clinical 
development program, it may not be practical to address all research questions arising 
from a TPP; developers may decide some questions are best be answered in studies 
after regulatory approval.  
 
CASE STUDY: TPPS AND CLINICAL TRIAL DESIGN FOR MALARIA VACCINES 
MVI, GSK and partners developed iterative plans for the phase III trial of RTS,S from 
2005 through 2008. At the beginning of the process, there was no clear agreement on 
the trial endpoints or the best way to measure them. WHO, with support from MVI, 
organized an international consultation in 2006, culminating in a consensus position 
that a primary study endpoint for licensure of uncomplicated, clinical malaria was 
appropriate for submission to regulators and policy-makers, and that additional data 
on efficacy against severe malaria might be useful [93]. Once the primary endpoint 
was defined, WHO convened a consultation to establish standards for measuring 
efficacy of a malaria vaccine against uncomplicated, clinical malaria [94]. The 
measurement is less straightforward for malaria than for other diseases because 
individuals can have multiple episodes while developing natural immunity over time.  
 
WHO’s efforts were complemented by MVI. MVI reviewed past policy 
recommendations for vaccines and malaria interventions to anticipate the policy 
process and to consider what data might be needed for a policy recommendation [95]; 
findings were reported to WHO’s Malaria Vaccine Advisory Committee (MALVAC). 
MVI, WHO and others also worked with African countries to identify what data were 
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needed for policy decisions [22,96]. The iterative, collaborative applied research, with 
WHO’s leadership, to define standards in trial design were critical to ensuring that the 
target product profile characteristics were aligned with what could be measured and 
would be used by regulators and policy-makers.  
 
RTS,S trials were designed to address as many questions potentially affecting adoption 
decisions as feasible. Among the questions investigated were efficacy in settings with 
different malaria epidemiology; efficacy against severe, hospitalized malaria and all-
cause mortality; duration of protection to 30 months and beyond; co-administration 
with current and anticipated vaccines and need for a booster dose.  
 
The target population and safety requirements identified in the TPP also led to specific 
research questions. RTS,S is intended for infants in Africa. It was determined that the 
Phase III study should be undertaken in as representative a population as ethically 
feasible in order for the vaccine to be used widely in this target population, and in 
anticipation of potential WHO requests for studies in the target subjects before issuing 
a policy recommendation. Therefore the study design included subjects that would 
often be removed from typical trials. For example, only subjects that were acutely 
malnourished or had late-stage AIDS were excluded, while infants and children with 
more mild forms or low birth-weight were included. An additional safety study was 
planned in HIV positive infants and children in parallel with the phase III efficacy study, 
rather than after regulatory approval. Including these subjects and collecting robust 
data during phase III studies will enable regulatory agencies to conclude on its use in 
these higher-risk groups in parallel with use in healthy infants. Without such data, 
universal immunization in countries could be overshadowed by the unknown risk to 
these vulnerable segments of the population. 
DISCUSSION  
The applied research and approaches described herein reflect lessons, which, if 
implemented, help ensure that new interventions incorporate characteristics suited to 
the unique needs of DCs. The approaches also reflect the links between intervention 
characteristics, affordability, and decisions on adoption in DCs. TPPs should state a 
clear rationale for desired characteristics to ensure continuity throughout the 
intervention development period, and increase the likelihood of achieving the desired 
public health impact. In some cases, the rationale should be the product of specific 
research activities to quantify the trade-offs, particularly if the trade-offs have 
implications for private sector collaborators. Trials need to be carefully designed to be 
consistent with the TPP and unique challenges of DCs. Examples from malaria vaccine 
development illustrate these points.   
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There are many challenges to consider in the development of TPPs. A TPP can be a 
complex document with many different targets, and it can be difficult to ensure that 
the targets are mutually consistent. For example, if one target is used in a large 
proportion of a population, such as part of a disease eradication initiative, the 
intervention would likely need to be relatively inexpensive, easy to store and transport 
at ambient temperatures, require one or few doses, and be the product of a 
manufacturing process that is very scalable. It follows from this example that targets in 
a TPP interact with and influence each other. This is why an interdisciplinary team is 
best positioned to develop TPPs, perhaps led by someone familiar with 
implementation of interventions, as MVI has done. Modeling can help identify critical 
targets, and their significance in achieving the desired public health impact. 
 
Questions may arise as to who bears which costs for achieving TPP targets and 
whether or not these targets can be addressed through studies after regulatory 
approval; this forces developers to clearly define their responsibilities. For example, 
developers of a DC intervention could spend additional resources and time striving to 
improve its thermostability because this would save money for countries and donors 
later. Alternatively, they may decide to seek regulatory approval as quickly as possible; 
leaving the costs associated with cold chain expansion and associated implementation 
to others. If developers assume that their TPP role ends at regulatory approval, this 
may lead to inconsistently defined targets and lack of accountability because 
important outstanding questions have to be addressed by others during later studies.  
Clearly, some final characteristics of an intervention may not be discerned until late in 
development. For characteristics that can be foreseen, such as product presentation 
and packaging, the public sector must make its preferences and requirements clear; 
for interventions such as pharmaceuticals, perhaps five years, or more, ahead of 
regulatory approval. The public sector cannot wait to discuss alignment of 
interventions with DC needs until after regulatory approval has been granted. 
 
WHO can play an important role in standard-setting during the research and 
development process. Regulatory agencies, international financing organizations and 
donors, and developing country governments look to WHO for guidance. It takes years 
to put such standards into place. Partners involved in the development of 
interventions can support WHO in its role, without influencing its neutrality. Central to 
WHO’s role is long-term predictability, looking ahead to clarify what type of data it will 
need to set policies, prior to finalizing the design of late clinical trials and years before 
regulatory approval of interventions, as was largely done for malaria vaccine 
candidates. 
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CONCLUSION 
Misalignment of novel interventions with DC needs can delay access to essential 
innovations, and may add years to the delivery of their potential public health impacts. 
However, developers can anticipate the needs of DCs in a systematic manner before 
making an intervention available. We have shown how concrete strategies can be 
developed to achieve well-structured and carefully reasoned target product profiles. 
The rationale behind a well-structured TPP may be as, or more, important than the 
TPP target itself.  One way to strengthen collaboration with private sector partners, 
and to increase the likelihood that TPP characteristics sought by DCs will be realized, is 
to work with partners years in advance of regulatory approval, and to support public 
sector requirements and preferences with solid data. Identifying the research 
questions needed to address TPP characteristics also helps developers time their 
studies and efficiently tackle those questions.  This approach can help minimize the 
duration between the development and successful implementation of new 
interventions.  
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ABSTRACT  
BACKGROUND 
International organizations are essential for transitioning health interventions from 
research and development (R&D) into use within developing country health systems. 
Their decisions (e.g. policies, recommendations, and guidelines), and the associated 
actions, directly inform country decisions, including those related to the use and 
subsequent implementation of an intervention. However it is unclear for a new 
intervention like a malaria vaccine, which international organization takes what 
decisions, when, to facilitate the transition from R&D to implementation.  
METHODS 
Literature review, semi-structured interviews, and temporal relationship mapping with 
Gantt charts were used to analyze the roles, decisions, timing, and interactions of 
international organizations which may impact the implementation of the RTS,S/AS01 
(RTS,S) malaria vaccine in developing countries. The work was undertaken by the PATH 
Malaria Vaccine Initiative. International organizations were identified based upon the 
experience of existing vaccines and malaria interventions. Websites and publications 
outlining each organization’s roles were reviewed. Semi-structured interviews were 
conducted with representatives from, or key informants knowledgeable about, each 
organization. Actions and decisions were classified into categories of policy, regulation, 
financing, manufacturing, and procurement. The sequence of actions and decisions 
from each group or organization were placed into a decision pathway (i.e. Gantt chart) 
relative to the timing of critical R&D and regulatory milestones.  
RESULTS & DISCUSSION 
Fourteen decision-making groups were identified within the following seven 
international organizations: the World Health Organization; European Medicines 
Agency; GAVI Alliance; Global Fund to Fight AIDS, Tuberculosis, and Malaria; Roll Back 
Malaria Partnership; GlaxoSmithKline; and UNICEF. Most organizational 
representatives had relatively little insight into the overall path for an intervention 
from R&D to implementation in developing countries beyond their discrete roles, 
particularly for a novel intervention. The findings illuminated who might provide 
technical recommendations, pay for, and procure RTS,S as well as who might 
coordinate these processes with regulators and the manufacturer. The implications of 
various RTS,S phase III trial results were considered for their potential impact on 
decisions by these organizations. Safety concerns in the trial appeared to have the 
largest potential impact on decision processes. Interim efficacy findings could speed or 
slow planning for eventual decisions and implementation, pending final study data and 
regulatory review.  
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CONCLUSIONS 
The research described in this paper helped provide clarity into the potential roles of 
different organizations relative to an intervention that is in R&D. Such clarity should 
contribute to efficient processes, and more rapid evidence-based decisions than has 
been seen for past interventions. Similar research into international decisions should 
be considered for other interventions under development. 
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INTRODUCTION  
The way international organizations fulfill their roles have global repercussions. Their 
decisions and associated actions leading up to and following from those decisions 
impact developing countries. They impact country decisions to use new health 
interventions, and the subsequent implementation processes through national health 
systems. For example an organization could establish a policy recommending countries 
use an intervention or agreeing to finance it. Supportive decisions mean hundreds of 
millions of individuals may be protected from or treated for a disease, while decisions 
that are cautioning, unclear, or absent may slow or stop national decisions to 
implement an intervention. This paper considers the need for and reports on research 
into the roles of international organizations in relation to the RTS,S/AS01 (RTS,S) 
malaria vaccine. 
New health interventions can pose systemic challenges to international organizations. 
New coordination or advisory structures may be needed. Weighing decisions for a 
“first in class” intervention, like a malaria vaccine, may be more complex than 
decisions for a second generation intervention like a new anti-malarial drug.  
Published literature reflects the important and diverse roles played by multiple 
international organizations prior to national decisions and implementation of new 
health interventions. Critical decisions of such organizations at the international level 
broadly relate to the following categories: 
Providing recommendations on safety, quality and use:  
 Regulatory agencies provide a critical determination of safety, quality, and 
efficacy. The World Health Organization (WHO) complements regulators 
through its pre-qualification function which considers the appropriateness of 
interventions for procurement by international agencies and use in developing 
countries [9,97–99]. 
 Input from WHO is critical for many developing countries’ policies [100–102]. 
WHO routinely issues regional or global policy positions and guidelines, often in 
consultation with external experts, which inform decisions by financing 
organizations, countries and others [53,103–105]. WHO also provides technical 
guidelines on treatment or use of interventions, “how to” manuals which may 
have recommendations embedded [106–108]. 
Subsidizing costs:  International financing organizations (e.g. Global Fund to Fight AIDS, 
TB, and malaria (GFATM); GAVI Alliance (GAVI)) take decisions on which purchase and 
implementation costs they will subsidize for an intervention [109,110]. 
Manufacturing:  Manufacturers, typically private companies, determine the quantity 
and pricing of interventions they produce [111–113]. 
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Procurement:  Individual countries, or international agencies on behalf of countries, 
determine which interventions they will purchase [114–117].  
Actions and decisions by international organizations have also been associated with 
delays in countries deciding to use and implementing new interventions. For example, 
a new form of anti-malarial treatment, artemisinin-based combination therapies 
(ACTs), was first licensed in 1999. In 2004 WHO and the GFATM were continuing to 
support countries purchasing chloroquine and sulfadoxine-pyrimethamine for treating 
malaria. These drugs were relatively cheap but malaria had high levels of resistance to 
them in many countries. Significant changes in malaria treatment only occurred after 
international pressure and charges of “medical malpractice”:  WHO clarified its 
treatment policies and GFATM decisions moved systematically to supporting the 
newer, more effective treatment, ACTs. Nonetheless, WHO’s formal, new treatment 
guidelines took an additional two years to be published, seven years after the drugs 
were first licensed [57,118]. More generally, Senior WHO staff identify timeliness of 
their recommendations as a re-occurring, systemic problem [105]. Supply shortages 
from manufacturers have caused delays in implementation by countries [112] (UNICEF 
Supply Division; http://www.unicef.org/supply/index_55207.html; Accessed August 
24, 2011). Decisions of international organizations impacting procurement approaches 
by countries have also been identified as a cause of delayed implementation of 
interventions [119].  
In addition to the ACT example above, examining policy and financing decisions 
associated with recent vaccines reveals that critical international decisions can take 
most of, or more than, a decade after an intervention is approved by regulators. Lives 
are lost during such delays. The first pneumococcal conjugate vaccine was licensed in 
2000 but did not receive a WHO recommendation until seven years later [95]. GAVI 
signaled its commitment to funding in the same year (Available at: 
http://www.gavialliance.org/vision/programme_support/new_vaccines/adips/index.p
hp; Accessed: April 14, 2011). Haemophilus influenzae type B (Hib) vaccine required 18 
years from licensure to global recommendation and financing. Although it was 
licensed in 1988, it did not receive its initial WHO recommendation for 10 years [95]. 
The financing commitment was made two years later by GAVI (Available at: 
http://www.gavialliance.org/vision/programme_support/new_vaccines/index.php; 
Accessed: April 14, 2011) and WHO issued a global recommendation for use after an 
additional six years, in 2006 [95]. The lengthy timeframes for decisions seen with ACTs 
and pneumococcal and Hib vaccines do not appear to be unique. 
There are reports of efforts to strengthen or accelerate the decision processes of 
international organizations for new interventions, although the ultimate impact of 
most is unclear. Some authors consider steps to inform regulatory and policy decisions 
[8,86,120–123]. Others provide economic and costing data to inform prioritization and 
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financing decisions by international organizations [110,124–126]. Forecasting to match 
manufacturer supply with demand from countries is an important function of the Roll 
Back Malaria Partnership (RBM), GAVI, UNICEF and other organizations [127]. Authors 
have also sought to foresee and address procurement strategies [128]. A number of 
authors describe efforts across multiple roles and international organizations for 
individual interventions [23,129–131]. 
Research reported here centers upon GlaxoSmithKline Biological’s (GSK’s) RTS,S, the 
most advanced malaria vaccine candidate. RTS,S, is in phase III trials in Africa, the 
region of the world with the most deaths from malaria. It is being developed in 
collaboration with the PATH Malaria Vaccine Initiative (MVI) and researchers across 
Africa [83]. The vaccine is being evaluated in two age groups: infants from six weeks 
administered at the same visits as routine EPI vaccines; and older than traditional EPI 
ages and up to 17 months at first dose. Phase III data is anticipated to be available in 
three batches in late 2011, late 2012, and 2014 (Available at: 
http://malariavaccine.org/from-the-field.php; Accessed: September 1, 2011). During 
2007-08, MVI researched the roles, decisions, timing, and interactions of international 
organizations which may impact the transition of RTS,S from R&D to implementation 
in developing countries. The work was carried out in order to help accelerate, 
strengthen and increase the efficiency of those processes. 
METHODS 
The research was conducted primarily using literature review and semi-structured 
interviews. The data was analyzed using Gantt charts to visualize the relationships and 
sequences of actions and decisions for each organization. 
An initial list of international organizations, or groups within those organizations, 
whose decisions might impact the transition of RTS,S from R&D to country 
implementation was developed and categorized. The list and categorization were 
based upon the literature and informal interviews with experts with experience from 
Hib, rotavirus, pneumococcal, and other vaccines, as well as ACTs and intermittent 
presumptive treatment of infants (IPTi) for malaria. Websites and publications 
describing the mandates of each organization were reviewed for formal descriptions 
of their roles which would have implications for RTS,S, and compiled into a draft 
working document. 
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Eighteen semi-structured interviews were conducted with representatives of, or key 
informants about, the organizations and groups identified. The interviewees were 
informed about the latest progress in the development of malaria vaccines, and were 
asked about: 
 Their organization’s/group’s potential role(s) in regards to international 
decisions for malaria vaccines. 
 When their role(s) takes place.  
 What organizations/groups they rely on prior to being able to fulfill their role(s) 
(i.e. who should take a decision before they can begin). 
 What organizations/groups rely on them in order to fulfill its role(s) (i.e. who 
comes after them). 
 What other organizations/groups that should be contacted as part of this 
research. 
Based on the interview data, a decision pathway (i.e. Gantt chart) was created in 
Microsoft Project of the international decisions related to RTS,S. It mapped the major 
activities leading up to and culminating in decisions by each organization, and the 
dependencies between the organizations and individual decisions. Activities and 
decisions on the pathway were categorized as related to policy, regulation, financing, 
manufacturing, and procurement. The decision pathway was constructed relative to 
the two most fundamental milestones that determine if a vaccine will be safe, of 
assured quality and efficacious: the estimated timings of phase III trial data and 
regulatory approval.  
The interviews and decision pathway were used to expand the draft working 
document noted above so that it would describe what role each organization was 
thought to play in regards to RTS,S and to summarize the relevant processes within the 
organizations. Interviewees were given an opportunity to review the decision pathway 
and draft working document for accuracy. 
A meeting was hosted by WHO to get collective feedback from the organizations to 
the decision pathway. Six of the organizations playing critical roles attended. One 
organization, WHO, had participants from five discrete departments or areas of 
expertise. The European Medicine’s Agency (EMA) was the only organization which did 
not attend, although other regulatory experts participated as key informants. The 
group spent a half day discussing potential roles and responsibilities, and the 
implications of and revisions to the pathway. Revisions were subsequently made and 
electronically shared with participants for feedback.  
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RESULTS  
ORGANIZATIONS, OR GROUPS WITHIN ORGANIZATIONS, WITH ROLES IN CRITICAL 
DECISIONS FOR RTS,S 
All seven organizations identified at the outset of the research were found to be 
responsible for critical decisions related to RTS,S (Table 12 and Table 13). Within one 
of these organizations, WHO, there were eight offices, departments or groups 
contributing to decisions, as well as a number of additional sub-groups.  
POLICY 
Formal policy positions of WHO were found to be issued by the Director General, 
drawing upon advice from WHO departments and regional offices, and 
recommendations from their respective external advisory committees. RBM was 
found to assist partner organizations to align malaria-related policies.  
WHO  HEADQUARTERS - MALARIA 
The malaria department, the Global Malaria Programme (GMP), sought external 
advice and malaria-related recommendations from the Strategic and Technical 
Advisory Group (STAG), as well as more narrowly mandated Technical Expert Groups 
(TEGs).  
WHO  HEADQUARTERS - IMMUNIZATION 
The Immunization Vaccines and Biologicals (IVB) department, sought external advice 
and immunization-related recommendations from the Strategic Advisory Group of 
Experts (SAGE). A number of more narrowly mandated groups reported to the SAGE, 
including one for early malaria vaccine R&D (MALVAC) and one for quantitative 
research (QUIVER). IVB also convened the Expert Committee on Biological 
Standardization (ECBS) which established production standards for vaccines 
referenced by companies and which may be used by regulators when licensing 
vaccines. The department was home to an advisory body which evaluated the safety of 
vaccines, the Global Advisory Committee on Vaccine Safety (GACVS). The Quality 
Safety and Standards unit within IVB pre-qualified vaccines, determining their 
appropriateness for purchase by other United Nations (UN) agencies.  
WHO  REGIONAL OFFICE FOR AFRICA (AFRO) 
AFRO informed global policies, and played a key role supporting implementation of 
policies by countries. The African Advisory Committee on Malaria and the Task Force 
on Immunization were external groups which informed and made recommendations 
for AFRO’s work.  
JOINT TECHNICAL EXPERT GROUP (JTEG) 
WHO’s GMP, IVB, and AFRO came to recognize, partially supported by this research, 
that there was no clear pathway to establish WHO recommendations for 
implementation of a malaria vaccine. The challenge was that each group had discrete 
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advisory processes and no clear means to bring them together. Therefore in 2009 
WHO established a JTEG to advise all parts of the organization, with terms of reference 
approved by the SAGE. (Available at: 
http://www.who.int/vaccine_research/jteg/en/index.html; Accessed: June 7, 2011)  
REGULATORY 
The European Medicines Agency was anticipated to evaluate the safety, quality and 
efficacy of RTS,S as the primary regulatory reviewer, given that it was manufactured in 
Belgium. RTS,S was planned to be submitted to the EMA under Article 58, a regulatory 
pathway allowing EMA, at WHO’s request, to provide an approval similar to licensure 
but for an intervention to be used outside of Europe [9]. 
FINANCING 
Both the GFATM and GAVI were identified as possible financing organizations for 
RTS,S, although with different internal procedures and requirements of countries. 
There was no established process to resolve if one organization was better placed to 
support the vaccine, or if both should provide support. A number of differences would 
need to be resolved if both were to eventually provide support. For example, it was 
noted that the GFATM supported a larger number of countries, including wealthier, 
middle-income countries, than GAVI. They had different means of determining which 
interventions countries may request. GFATM could begin to support interventions 
requested by countries and recommended by WHO, while GAVI required that a WHO 
recommendation and a formal investment case be approved by its board prior to 
allowing countries to request support for a vaccine. GAVI also required countries to 
achieve certain levels of coverage with existing vaccines prior to supporting 
introduction of new vaccines. Finally, GFATM and GAVI had different approaches and 
requirements for the amount of co-financing countries must provide from national 
budgets. 
MANUFACTURING & PROCUREMENT 
GSK’s decisions were found to relate primarily to supply, regulatory, pricing, and 
procurement strategies. UNICEF’s decisions related primarily to forecasting, pricing, 
procurement, and shipping. RBM, GAVI, GFATM and others also contributed to 
forecasting, and similar activities helping to match supply and demand. 
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TABLE 12. WHO AND RBM CONTRIBUTIONS TO DECISIONS IMPACTING RTS,S’ 
TRANSITION FROM R&D TO IMPLEMENTATION. 
Organization Department/group (if relevant) Decisions 
WHO Global Malaria Programme Guidelines on implementation and 
integration with other malaria 
prevention and treatment 
activities, in the context of malaria 
epidemiology 
Strategic and Technical Advisory 
Group for malaria, supported by 
Joint Technical Expert Group 
Recommendations to WHO from 
independent malaria experts, 
contributing to an organization-
wide policy 
Immunization Vaccines and 
Biologicals (IVB) Department 
Guidelines on implementation and 
integration with other vaccines 
Strategic Advisory Group of 
Experts for immunization, 
supported by Joint Technical 
Expert Group 
Recommendations to WHO from 
independent immunization 
experts, contributing to an 
organization-wide policy 
Quality Safety and Standards 
Unit in IVB 
Determination of vaccine 
suitability for UN purchase (pre-
qualification) 
Expert Committee on Biological 
Standardization, coordinated by 
IVB 
Guidelines on vaccine production 
Global Advisory Committee on 
Vaccine Safety, coordinated by 
IVB 
Determination of safety 
African Regional Office, 
Brazzaville (AFRO), supported by 
the Joint Technical Expert Group 
Guidelines on implementation for 
African countries, in coordination 
with GMP and IVB; contributing to 
an organization-wide policy 
RBM  Support harmonized policies 
across international organizations 
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TABLE 13. ADDITIONAL INTERNATIONAL ORGANIZATIONS CONTRIBUTING TO 
DECISIONS IMPACTING RTS,S’ TRANSITION FROM R&D TO IMPLEMENTATION.  
Function Organization Decisions 
Regulatory European 
Medicines Agency 
(EMA) 
Determination of vaccine quality, efficacy and if 
there are safety concerns 
Financing GFATM Policy to financially subsidize vaccine 
procurement and implementation costs 
GAVI Policy to financially subsidize vaccine 
procurement and implementation costs 
Manufacturing GlaxoSmithKline 
Biologicals (GSK) 
Determination of supply matched with 
demand; Determination of public sector price 
with procurement and financing organizations; 
Recommendation of post approval activities to 
EMA (Risk Management Plan) 
Procurement UNICEF Supply 
Division 
Policy to procure vaccine and ensure shipment; 
Determination of price with funders and GSK  
 
TIMING AND SEQUENCE OF SPECIFIC ROLES OF ORGANIZATIONS FOR RTS,S 
The pathway synthesized how and when the role of each organization contributed to 
international decisions, and how they related to those of other organizations. The 
timing of activities and decisions were established relative to the anticipated timings 
of phase III data and EMA regulatory approval, summarized in Figure 11. The findings 
facilitated the identification of and planning for critical actions and decisions, and 
supported the efforts of international organization to strengthen and accelerate 
decision-processes. 
The pathway assisted organizations to anticipate and schedule work that needed to be 
done in preparation for, or prior to, the availability of phase III data (Table 14 and 
Table 15). Although this R&D period will not be complete until approximately 2014/15, 
there are preliminary indications of results supported by or arising from the decision 
pathway and associated research. For WHO it assisted in highlighting the need to 
establish a means to coordinate across the malaria and immunization decision 
processes, a need which WHO ultimately decided to address by the establishment of 
the JTEG noted above. It also highlighted WHO’s contributions to the design of the 
clinical trial program, such as the importance of WHO identifying in advance the data 
its advisory bodies would need for eventual policy decisions. It led MVI to conduct, 
with input from WHO staff, an analysis of past WHO policy decisions and supporting 
data, in order to project what data might be needed for a policy decision on a malaria 
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vaccine [95]. MVI was invited to present the outcomes of the analysis to a WHO 
meeting. The pathway highlighted the timing of ECBS work on production standards so 
that they would be completed prior to the anticipated date of regulatory submission. 
It allowed GACVS to anticipate and schedule reviews of safety data from the trial.  
A particularly striking result of WHO’s preparatory work, such as described above, and 
supported by the decision pathway, has been reflected in public statements from 
WHO. It has indicated that if all goes well in the phase III trial, a policy 
recommendation for RTS,S is possible as early as 2015, only one year after trial 
completion, paving the way for implementation in countries through their expanded 
programs on immunization (EPI) (Available at: 
http://www.who.int/vaccine_research/diseases/malaria/vaccine_candidate_policy/en
/index.html; Accessed September 1, 2011). 
The pathway helped highlight the potential value of releasing the phase III data in 
three batches to regulators and WHO pre-qualification staff. Doing so would allow the 
organizations months or years to review elements of the dossier which draw upon 
data that is unlikely to change, such as that from phase II studies or about the 
vaccine’s chemistry. The review could take place while the phase III trial continues, 
potentially allowing the final review by regulators and WHO to be done in months 
instead of years since it would only need to consider the new data. 
The decision pathway also led to a series of analyses and preliminary discussions 
between technical staff of GAVI and the GFATM related to possible means of future 
collaboration between the organizations in relation to funding a malaria vaccine. The 
pathway identified the need for early demand forecasting to inform manufacturing, 
financing and procurement plans. It highlighted that the public sector needed to 
provide input to GSK on vaccine characteristics, such as the formulation, presentation 
and packaging of RTS,S in order for the vaccine to be acceptable and integrate 
smoothly within developing country health systems. A report of public sector 
preferences for vaccine characteristics was developed jointly with WHO and the 
conclusions were endorsed by senior WHO immunization staff [84]. The report was 
provided to GSK to inform its planning. 
The pathway also demonstrated the potential implications for decisions in future 
stages of the transition from R&D to implementation by looking forward to the period 
between phase III data becoming available and EMA regulatory approval. The pathway 
highlighted that international organizations would begin to consider the data and 
prepare for possible decisions. WHO advisory bodies would intensify their 
consideration of RTS,S including beginning to weigh implementation options and 
guidance to countries but without issuing implementation recommendations. It was 
found that ECBS guidelines needed to be issued, and GACVS would review safety data. 
Discussions between GSK and financing and procuring agencies would intensify. GSK 
PLANNING FOR NEW HEALTH INTERVENTIONS   
Roles of international organizations 73 
would submit regulatory dossiers to African authorities for review in parallel with EMA 
review. 
After approximately 2015 when the final EMA regulatory approval is anticipated, RTS,S 
would be the first malaria vaccine to be of assured quality, safety, and efficacy. WHO 
could pre-qualify RTS,S in parallel with, or immediately following, EMA approval. After 
EMA approval it would be ethical for countries to move concretely towards decisions 
on use, and subsequent implementation. The pathway highlighted that WHO’s 
advisory committees could then finalize their recommendations. When integrated 
with input from its departments and AFRO, WHO would issue a policy position. The 
recommendations and WHO’s policy positions would assist RBM to coordinate partner 
policies regarding support for implementation by countries. WHO’s decision would 
also inform final decisions by funding and procuring bodies, leading them to conclude 
supply and pricing negotiations with GSK. GAVI and the GFATM could begin to accept 
proposals from countries for support. GSK would continue to seek approval from 
individual African regulatory authorities and need to implement its post-approval 
commitments as outlined in an agreed Risk Management Plan with the EMA. 
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FIGURE 11. FLOW-CHART SUMMARIZING MAJOR DECISIONS AND ACTIONS BY 
INTERNATIONAL ORGANIZATIONS FOR RTS,S’S TRANSITION FROM R&D TO 
IMPLEMENTATION. 
 
Legend 
The vertical text in black boxes indicates major time periods from late R&D through regulatory approval. 
Bold outlined boxes determine if RTS,S can progress to the next period. Solid arrows reflect an essential 
sequence in decisions, while dotted arrows reflect informal or optional sequences.   
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TABLE 14. SUMMARY OF WHO AND RBM ROLES RELATIVE TO R&D TIMEPOINTS. 
Organi
zation 
Department/group Prior to phase 
3 data 
Prior to 
regulatory 
approval 
After regulatory 
approval 
Approxim
ate time 
required 
WHO Global Malaria 
Programme 
Inform trial 
design; 
Anticipate 
ancillary 
data 
Prepare 
for policy 
process 
and 
guidelines 
Propose 
policy 
position; 
Issue 
guidelines 
Ongoing 
STAG (Malaria 
advisory body; 
supported by the 
JTEG) 
Monitor 
progress 
Monitor 
progress 
Recommend 
policy 
position 
Every 1-
3 years 
Immunization 
Vaccines & Biologicals 
Department 
Inform trial 
design; 
Anticipate 
ancillary 
data 
Prepare 
for policy 
process 
and 
guidelines 
Propose 
policy 
position; 
Issue 
guidelines 
Ongoing 
SAGE (Immunization 
advisory body; 
supported by the 
JTEG) 
Monitor 
progress 
Monitor 
progress 
Recommend 
policy 
position 
Every 1-
3 years 
Quality Safety & 
Standards Unit 
Inform 
regulatory 
considerati
ons 
Review for 
pre-
qualificati
on  
Pre-qualify 
the vaccine 
1-2 
years 
Expert Committee on 
Biological 
Standarization 
Develop 
standards 
Issue 
standards 
N/A 2 years 
Global Advisory 
Committee on 
Vaccine Safety 
Review 
safety data 
Review 
safety 
data 
Review 
safety data 
Every 1-
3 years 
AFRO (Supported by 
the JTEG) 
Inform trial 
design; 
Anticipate 
ancillary 
data 
Prepare 
for policy 
process 
and 
guidelines 
Propose 
policy 
position; 
Issue 
guidelines 
Ongoing 
RBM  Monitor 
progress 
Prepare 
for policy 
process 
Harmonize 
decisions of 
partners 
Ongoing 
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TABLE 15. SUMMARY OF ROLES OF ADDITIONAL INTERNATIONAL ORGANIZATIONS 
RELATIVE TO R&D TIMEPOINTS.  
Function Organization Prior to phase 3 
data 
Prior to 
regulatory 
approval 
After regulatory 
approval 
Approximate 
time 
required 
Regulatory European 
Medicines 
Agency 
Approve 
protocol and 
monitor trial 
Review data 
for safety, 
quality and 
efficacy 
Monitor post- 
approval 
commitments 
Ongoing 
Financing GFATM Monitor 
progress 
(Secretariat) 
Monitor 
progress; 
Potentially 
indicate 
future 
support 
Accept 
country 
proposals, 
after WHO 
recommenda
tion 
Every 1-2 
years 
GAVI Monitor 
progress 
(Secretariat) 
Monitor 
progress; 
Potentially 
indicate 
future 
support 
Accept 
country 
proposals, 
after WHO 
recommenda
tion 
Every 1-2 
years 
Manufacturing Glaxo- 
SmithKline  
Inform other 
processes; 
Align 
intervention 
with DC 
needs; 
Generate 
demand 
forecasts; 
Plan 
manufacturin
g; Build 
facility 
Inform other 
processes; 
Generate 
demand 
forecasts; 
Negotiate 
price; 
Propose post- 
approval 
commitments 
Inform other 
processes; 
Generate 
demand 
forecasts; 
Agree price; 
Implement 
post- 
approval 
commitments 
Ongoing 
Procurement UNICEF 
Supply 
Division 
Monitor 
progress; 
Inform 
demand 
forecasts 
Generate 
demand 
forecasts; 
Negotiate 
price 
Generate 
demand 
forecasts; 
Agree price; 
Procure 
Every 1-2 
years 
 
  
PLANNING FOR NEW HEALTH INTERVENTIONS   
Roles of international organizations 77 
DISCUSSION  
The interactions and decision-making processes of international organizations are 
complex. There is no “how-to manual” with instructions for developers of new health 
interventions. In the case of RTS,S, which spanned two distinct domains of expertise—
vaccines and malaria—it was not clear who would coordinate the process to achieve 
technical consensus leading to recommendations for countries, who would pay for the 
vaccine, who would procure it, and who would ensure that these steps were 
coordinated with the roles of regulators and the manufacturer.  
A collaborative research approach led to unique insights into how a malaria vaccine 
might progress from R&D, through activities and decisions by international 
organizations, towards being ready for decisions on use by countries and potentially 
implementation through national health systems. Without forward planning, and 
associated predictable and transparent processes, interventions will be delayed in 
getting to those in need in developing countries by most of, or more than, a decade. It 
also means that if millions, or tens of millions of dollars, are invested in innovative, 
accelerated clinical trial designs, the value of these funds could be lost because of 
delays by international organizations. 
OPPORTUNITIES ARISING FROM A DECISION PATHWAY 
The future will only get more complex for international organizations. There are a 
growing number of new health interventions on the horizon due to the significant 
funds now flowing into research and development (R&D) that targets diseases 
prevalent in developing countries [60]. Those developing new interventions can 
collaborate with international organizations to anticipate decisions and their 
associated actions. Without such collaboration and planning, international 
organizations could have a negative impact on national decision processes and 
implementation, decreasing the public health impact of new interventions. They may 
take decisions based upon incomplete information, become bottlenecks due to 
unclear decisions or be unable to make a timely decision due to a lack of essential 
evidence.  
Completing phase II and III trials can easily span 5-10 years for a new intervention, or 
more as will be the case with RTS,S. During such a length of time, there will be many 
staff transitions in organizations. Such timelines support the importance of strategies 
which strengthen the continuity and predictability of processes over time. This 
research reportedly helped improve the understanding for other organizations, and 
WHO staff, of the multiple WHO entities. The pathway helped stimulate questions 
about the relative roles of WHO’s immunization and malaria departments and AFRO. 
WHO created a new advisory body, the JTEG, designed from its inception with 
collaboration from all three, relevant parts of WHO. The pathway identified questions 
regarding the status of the malaria program’s advisory body, the STAG, given that it 
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had not operated regularly in recent years, and how it would relate to the highly active 
SAGE for immunization. It challenged GAVI and the GFATM to begin discussing 
similarities and differences in their systems and requirements of countries. For 
example GAVI primarily supports group procurement through UNICEF, while GFATM 
has traditionally encouraged countries to procure interventions independently.  
Part of planning is identifying the relationships between activities of different 
organizations, and when each needs to begin in order for other activities and decisions 
to progress efficiently. This can lead to strategies as simple as determining if the 
release of scientific data can be coordinated with calendars of advisory bodies which 
may only meet once or twice per year. It can also assist in ensuring that those advisory 
bodies receive sufficient background data well in advance to allow decisions to be 
taken when convened. This is not to suggest that corners be cut, but instead that 
coordination and planning leading to predictability and transparency will make 
processes more efficient and faster. 
Decisions which are foreseen in advance also can be stronger or more conclusive. They 
can draw upon appropriate evidence created for those decisions. This suggests that, 
when possible, data requirements should be stipulated by agencies in sufficient time 
for the design of phase II and III trials. It also suggests that researchers seek input from 
international organizations, particularly WHO, on trial designs, as was done extensively 
for RTS,S.  
FURTHER ANALYSES BUILDING UPON THE PATHWAY 
MVI built upon the decision pathway to independently analyze and anticipate ways in 
which results from the phase III trial might impact the pathway. It identified potential 
scenarios related to endpoints being studied in the phase III clinical trial which could 
impact decisions of one or more international organizations. Possible results for the 
following trial endpoints were identified:  
 Safety;  
 Efficacy against a) first or only episode of uncomplicated, clinical disease, b) 
multiple episodes of uncomplicated, clinical disease, c) severe disease, and d) 
mortality;  
 Duration of efficacy;  
 Additional efficacy from a booster dose administered 18 months after the 
primary vaccination;  
 Efficacy in different transmission settings; and  
 Results in each of the two age groups in phase III.  
A series of scenarios were generated by creating tables with the results of one 
endpoint on each axis (e.g. safety versus efficacy against severe disease). Over 500 
scenarios of trial results were generated and evaluated against pre-determined criteria 
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(Table 16). A key interpretation was that any scenario with a concerning safety 
imbalance in RTS,S vaccinees over the control group, regardless of the efficacy, may 
lead to meetings with key stakeholders to discuss overall implications for study 
continuation. 
TABLE 16. FIVE POSSIBLE RESULTS FOR EACH SCENARIO ANALYZED, WITH POSSIBLE 
IMPLICATIONS. 
Score Category of result  Possible implications 
1 Exceptional Potential change of course; evaluate options for 
acceleration. Meet with key stakeholders to discuss 
overall implications 
2 Equivalent to phase II Proceed with current plans 
3 Worse than phase II 
on a key variable 
Cautious planning for implementation; ensure strong 
contingency plans in place 
4 Slightly worse than 
phase II on multiple 
variables 
Decision based upon final study data and/or booster 
dose before moving to implementation planning; look 
for site- or transmission setting-specific trends  
5 Significantly worse 
than expected  
Meet with key stakeholders to discuss overall 
implications  
 
LIMITATIONS AND CHALLENGES 
The research had a number of limitations. The decision pathway was premised upon 
organizations making largely supportive decisions; i.e. planning for success. Initial 
decisions can be qualified or limited; potentially leading to more comprehensive 
decisions after additional data is available. This was the case with WHO’s initial 
decisions regarding ACTs and Hib vaccine, which were followed by more 
comprehensive decisions recommending implementation of the interventions some 
years later. The analysis of scenarios by MVI, described above, was one strategy to 
anticipate the implications of different trial data on organizations’ decisions. The 
phase III trial design also seeks to increase the likelihood of comprehensive 
recommendations. The trial includes eleven sites in settings with different malaria 
epidemiology in order to be able to provide data leading to policy recommendations 
across sub-Saharan Africa. If RTS,S is safe and efficacious, decisions on trials in other 
parts of the world would need to follow.  
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The research was limited to roles and decisions (e.g. policies, recommendations, and 
guidelines) of international organizations, while use of an intervention by an individual 
person in a developing country requires many additional steps. It excluded the 
decisions of international organizations about the technical assistance they might 
provide to support regulatory review and/or implementation by countries. MVI and 
WHO worked separately with African countries on regulatory strengthening through 
the African Vaccine Regulatory Forum (AVAREF). It intentionally excluded decision-
making of individual countries, and communities and individuals as it was felt those 
groups were best addressed with different methodologies. MVI, WHO, and partners 
worked with countries to anticipate the processes and data needed for national 
decisions on malaria vaccines, and MVI worked with African collaborators on 
community and individual acceptability of malaria vaccines [81,96]. These activities 
have been mutually reinforcing. For example countries identified that they wanted to 
give input into decisions on characteristics of a malaria vaccine to ensure they would 
be programmatically suitable for developing country health systems and acceptable to 
end-users. Including country input into intervention characteristics was identified in 
parallel as an activity on the decision pathway as contributing to policy decisions, and 
addressed as noted above.  
It is unclear what organization is best placed to implement, or serve as the coordinator 
for such research. In this situation, MVI foresaw the need and supported it financially 
and managerially. This role was consistent with its mandate as a product-development 
partnership (PDP) building collaborations between non-profit and for-profit 
organizations. Universities and research institutes in the developed or developing 
countries, WHO, and others could all implement such research. It is most likely 
important for WHO to be deeply involved, regardless of who leads it. MVI did not 
explicitly show up on the pathway. MVI’s main responsibilities related to the clinical 
development plan and supportive coordination, while international decisions were 
seen as the role for WHO and others. MVI did help address specific research questions 
arising from the pathway, such as analyzing historical data required for WHO 
decisions, as described previously.  
The use and maintenance of a decision pathway is not without challenges. After 
completing the first decision pathway, maintenance may be complex and time 
consuming as R&D and organizational timelines shift. It can also be difficult to manage 
confidential and non-confidential information if the pathway is widely shared. In 
addition, some may see it as a workplan, particularly if developed with target dates for 
activities and decisions. However it is probably better seen as a strategic plan or 
roadmap while an intervention is some years before regulatory approval. It can trigger 
someone to enquire if an activity should still be done in a given timeframe and show 
up on an organization’s internal workplan, as opposed to being a list of deliverables at 
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the end of a year. It can also get more concrete and precise in each iteration as an 
intervention progresses through clinical development.  
A new health intervention, particularly one that is on track to be the first of its kind, 
requires an at-risk commitment of time and resources from international 
organizations; an intervention can fail at any point. This risk needs to be balanced 
against the delays documented previously from not acting. Activities need to be 
carefully paced to match scientific milestones. Planning should not get ahead of 
scientific progress, but also not fall behind as appears to have happened for other 
interventions.  
OPPORTUNITIES FOR INNOVATION AND FURTHER ACCELERATION 
The RTS,S decision pathway helped inform, and was informed by, an innovative phase 
III design. Data will be available in a series of three batches, over approximately four 
years. This design was intended to support faster, more conclusive and more efficient 
decision processes by making as much data available as soon as possible. It allows 
regulators and other international organizations more time to consider data and 
prepare for their decisions, strengthening predictability and planning. It should further 
accelerate decisions once the final data is released, as WHO has suggested is possible 
relative to the years needed for past interventions.  
The release of trial data in three batches raises an intriguing strategy for acceleration. 
It raises the possibility that some organizations might consider making preliminary 
decisions after the first or second batch of data. For example, GAVI and/or GFATM 
could decide in late 2012 or 2013 that if the final data were to be consistent with or 
better than the initial batches and RTS,S were to be approved by regulators and 
recommended by WHO, then they would anticipate subsidizing its use in countries 
from 2015. Such a financing indication might impact organizations across the decision 
pathway. Perhaps most importantly, it could strengthen GAVI and/or GFATM given 
that they may require multiple years of advance planning to generate funds for future 
commitments.    
CONCLUSIONS  
Research leading to the creation of the decision pathway reported in this paper should 
contribute to faster, more conclusive and more efficient decisions by international 
organizations regarding the potential implementation of what is anticipated to be the 
first malaria vaccine. It should lead to decisions in months or a few years, as opposed 
to years or decades. The indications to date suggest that such promises can be 
realized. Five years in advance of the end of the RTS,S phase III trial, WHO has already 
indicated it may be able to make a policy recommendation within a year of trial data 
being available. Such an indication is unprecedented from WHO, to the author’s 
knowledge. This also reinforces the vision arising from the collaboration with countries 
PLANNING FOR NEW HEALTH INTERVENTIONS   
Roles of international organizations 82 
described above, that each country will be in a position to take a decision to use, or 
not, RTS,S within one to three years of its availability.  
A full measurement of the impact of the decision pathway work will only become 
feasible from 2015 and beyond as final decisions by international organizations and 
countries are made on RTS,S. But the evidence and experience to date gives 
confidence that such an approach will have a positive impact, leading to more timely 
decisions, early implementation of interventions, and additional lives saved. And as 
such, it should be considered for other new interventions that are being developed.  
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ABSTRACT 
When a new health product becomes available, countries have a choice to adopt the 
product into their national health systems or to pursue an alternate strategy to 
address the public health problem. Here, we describe the role for product 
development partnerships (PDPs) in supporting this decision-making process. PDPs are 
focused on developing new products to respond to health problems prevalent in low 
and middle income settings. The impact of these products within public sector health 
systems can only be realized after a country policy process. PDPs may be the 
organizations most familiar with the evidence which assists decision making, and this 
generally translates into involvement in international policy development, but PDPs 
have limited reach into endemic countries. In a few individual countries, there may be 
more extensive involvement in tracking adoption activities and generating local 
evidence. This local PDP involvement begins with geographical prioritization based on 
disease burden, relationships established during clinical trials, PDP in-country 
resources, and other factors. Strategies adopted by PDPs to establish a presence in 
endemic countries vary from the opening of country offices to engagement of part-
time consultants or with long-term or ad hoc committees. Once a PDP commits to 
support country decision making, the approaches vary, but include country 
consultations, regional meetings, formation of regional, product-specific committees, 
support of in-country advocates, development of decision-making frameworks, 
provision of technical assistance to aid therapeutic or diagnostic guideline revision, 
and conduct of stakeholder and Phase 4 studies. To reach large numbers of countries, 
the formation of partnerships, particularly with WHO, are essential. At this early stage, 
impact data are limited. But available evidence suggests PDPs can and do play an 
important catalytic role in their support of country decision making in a number of 
target countries.  
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INTRODUCTION 
For health innovations to have their full impact, they must reach those in need. This 
job of achieving access is a multifaceted endeavor[132–134] requiring consideration of 
issues such as financing [135], manufacturing [136], pricing [137], international policies 
[138], regulatory approval [139], translational research [140], end-user acceptance 
[141] and a strategic communication approach to decision makers [142]. Here we 
consider country decision making – the process by which a country weighs evidence 
and decides whether or not to adopt a new product into its national guidelines and 
practice [143,144]. Such policy decisions are necessary, but not sufficient, for 
subsequent implementation and public health impact [145], as has been shown by the 
delays from decision to implementation of artemisinin-based combination therapies 
for malaria treatment [146].  
Although the policy change process is ultimately controlled by the country, in low and 
middle income settings in particular there are many other actors who provide input 
and can strengthen local decision making [147]. One such set of actors is the product 
development partnerships (PDPs). These not-for-profit organizations were formed 
because commercial incentives had proven insufficient to draw for-profit companies 
into certain important areas, such as drug development for tuberculosis (TB), malaria, 
sleeping sickness and visceral leishmaniasis, vaccine development for HIV, TB, malaria, 
dengue fever, meningococcal meningitis and pneumonia, microbicide development for 
HIV, and insecticide development for vector-borne diseases [148].  
Over the last several years, these not-for-profit organizations have catalyzed the 
production of an increasing number of health products designed specifically for use in 
low and middle income settings, such as drugs for malaria and trypanosomiasis and 
diagnostics for TB. Although PDPs have been focused primarily on product 
development, they share a vision of realizing the public health impact promised by 
new products. PDPs have generally translated this vision into catalytic support both for 
global policy change and, in a limited number of countries, for activities which could 
lead to decisions on use, and therefore support uptake and introduction of the 
resulting products. Such activities are implemented in partnership with endemic 
countries and other organizations.  
Here, we explore how the PDPs can assist in the country decision making aspect of 
product introduction. Although we recognize the leadership of other actors including, 
most notably, country stakeholders themselves, our primary focus for this article is on 
the role of PDPs. Certain other organizations, such as the Hib Initiative, have focused 
on product introduction specifically, rather than on product development; these are 
considered more briefly for relevant lessons. After defining country decision making, 
we investigate the various roles for PDPs, how those roles are prioritized 
geographically, the partnerships required, and the specific approaches used by a 
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number of PDPs. This paper provides a set of baseline insights into support by PDPs for 
country decision-making. It will not define exactly what should be done in each 
situation, but provides extensive, concrete examples of what has been done and 
analyses why these approaches were chosen. It also summarizes the initial, as yet 
limited, data evaluating the impact of such work by PDPs. Although the role of PDPs in 
supporting country decision making is still evolving, we find some themes that we 
believe will be generally applicable for future efforts. 
HOW PDPS FIT INTO COUNTRY DECISION MAKING 
CORE AND VARIABLE CONTRIBUTIONS BY PDPS  
A definition of country decision making will be a useful starting point, before 
discussing a possible PDP role. Previously, country decision-making on new health 
interventions has been investigated from a variety of perspectives. This has resulted in 
decision-making frameworks [145,149–152], guidance on introduction [134,153], and 
descriptions of the types of evidence considered [143,154,155] or the methods [156] 
or processes [157] used for considering them. Multi-variate analyses have suggested 
which interventions are related to faster uptake [158]. Although some authors have 
described supportive roles played by outside actors [147,151,152], in general the 
possible mechanisms for PDPs to support country decision making remain largely 
undocumented. 
Decision-making processes occur within the unique socio-political and economic 
context of an individual country, whereas a multi-country analysis such as this one 
must rely instead on broad process categories (see below). The relative importance of 
other elements influencing decision-making, such as media pressure, corruption and 
politics, may vary greatly from country to country [159], and therefore are not 
addressed in detail here. Furthermore, we acknowledge that in any political system 
the use of evidence-based decision making is a goal, and not always a reality.  
For the purposes of this paper, we have adopted a simplified framework, assuming 
country decision making requires background information (to elicit problem 
identification [160]), evidence to feed into decision making, and a process to consider 
that evidence. Within the information and evidence categories are many sub-
categories to be considered by country stakeholders, including public health priority, 
disease burden, efficacy, quality, safety, comparison with other available 
interventions, presentation, supply (procurement and distribution), financial impact, 
and programmatic strength [153]. The process category includes, critically, the 
identification and convening of a sufficiently broad group of stakeholders who have 
the mandate and resources to identify and review evidence; this group can be under 
the aegis of the government (a specific disease control program, the broader Ministry 
of Health, the Ministry of Finance, a specific agency for technical assessment, or some 
PLANNING FOR NEW HEALTH INTERVENTIONS   
PDP support for country decision-making   88 
combination of these agencies) or independent of but mandated by the government 
[144,147]. The final result should be a policy conclusion and, if the decision is 
supportive, implementation. At the center of this process is the country itself, 
supported by a range of local stakeholders and partner organizations.  
As noted by Frost and Reich, “the production of acceptance [is] an active process of 
social construction, not a passive process of waiting for various experts to agree on key 
elements related to the use of a health technology” [132]. If this active process is 
missing or under-resourced, effective country decision making is jeopardized. Indeed, 
many challenges have arisen during country decision making. For example, malaria 
regimen change in Kenya was delayed due to a lack of national and international 
standards (e.g., varied criteria for chloroquine sensitivity and efficacy markers), 
insufficient evidence (of side-effect incidence and the true costs of new drug 
implementation), no national compendium of relevant data, uncoordinated local 
research studies that could not be compared to each other, and ineffective 
mechanisms for communicating research evidence to sub-national stakeholders. This 
resulted in national guideline change happening 6 years after a call for evidence 
review and 14 years after the first local data on resistance [161], with the consequence 
that millions of patients were treated with ineffective regimens. In the area of TB 
regimens, the current data available (e.g., on drug resistance patterns) are useful for 
programmatic monitoring of current TB treatment but leave gaps for decision-making 
around future regimen changes [162]. On the process side, there were delays in 
another malaria regimen change due to insufficiently broad participation in decision 
making (e.g., exclusion of local manufacturers, the Ministry of Finance, and sub-
national implementers) [163]. Similarly, the change from 8- to 6-month TB regimens 
was delayed in high burden countries not only by insufficient evidence but also, in 
some countries, by unclear or non-existent procedures or bodies to consider regimen 
change [143].  
Table 17 presents examples of how PDPs can contribute to the core activities of 
country decision making. These contributions build on the familiarity of PDPs with the 
research programs and evidence base surrounding a particular intervention. 
There are a variety of additional PDP activities that can support country decision 
making but are only important under certain circumstances (Table 17). Such PDP 
access strategies and activities are project specific and focus on identified gaps: an 
awareness gap requires burden of disease studies or advocacy; whereas an evidence 
gap may require a cost-effectiveness study or operations research. Some of these 
activities require substantially more investment by a PDP. Furthermore, it cannot be 
assumed that global activities will reach policy makers in each country. 
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TABLE 17.  EXAMPLES OF COUNTRY DECISION MAKING ACTIVITIES.  
Country activity PDP support role 
Background information  
 Define national health priorities. 
 Obtain information on the 
future products that are likely 
to become available. 
 Conduct research to understand priority of disease 
area, generally, and likely desire for proposed 
product, specifically. 
 Disseminate product and pipeline information. 
Process and people  
 Ensure a decision-making body 
(or person) is identified, active, 
and has members empowered 
to make decisions based upon 
available evidence. 
 Define a clear, step-wise and 
timely process for country 
decision-making in general (in a 
particular disease or 
intervention area) and then for 
adoption of new products 
specifically. 
 Facilitate awareness raising and transparent 
information sharing among appropriate 
stakeholders. 
Evidence base  
 Define the specific evidence 
base required for decision 
making, including local data 
requirements. 
 Make plans to generate this 
required local evidence base. 
 Determine what information is expected to be 
needed for national decision-making (e.g., what 
efficacy endpoints). 
 Integrate consideration of these information needs 
into R&D activities. This affects, for example, 
clinical trial planning, development of regulatory 
strategies, and post-introduction strategies to 
monitor safety and impact. 
 Assist countries to define data needs and gaps, 
including clarifying if the information (e.g., on 
program and budget impact) should be generated 
in a country or internationally. 
 Gather and disseminate a standard evidence 
package informing decision making, or see that 
others do so. The data should come from a source 
or partnership that is credible to countries. 
 Train key personnel to respond to questions about 
the data or lack thereof. 
 Address concerns that are common across 
countries (e.g., price, cost-effectiveness, ease of 
use, source and geography of manufacturing, and 
impact on supply chain and existing program 
delivery). 
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A number of these PDP activities are focused on capacity building for decision making 
in general, including the capacity for a country to decide not to adopt a PDP-related 
intervention. For example, a PDP can help to catalyze the establishment of decision-
making structures or processes by identifying current gaps and highlighting future 
decision-making needs [164]. These capacity building efforts are likely to be 
insufficient for health systems in general, however, given the limited geographic and 
product foci of PDPs, and the lack of mandate from the PDPs’ donors for open-ended 
capacity building. For example, the categories in Table 17 and Table 18, and the case 
studies provided below, are based on the PDPs’ analyses of the bottlenecks within a 
specific modality and disease area. Thus, the activity of other organizations to 
implement broader capacity building efforts, such as the establishment of National 
Immunization Technical Advisory Groups (NITAGs) [165], will remain critical and can be 
complemented by the work of PDPs. 
Experience from the Hib Initiative suggests that generating data, and bringing the data 
to the attention of country stakeholders, may be an important part of catalyzing 
decision-making [142]. PDPs are one contributor to this activity, as part of the complex 
decision-making environment described previously. Each of the many stakeholders will 
bring some perspective, history, and perceived conflict. For PDPs, they may be seen as 
contributing a product or technology-biased emphasis. In contrast, a local researcher 
may emphasize the need for additional studies for which he or she would be funded, 
or a government official may be under pressure from a politician. It is critical to note 
that PDPs, to the authors’ knowledge, do not have direct profit motives, unlike 
manufacturers, when supporting decision-making. The underlying rationale for PDPs is 
to help address a public health problem, for which the intervention arising with PDP 
support can be evaluated by a country for its role, or not, as one locally appropriate 
solution. 
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TABLE 18. EXAMPLES OF ADDITIONAL SUPPORT ACTIVITIES BY PDPS. 
Additional support activity by PDP Situation when needed or not needed 
Background information  
Investigate disease burden, and share 
information with policy-makers. 
Less need if disease is well characterized 
and recognized, and if there is already 
sufficient baseline surveillance to monitor 
impact. 
Prioritize product introduction activities 
geographically based on disease burden, 
resistance patterns, or risk in specific 
populations. 
Less relevant if disease is widespread and 
resistance patterns and risk factors vary 
little. 
Process and people  
Catalyze the establishment of decision-
making structures. 
More need if bridging two fields in public 
health (e.g., immunization and malaria); 
less need if strong, defined structures 
already exist. 
Support local advocacy or 
communications activities to inform 
policy makers about a disease and/or 
options for addressing a disease. 
Depends on involvement of others who 
may undertake this, e.g., WHO and/or 
global disease partnerships. Global 
communications cannot be assumed to 
reach country level. 
Evidence base  
Influence key aspects of the product 
development process that impact 
decision-making, such as pricing, supply, 
financing and regulatory issues, and 
demand estimation. Support the 
development and sharing of international 
policies, and of a post-introduction 
surveillance plan. 
Depends on specific role of PDP in a 
country and in developing the product. 
Generate or compile local evidence 
required for decision making, potentially 
including the funding and/or running of 
Phase 4 studies or operations research. 
Depends on clearly defined needs from a 
country, whether the country can act as a 
regional or global source of data, and the 
willingness, local staffing, and available 
resources from PDP. 
Support countries to make decisions 
about a complementary mix of 
interventions. 
Only relevant if other interventions for 
the disease are widely used or being 
considered. 
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BASIS IN RESEARCH 
Country decision-making, if it is evidence based, should be a mechanism to link 
research to policy. For PDPs, such a link forms most readily in countries where PDP-
sponsored clinical trials are underway. In turn, a PDP’s access strategy, and in 
particular its approach to country decision making, often emerges from engagement at 
country level during the clinical trial stage.  
During the clinical trial approval process, PDPs naturally form links with countries via 
national regulatory authorities and ethics committees. But it is local researchers who 
generally lead the local implementation of PDP-supported clinical trials. To date, PDPs 
have found that it is important to proactively support a link between these local 
researchers and other endemic country stakeholders. This link can be through formal 
committees from the conception of the project and during the clinical trial phase, or 
via regular, informal briefings. If initiated early enough, this allows the PDP to share 
relevant background information with the country, increase the trust in and 
interpretability of resulting trial data, and ensure the product developed meets the 
country’s needs. Local stakeholders can become partners in the project and can help 
to build country ownership of, and familiarity with, a product.  
Once it is time for a decision, local researchers (rather than the PDPs) are best suited 
to present evidence to local decision makers and communicate directly with a 
government agency. Furthermore, it is more credible for the PDP to engage local 
stakeholders on technical grounds, and to provide them with the technical arguments 
they need so that they (rather than the PDP) can take part in the later, more political 
parts of the decision making process. In countries where no clinical trials are 
underway, the scientific and academic community is a key partner and translator of 
research findings in policy discussions. 
MORE EXTENSIVE PDP INVOLVEMENT: THE ACCESS ARCHITECT AND LOCAL EVIDENCE 
Ultimately, it is country stakeholders who drive the two critical processes: defining 
what evidence base is necessary for product adoption and launch; and making the 
decision itself. The extent to which international actors assist this process depends on 
the country: it occurs more in the lowest income countries and less in more technically 
experienced, research-intensive countries [143]. At the country level, as at the global 
level, the PDP can provide information on programmatic implications and a 
standardized public health case weighing the evidence for and against adoption. This 
may represent a time-limited, targeted commitment from a PDP. 
Typically, however, passive provision of this information is not enough to lead to clear 
country decisions [132]. Financing solutions are a key additional requirement, and 
there is often a need for an organization specifically responsible for tracking and 
coordinating all of the activities needed for access, including those activities needed 
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before decision makers will reach an adoption decision. Others have referred to such 
an organization as providing the “architecture” for access [132]. PDPs may either be 
prominent in this role or it may be taken by others such as a local research institute, 
an implementing NGO, or an international partner such as the World Health 
Organization (WHO) (see section below on partnership). 
Whichever organization is primarily responsible for supporting decision-making, they 
must interact extensively and directly with country stakeholders, particularly in 
countries identified as potential early adopters. This is not a role to be undertaken 
lightly.  
The other, often overlapping area in which PDPs may become more heavily involved is 
the generation of local evidence. PDPs have an awareness of the evidence currently 
available, so they can help countries to determine which data need to be generated at 
a local level, versus provided from global studies. To support local processes, PDPs can 
also introduce models that can be adapted to generate local data for multiple 
countries (e.g., the International Vector Control Consortium (IVCC)’s monitoring tool 
(see below) and the PATH Malaria Vaccine Initiative’s (MVI) impact and cost models). 
Finally, PDPs can minimize the need to generate local data by uncovering existing local 
data at universities (programs and WHO may be unaware of these data) and by 
explaining why certain data were not needed if they would not affect the final 
decision. 
Some PDPs devote considerable resources to the generation of local data; others 
devote almost none. This variability is determined in part by the earlier gap analysis – 
local data may or may not exist or be needed. The effort to generate local data is also 
determined by how novel an intervention is, either within its disease arena (e.g., a 
malaria vaccine coming into malaria control raises a number of local data questions) or 
by the existence of a program with clear accountability in the country which is already 
collecting such data (e.g., TB programs already hold extensive data on existing 
treatment regimens).  
When PDPs do engage in these local processes, it is important that they do so with a 
health system rather than single product perspective. The PDP should define how the 
new intervention will fit with, affect, and strengthen other aspects of the existing 
public health environment, including all current and potential strategies to address a 
disease. This is how decision-makers in disease control programs think and they will be 
more likely to engage with the PDP if such an approach is demonstrated [166]. A 
disease approach can also bring in allies from other areas that might otherwise be 
competitors. An example of this is the Introducing New Approaches and Tools (INAT) 
sub-working group of the Stop TB Partnership, which looks at ways to encourage the 
adoption both of new technologies and of new guidelines and practices [167]. Finally, 
if necessary, PDPs and other partners should facilitate the formation of a normative 
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decision making process that covers all interventions in an area, not just those 
sponsored by the PDP [147].  
THE GEOGRAPHY OF PDP SUPPORT OF COUNTRY DECISION MAKING 
ROLE OF INTERNATIONAL PROCESSES 
International institutions reach decisions and issue guidelines that are often 
precursors to country-level decision making. For example, WHO recommendation will 
be essential for adoption of PDP-related products in many if not all of the relevant 
endemic countries. PDPs generally interact extensively with WHO to discuss what 
evidence is available or needs to be generated for the international guidelines process.  
For some new health interventions, there is no specific, historical pathway for 
establishing international policies. This was the case for a candidate malaria vaccine, 
so MVI analyzed past WHO policy processes for vaccines and malaria interventions, 
identified data that could be required for a policy on malaria vaccines, and considered 
additional options for adjusting policy processes to accommodate a malaria vaccine 
[138]. PDPs can support the formation of international advisory and advocacy boards 
such as the Pneumococcal Awareness Council of Experts (PACE) and the All-Party 
Parliamentary Group on Pneumococcal Disease Prevention in the UK. These initiatives 
were instrumental in supporting the GAVI Alliance investment case and advance 
market commitment (AMC). It is reasonable to assume that working with or modifying 
existing policy processes, where feasible, will be less costly and more efficient for 
international partners than developing new processes. 
HOW MANY COUNTRIES CAN A PDP REACH? 
The number of individual countries with which a PDP can expect to interact directly is 
not clear. It seems likely that most PDPs would interact significantly with perhaps 5-8 
countries – notably those that have high disease burdens, are potential early adopters 
and are countries where the PDP is supporting clinical trials – but many PDPs would 
then rely on existing multilateral, NGO, and pharmaceutical partners to reach other 
countries for detailed work on adoption and implementation.  
At one extreme is the PDP-like Hib Initiative, which worked together with WHO to 
support directly or indirectly 72 countries [142]. GAVI supported this group with a 
four-year, $37 million grant, after noting the existing 15-20 year uptake delay in most 
low income countries. The Hib Initiative had no real role in product development but 
was funded to support evidence-driven decisions on Haemophilus influenzae type b 
(Hib) vaccine use at global, regional and country levels. Their approach, which involved 
engaging directly or indirectly with a larger number of countries, was seen to be 
necessary to implement a global recommendation for use of a long-available product. 
Substantial savings may be realized and less engagement needed if appropriate steps – 
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on financing, global policy and market preparation, for example – are taken during 
product development. 
PRIORITIZING COUNTRIES FOR ACCESS ENGAGEMENT 
If a PDP is going to invest significantly in supporting a country, it first needs to 
determine which countries are the highest priority. Prioritization generally considers 
two goals, which may or may not overlap: maximizing final public health impact; and 
identifying early adopters. Prioritization may also reflect an effort to include settings 
reflecting the full range of epidemiologic patterns of the disease (e.g., for malaria). 
Prioritizing countries for engagement on access-related issues is not a science – there 
is no perfect answer. Different PDPs are likely to use shorter or longer lists of criteria in 
making such decisions. However, most PDPs will consider a number of the following 
criteria, with the more important listed first: prior engagement via PDP-sponsored 
trials; high burden of disease (absolute or reflecting specific patterns of resistance or 
vulnerability); potential health benefit (e.g., based on drug resistance patterns); 
political stability; capacity of national program to deliver treatment (e.g., focusing new 
vaccine interventions on those countries with strong EPI programs); existence of local 
champions and openness to change; research capability for a pilot, which would 
generate evidence for other countries; regional importance of country; regulatory 
capacity and influence; and availability of other information for decision making. 
WHO regional advisers can also provide prioritization guidance. In support of the 
introduction of Hib vaccine, WHO regional EPI officers helped the Hib Initiative to 
identify issues and barriers for each country and define whether country stakeholders 
were already including Hib in their multi-year plans. A country’s application to the 
Global Fund to Fight AIDS, TB and Malaria can provide similar insights. History can 
provide some hints about likely future actions [143], although the history of Hep B 
adoption provided the Pneumococcal Vaccines Accelerated Development and 
Introduction Plan (Pneumo-ADIP [140]) with few clues for the introduction of the 
pneumococcal vaccines, probably because of turnover of decision makers and 
different local champions for the two vaccines. 
Once countries are prioritized, they may express an interest in conducting 
demonstration projects. As product developers, PDPs are focused on generating 
evidence from randomized, controlled clinical trials. Often, however, such evidence is 
not sufficient for adoption. After Phase 3 trials are complete, a deep investment may 
be needed in a few countries to help generate examples or evidence that an 
intervention works under real-world conditions (e.g., community effectiveness). 
Although countries vary, such test cases can boost the profile of a new intervention 
and result in funding for roll out in further countries. PDPs may help to build these 
early success cases and formulate roll-out plans.  
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STRATEGIES FOR ESTABLISHING A LOCAL PRESENCE 
Once a country has been prioritized, a PDP must decide whether and how to establish 
a local presence. A PDP with staff in an endemic country will have clear opportunities 
for improved information flow and closer engagement with local stakeholders. 
However, PDPs were primarily founded as research organizations, so budgets for an 
endemic country presence are usually driven by organizational needs such as those 
related to clinical trials. Aside from the Medicines for Malaria Venture (MMV)’s office 
in Uganda, offices associated with PDPs are not generally set up primarily for an 
access-related purpose. 
The options for establishing a local presence, listed from most to least committed, 
include: country or regional offices, including with a partner organization; consultants 
on partial retainer; sustained engagement with existing committees or structures; 
engagement with ad hoc committees or structures formed at the prompting of a PDP; 
or ad hoc engagement with existing structures (e.g., regional or sub-regional disease-
specific committees or meetings organized by WHO). 
Local expertise, in the form of either PDP staff or consultants, is critical to ensure a 
high quality interaction with government officials and partner organizations. For 
example, disease-specific and health systems knowledge, and sufficient standing to 
collaborate with government officials, physicians and researchers are important. Such 
individuals can help to design and facilitate local research and to provide local 
researchers and policy makers with PDP support for decision-making activities. Even 
beyond their own staff and consultants, PDPs may also help to strengthen the pool of 
scientists, who at the same time become stronger advocates within their regions and 
countries; examples include MVI’s annual Malaria Vaccine Advocacy Fellowship 
Program, the Drugs for Neglected Diseases Initiative (DNDi)’s research platforms, or 
Pneumo-ADIP and Hib Initiative’s local advocates. 
PDPs vary in their in-country presences (Table 19), with the extent usually increasing 
as products move further through the pipeline. PDPs within larger institutions such as 
PATH are also able to leverage competencies in multiple offices. 
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TABLE 19. PDP OFFICES IN ENDEMIC COUNTRIES. 
PDP Offices in endemic countries 
Drugs for Neglected Disease Initiative 
(DNDi) 
Kenya, Brazil, Democratic Republic of the 
Congo, India, Malaysia, where it may be 
as small as a 1-person office 
PATH Malaria Vaccine Initiative (MVI) PATH office in Kenya with dedicated MVI 
program staff, plus PATH offices that can 
be called upon such as in Senegal, Ghana, 
Ethiopia, Uganda, Tanzania, Zambia, and 
South Africa 
Medicines for Malaria Venture (MMV) Uganda, initially for pilot of AMFm 
(Affordable Medicines Facility – malaria), 
now for regional interactions on guideline 
revisions 
Institute for One World Health (iOWH) India 
Global Alliance for TB Drug Development 
(TB Alliance) 
South Africa – focused on clinical trial 
conduct rather than access 
Foundation for Innovative New 
Diagnostics (FIND) 
India, Uganda 
International AIDS Vaccine Initiative (IAVI) India, Kenya, South Africa 
Aeras Global TB Vaccine Foundation 
(Aeras) 
South Africa 
International Partnership for Microbicides 
(IPM) 
South Africa 
 
In sum, the rationale for the country presence of PDPs has been driven by research 
and development (R&D) or organizational needs (including limited funding), with 
access activities building upon that presence. This suggests that access teams should 
seek to be part of decisions on where R&D activities are undertaken. PDPs have also 
tended to take advantage of less costly means for engaging with greater numbers of 
countries by working through existing committees and structures (including WHO), 
developing new structures for sustained engagement where feasible, or otherwise 
working through ad hoc collaborations. 
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THE ESSENTIAL ROLE OF PARTNERSHIP 
For PDPs to achieve their goals, partnership is essential. PDP access staff can initiate 
these partnerships by bringing together different parties, such as scientists, 
manufacturers, regulators, and implementers. This combination of perspectives from 
the scientific, commercial and public health worlds can support more informed 
decision making [165].  
In order to reach multiple countries, the involvement of WHO headquarters, country 
and, in particular, regional offices has been and will remain critical, particularly for 
diseases such as HIV/AIDS, TB and malaria that have a significant number of WHO 
staff. Regional WHO offices can track the progress of multiple countries as they move 
through the multi-part decision process. Table 20 describes possible partners, 
including WHO, and some of their advantages and disadvantages. 
Manufacturers have traditionally supported some aspects of country decision-making 
and all the aspects of product launch. However, many originator companies may have 
limited experience of introduction into low and middle income country markets (some 
Indian and Chinese generics may be more established in these markets). Companies 
may also be concerned that they could be perceived to be self-serving if supporting 
decision-making around the introduction of a new product directly in countries. Thus, 
the initial information sharing and country decision making step will generally require 
the involvement of other actors, including PDPs. 
An interesting example of division of labor comes from Uganda, where PATH, a not-
for-profit that has worked extensively as a PDP, is supporting a demonstration project 
for human papilloma virus (HPV) vaccines (E. Mugisha, pers. comm.). Before any 
activities started, PATH signed a Memorandum of Understanding (MOU) with the 
Government of Uganda (GoU) to specify who would do what. The GoU committed to 
provide health services delivery infrastructure, human resources in the districts, and 
EPI staff for delivery of the vaccine. The two PATH technical staff members, located in 
the WHO Uganda office, provided technical and logistical support. PATH also provided 
transport allowances (but no per diems) to health workers in the field and funded local 
university researchers to conduct the formative research and operations research. 
WHO and UNICEF participated in a technical advisory committee set up by the Ministry 
of Health (MoH) to oversee the demonstration project, and also helped with 
monitoring of vaccination. The relevant pharmaceutical company (GlaxoSmithKline 
Biologicals (GSK)) donated and shipped vaccines to Uganda, but had no other role in 
the project. UNFPA and other stakeholders provided input on reproductive health 
issues, and NGOs (e.g., CARE and Save the Children) helped with mobilization in the 
districts. Thus, PATH served as the glue across the various organizations in support of 
the MoH.  
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TABLE 20. PARTNERS WHO CAN SUPPORT COUNTRY DECISION MAKING, IN 
COLLABORATION WITH PDPS. 
Partner Advantages Disadvantages 
Multilaterals such as WHO Extensive reach and 
impartiality 
Limited staff and restricted 
funding; May be 
overwhelmed by other 
initiatives and thus lack 
time and resources to 
devote to new 
interventions 
Organizations dedicated to 
new product access, such 
as those funded by GAVI 
(e.g., Hib Initiative, 
Accelerated Vaccine 
Introduction Initiative 
(AVI)) 
Dedicated funding for 
access activities 
Typically have a multi-
country remit which limits 
depth of engagement in 
individual countries 
Local academia, 
researchers and/or 
professional organizations 
Close to in-country 
processes, needs and data; 
Credible with local policy-
makers 
May not have a broad view 
of a problem; May be 
influenced by personal 
research interests 
NGOs Some have specific 
expertise in new product 
introduction 
May require funding 
specific to the new product 
to support their activities, 
and may not be involved in 
official decision-making 
bodies 
Pharmaceutical and/or 
manufacturing partners 
Product-specific expertise, 
regulatory expertise, and 
in some cases extensive 
sales networks in some 
markets 
May be seen as a biased 
source of decision making 
information; may lack 
experience in the disease 
and/or in low and middle 
income settings 
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CHALLENGES TO PDP IMPLEMENTATION 
There are many challenges for PDPs in supporting country decision making. Creating a 
success story in one location is certainly important, but just getting the process right in 
one country won’t necessarily allow replication, as each country is different. The PDP, 
however, is unlikely to have the resources to replicate the same breadth of activities 
with all endemic countries.  
There is also an issue of managing expectations. Country decision making is driven by 
the country, not the PDP. Conveying this idea of public sector policy change to R&D 
staff, PDP boards and funders can be challenging. Furthermore, PDP boards often 
think that local implementation partners can do it all, so local engagement by the PDP 
is not necessary. But partners are focused on many other issues, and often do not 
have the full depth of information on a given intervention.  
Finally, optimal engagement timelines are unclear. Advance planning is risky as 
product timelines are uncertain, but without early engagement (e.g. 5 years pre-
licensure), country decision making may be delayed and products will sit unused on 
shelves. In terms of PDP access budgets, a critical step will be to address the number 
and cost of Phase 4 studies, determine who will bear the burden of financing them 
(e.g., donors and PDPs, manufacturers, countries or some combination), and define 
models to bring those costs down. 
SPECIFIC PDP APPROACHES FOR SUPPORTING COUNTRY DECISION MAKING 
ACTIVITIES 
Despite these challenges, successful PDP support of country decision making is 
possible. The case studies below illustrate that PDPs have taken many distinct 
approaches to facilitating country decision making. These are examples of what has 
been done, rather than normative descriptions of what would be ideal. They were 
selected to represent a range of modalities (e.g., vaccine, drug, and insecticide) and 
disease areas, and the kinds of activities conducted at different stages of the decision 
process (presented below in roughly chronological order). Different PDPs have 
undertaken a range of activities, such as shown in Table 17 and Table 18, with this 
selection depending on needs identified by each PDP, typically in consultation with 
partners like WHO and countries. Not surprisingly, the more extensive experience 
generally lies with the PDPs who have approved products. 
ENGAGEMENT PRIOR TO PRODUCT AVAILABILITY 
For DNDi, country engagement begins with the identification of needs by and with 
endemic country stakeholders. Certain key research organizations in endemic 
countries contributed to DNDi’s founding, are represented on its Board of Directors, 
and greatly inform the definition of needs and of the related Target Product Profiles 
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(TPPs). These organizations also facilitate clinical and intervention trials and, 
ultimately, national decisions on adoption.  
Three additional PDPs, whose activities are outlined below, do not yet have products 
approved by regulatory agencies but nonetheless conduct activities related to country 
decision making. For malaria vaccines, MVI initiated a 3 year process with countries, 
WHO and, in the later stages, the Roll Back Malaria Partnership (RBM) to develop 
decision-making frameworks, initially for 9 individual countries and then for the 
African region [164]. The final framework builds upon existing WHO guidelines [153], 
and lays out what data are needed from different sources (global vs national), in 
different thematic areas (disease burden, other malaria interventions, impact, 
financial, efficacy, safety, programmatic, sociocultural), and at different times (pre-
licensure, licensure, and post-licensure); it also notes whether each is essential or 
desirable. It provides a similar framework for policy processes.  
The framework process has and will structure dialogues around malaria vaccines with 
countries around technical issues. In some countries, it has led to the formation of 
ongoing structures that have begun to collect data to inform an eventual decision 
(e.g., technical working groups – MVI now sponsors three of these).  
In contrast to MVI, the Global Alliance for TB Drug Development (TB Alliance) is 
entering an area that has existing products. There was, however, relatively little 
analysis of the market, of decision making, or of how new products would be 
considered. TB Alliance therefore focused on conducting sequential stakeholder 
studies in the following areas: the size and structure of the existing TB drug market; 
what local stakeholders want from a new TB regimen; how the experience with past 
TB regimen changes can inform future approaches; and what producers and products 
are dominant in the private sector. These studies helped to identify issues and 
categories of data relevant for future country decision making [143,162], initiate 
engagement with local stakeholders, provide opportunities for the promotion of 
regimen change issues in international fora, and frame conversations with local 
stakeholders during TB Alliance participation in WHO review missions. Finally, the 
findings of each study influenced the design and content of the next, and provided 
essential feedback for the research and development team [133]. TB Alliance selected 
this approach due to the opportunities and challenges presented by the availability of 
existing TB treatment regimens and partnerships. 
The long-term aim of IVCC is to facilitate the development and introduction of new 
insecticides. Already, however, IVCC is engaging country decision makers to address an 
identified gap in field implementation – the monitoring and evaluation of vector 
control programs. This gap is addressed via IVCC’s Malaria Decision Support System 
(MDSS), which is used to track clinical and survey data and insecticide resistance (T. 
McLean, pers. comm.). This tool is applicable to a wide range of diseases and, in 
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addition to monitoring and evaluation, it supports the management of advanced 
insecticides, and decision making on adopting new vector control products. Based on 
existing partnerships with the ministries of health, IVCC has validated the methodology 
in 3 countries – Mozambique, Malawi, and Zambia – with varied infrastructure and 
ecological environments; it is now planning wide-ranging implementation. As a central 
objective, the MDSS should be adopted and owned by the national malaria control 
program and serve their information needs.  
COUNTRY CONSULTATIONS AND REGIONAL MEETINGS 
Early and frequent consultations with countries are essential for the development of 
products that are suited to end users [133]. For DNDi, input is channeled via disease 
platforms, which were formed to assist and strengthen clinical research around 
specific diseases in a geographic area, e.g., VL in East Africa, sleeping sickness in West 
Africa, and Chagas Disease in Latin America. These platforms include country program 
staff, researchers, regulatory officials, NGOs and WHO and meet twice a year. Platform 
members became natural partners for country decision making as they gather relevant 
information on in-country issues, programs, and processes and convey key information 
to in-country decision makers. 
The Pneumo-ADIP (now part of the International Vaccine Access Center (IVAC)) built 
on experience with Hib and Hepatitis B vaccine introductions to support pneumococcal 
vaccine introduction [140]. Under the Pneumo-ADIP, the establishment of surveillance 
networks had two positive outcomes: it provided the requested data on projected 
coverage and impact and, via annual investigators’ meetings, led to the identification 
of local advocates. In addition, regional meetings organized in collaboration with WHO 
provided an opportunity to check back in and to move countries to put their decisions 
and proposed actions on paper by presenting their conclusions in front of others (L. 
Privor-Dumm, pers. comm.). These meetings included EPI managers, directors of 
health services, researchers, pediatricians, economists, and sometimes donors and 
financing people from MoH or other ministries, and were a particularly useful 
mechanism to support decision-making in countries not directly targeted through 
other interactions.  
MMV and its drug development partners have also made extensive use of country-
level dialogues such as subregional meetings (of WHO AFRO and Roll Back Malaria) 
and, in select cases, day-long workshops (G. Jagoe, pers. comm.). These provide 
opportunities to give product-specific briefings and to reinforce recommendations of 
normative entities (primarily WHO) in terms of best practice for the development and 
revision of treatment guidelines and for the correct use of new, quality medications in 
combination with proper diagnosis (case management). Longer-term programmatic 
collaborations in specific-countries are very limited; the focus is on any initiative (e.g., 
piloting of an affordable medicines private sector subsidy in Uganda) that address 
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specific access challenges and could serve as guiding lights for policy makers and 
funders across the larger stage of all malaria endemic countries. In terms of impact, as 
of September 2010, almost 42 million treatments of Coartem® Dispersible (co-
developed with MMV) had been delivered to 32 countries [168]. 
Regional meetings have been convened by the TB Alliance and partners to gain 
consensus around regulatory issues [169]. Existing TB drugs were developed more 
than 40 years ago, in a very different regulatory environment. Agreement was needed 
on the regulatory approach to development of not just individual new drugs, but new 
regimens. With the participation of national TB program managers in these meetings, 
these individuals became part of the conversation about what types of evidence would 
be available for decision making.   
IMPLEMENTATION STUDIES AS A BRIDGE TO ADOPTION 
When existing evidence is insufficient, implementation studies may be necessary. In 
India, the Institute for One World Health (iOWH) has supported studies to generate 
data for advocacy and decision making on Visceral Leishmaniasis (VL) treatment and 
elimination. In collaboration with a research institute of the Government of India, they 
documented the incidence of VL, the financial burden of disease, households’ 
willingness and ability to pay, and treatment-seeking behaviors in both public and 
private sectors (R. Sarnoff, pers. comm.). In addition, building on the necessary Phase 
3 study, iOWH sponsored a Phase 4 study with an effectiveness module that provided 
training, clinical support, and guidance on pharmacovigilance reporting, and 
demonstrated effective delivery in public and private facilities. The clinical trial 
investigators formed a core constituency for local advocacy for improved products.  
At the national level, iOWH leadership engaged with key stakeholders in the Indian 
government, World Bank and WHO to inform them of the progress of the studies, 
identify their key questions and concerns, and address future funding issues. Training 
modules and community communication models were developed for smooth transfer 
to the national authorities. 
DNDi has also used intervention or field trials as an essential step to demonstrate 
feasibility and generate necessary data for adoption into national programs (F. Camus-
Bablon, pers. comm.).  For example, Brazil conducted a 25,000-subject malaria 
intervention trial prior to adopting artesunate and mefloquine (ASMQ) for treatment 
of falciparum malaria in the Amazon basin. The trial monitored the effects of ASMQ 
introduction; during the study, a significant impact on malaria cases and related 
hospitalization also resulted from a more rational use of complementary resources 
such as insecticides, detection and reporting system, and from training of local human 
resources. In this study, one year after the introduction of the ASMQ fixed-dose 
combination (FDC) and the treatment of 17,000 patients, P. falciparum malaria cases 
were reduced by nearly 70% and malaria-related hospitalizations dropped by over 
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60%. Following the study, the Brazilian National Program updated the national malaria 
treatment guidelines and introduced ASMQ FDC as the first line treatment in the 
region. Advocacy is also a key component of DNDi implementation work, to inform 
both international audiences and endemic countries. 
In some areas, DNDi relies on pharmaceutical and other international partners. For 
example, WHO Neglected Tropical Diseases (NTD) department and Médecins Sans 
Frontières (MSF) are key drivers for the adoption of nifurtimox-eflornithine 
combination therapy (NECT) for the treatment of sleeping sickness, which, within a 
year, has been adopted in the national treatment policy of nine endemic countries and 
ordered by six. Sanofi-Aventis (SA), within two years of WHO pre-qualification, was 
planning to distribute 50 million artesunate-amodiaquine (ASAQ) treatments in 2010. 
Today, ASAQ is registered in 27 African countries and in India. SA is conducting a 
15,000 patient pharmacovigilance program in partnership with DNDi and MMV in Ivory 
Coast, and developed a specific package for social interventions and home based 
management programs. 
EVALUATION OF IMPACT 
There are significant challenges in estimating the impact of PDPs on country decision 
making. First, most PDPs are relatively young, being established in the last 10 years. 
Given the time required to develop a product, many have not yet had products 
launched, and the product launches that have occurred are recent. Second, there is 
not yet agreement on how to measure impact – in particular, whether to focus on 
usage (e.g., number of individuals treated; see the data on new product usage noted in 
this paper) or on process (the number of countries conducting a policy process and 
reaching the decision that is best for their particular situation; see [170] for an 
example). Third, if a product is suboptimal – too expensive, insufficiently efficacious, 
or too difficult to use, for example – it is unlikely to be rescued by PDP support of 
country decision making, even if those support activities are well executed. In other 
words, success under the first (“usage”) definition is only likely when the new product 
continues to meet identified country needs. This is why access input is essential 
throughout the product development process [133].  
There have, however, been efforts by PDPs to define metrics of success and to 
evaluate PDP work in support of country decision-making. For impact using the 
“process” definition of success, one example is the malaria vaccine decision-making 
framework [170]. The development of this framework has been independently 
evaluated [171]. Out of 84 respondents from 10 countries, 90% felt that the 
framework developed will be extremely or very useful in preparation for a decision 
(i.e., in deciding what activities to undertake prior to having a licensed product), and 
88% indicated the same for taking a decision after a vaccine is licensed. Facilitators 
were reported to be neutral instead of supporting one product.   
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A 2007 study by the GAVI Alliance tried to quantify the impact of the Pneumo- and 
Rotavirus ADIPs and Hib Initiative as compared to what may have happened if they 
had not been in place [172]. The authors found that the Pneumo-ADIP is likely to shave 
at least five years off the time from development to availability of vaccines in the 
poorest countries, and that the work of the Rotavirus ADIP may result in the poorest 
countries accessing vaccines only one year after availability in the developed world, 
which is years and decades shorter than historically. Based upon this, the authors 
reported “value in terms of lives saved and hospitalizations averted.” 
Given the constraints noted above, the current paper does not aim to provide a 
rigorous evaluation of PDP impact and strategies, but instead provides a situation 
analysis, reflecting the range of strategies undertaken by PDPs and detailing the 
rationale behind their choice. It is clear that having no engagement specifically around 
new products leads to lengthy delays in availability [132]. At the same time, it is too 
early to determine the optimal strategies for each situation and type of intervention. 
However, the current analysis provides an important baseline or reference point for a 
later impact analysis of PDP work on access. 
CONCLUSION 
A country’s decision to adopt a new health technology requires more than the 
existence of a good product. In low and middle income settings, a wide range of 
organizations can support country decision making. The role of PDPs in this process is 
based on the PDPs’ vision to see public health impact from the products they develop, 
and on their intimate familiarity with the products under discussion. 
A PDP as a whole can cover a wide spectrum of activities ranging from basic research 
to implementation of interventions. At the implementation end of this spectrum, 
there is no single definition of where the PDP role ends, as the technical needs and 
available partners in endemic countries vary for each intervention. However, as more 
PDP-related products progress, additional experience will assist in defining the areas in 
which PDPs are effective and should be held accountable. Funder, partner and country 
participation in the development of improved means to evaluate the relative roles and 
impact of PDPs will also be important. Building on the insights described here, PDPs, 
partners and country stakeholders can continue to provide critical support for 
decisions on interventions that will ultimately decrease the global burden of disease. 
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CHAPTER 6. COUNTRY PLANNING FOR HEALTH INTERVENTIONS UNDER 
DEVELOPMENT: LESSONS FROM THE MALARIA VACCINE DECISION-MAKING 
FRAMEWORK AND IMPLICATIONS FOR OTHER NEW INTERVENTIONS 
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ABSTRACT 
A growing number of new public health interventions targeting diseases found in 
developing countries are under development. Traditionally it has taken years or decades 
for these interventions to be accessible to those most in need. One reason for the delay 
has been insufficient anticipation of the eventual processes and evidence required for 
decision-making by countries. Development partners, international organizations, 
researchers, and product developers have not systematically identified the elements 
needed for national decision-making during intervention development, a factor that 
exacerbates the delays. This paper describes research into the anticipated processes and 
data needed to inform decision-making on malaria vaccines, the most advanced of 
which is still in phase 3 trials. From 2006-2008, a series of iterative country consultations 
in Africa led to the development of a guide to assist countries in creating a malaria 
vaccine decision-making framework. The guide identifies the processes and data 
countries believe would be critical or helpful, when the data would be needed relative to 
the development timelines of the intervention, and who should be responsible, broadly 
speaking, for generating the data. This generic guide can now be applied to any future 
malaria vaccine. The paper discusses the opportunities and challenges to early planning 
for country decision-making—from the potential for timely, evidence-informed decisions 
to the risks of over-promising around an intervention still under development. Careful 
and well-structured planning by countries is a critical way to ensure that new 
interventions do not remain unused for years or decades after they become available. 
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INTRODUCTION 
An increasing amount of money, $3.2 billion dollars in 2009 alone, is being spent on 
research and development for new products intended to address diseases prevalent in 
the developing world [1]. Assuming that even a fraction of these funds realizes the goal 
of creating new health interventions, low- and middle-income countries (LMICs) will face 
a growing number of decisions on which new interventions to use in the coming decade.  
This paper focuses on decisions related to the use of new interventions that are 
provided as part of national health systems in LMICs through public or donor funds. In 
this regard, it focuses on national decisions on whether or not to adopt a new 
intervention, once it becomes available (i.e. approved by the appropriate regulatory 
authorities and produced in sufficient quantities by a manufacturer.) Such decisions 
would be distinct from largely regulatory determinations to allow sales of a product 
through private-sector channels.  
National decision-making processes for public policies, and health policies more 
specifically, have been under study for decades. They can be seen as complex, non-linear 
processes, balancing evidence, policy alternatives and domestic and international 
politics [173–175]. Substantial efforts have been made to understand and therefore 
improve decision-making processes [176–181] and to generate the data needed by 
countries to facilitate decision-making, including data on burden of disease and on cost-
effectiveness of interventions  [182–185]. Countries also need to consider many factors 
specific to the targeted disease and the characteristics of the intervention, some of 
which are informed by international organizations and global experts (e.g. World Health 
Organization (WHO) policy positions; donor funding commitments) [176,186–189]. 
Within countries, there may be questions about coordination among different entities, 
particularly for an intervention that cuts across areas of specialization in public health. 
One example would be the human papillomavirus (HPV) vaccine that has required 
collaboration across reproductive health, immunization, and school health experts [190].  
The track record for adoption decisions and implementation of new health interventions 
in LMICs suggests that it takes years or decades for many countries to realize the 
benefits of new public health interventions [184,191–194]. Decisions are likely more 
complex for a novel, “first in class” intervention like a malaria vaccine, but less complex 
for a second-generation or follow-on intervention, such as a new anti-malarial drug that 
is meant to replace a less effective drug. While detailing the multiple reasons for these 
delays is beyond the scope of this paper, a recurrent theme has been the need for more 
thought during the development of a health intervention on what processes and data 
LMICs would need in order to make timely decisions on whether or not to introduce the 
intervention.  
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Evidence that insufficient planning for country decision-making is a major cause of 
delays in the use of health interventions is apparent in a number of areas.  The GAVI 
Alliance (GAVI) has pinpointed challenges in decision-making as a key factor in the delay 
to implement the Haemophilus influenzae type b (Hib) conjugate vaccine [195], a vaccine 
available in the developed world since 1987. The delay led GAVI in 2005 to invest 
USD$37 million in establishing the four-year Hib Initiative to provide support to 
countries wishing to decide if Hib vaccine is a priority for introduction and provide 
programmatic support to countries who have already decided to use it [196].  Reports 
on the process that is required to change malaria treatment policy suggest that the 
policy decision process itself takes one to five years, with an equal length of time for 
implementation [191,197–199]. One estimate suggests that changing treatment is likely 
to cost roughly $1 million in today’s currency for a reasonably large country like 
Tanzania [198]. Both GAVI and the Global Fund to Fight AIDS, TB, and Malaria (GFATM), 
the world’s largest organizations supporting adoption of new health interventions, 
recognize the challenges country-level decision-makers face. Proposals to either 
organization for support must demonstrate the functioning presence of a local partner 
and government coordination mechanism to support decision-making and 
implementation [200,201]. These requirements would not be called for if those 
organizations did not recognize the challenges inherent in national decision-making 
processes.  
The Hib Initiative and similar efforts are generally meant to “catch up” years or decades 
after an intervention is already available. Variability naturally exists between situations 
and across countries, at the same time, accelerating clinical trials to save one or two 
years on timelines to licensure of a new intervention only to have the policy and 
implementation process add years or decades suggests that more forethought is needed 
around national planning processes during intervention development. 
A different approach is for product developers, countries, and their development 
partners to plan in advance for new health interventions. Using the example of a malaria 
vaccine, this paper lays out a multi-year collaboration that was designed to anticipate 
the processes and data that countries would need to make decisions on whether or not 
to introduce a new health intervention. Such work was called for by the Malaria Vaccine 
Technology Roadmap, a plan laid out by 230 experts representing 100 organizations 
from 35 countries [202]. 
The most advanced malaria vaccine candidate is part-way through phase 3 clinical trials 
in Africa, the region where an estimated 91% of the nearly 800,000 annual malaria-
related deaths occur, almost entirely among children under five years of age [46,83]. If 
all goes well, WHO has indicated that a policy recommendation for RTS,S is possible as 
early as 2015, and implementation through routine infant immunization programs in 
Africa could follow. Anticipating national decision processes during the vaccine 
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development period is a critical part of making such a novel intervention accessible to 
those most in need. 
This paper will report on research to address the following specific questions during the 
clinical development period: 
1) What processes need to take place to allow countries to decide whether or not to use 
a malaria vaccine and when do they need to take place relative to the projected 
availability of a vaccine? 
2) What data would countries need for a decision on whether or not to introduce a 
malaria vaccine and when would they need the data relative to projected availability of 
the vaccine? 
The paper will go on to discuss the lessons gained from answering these questions for 
other new health interventions. 
METHODS 
The decision-making framework guide was developed through an iterative process from 
2005-2008 (Figure 12). The process was designed to create a framework applicable to 
any malaria vaccine developed. It was intended to understand what will be needed in 
order to achieve the following vision: National governments of malaria-endemic 
countries will have information to make timely and well-informed decisions about 
the appropriate use of a malaria vaccine within their national health systems within one 
to three years of licensure.  
A set of briefing papers was developed to provide background information on issues 
related to adoption of malaria control policies and new vaccines, and to serve as a 
foundation for consultations with countries. A series of country consultations was 
convened with a few dozen to more than 50 participants at each. The consultations 
included plenary presentations allowing African scientists and immunization, malaria, 
and other government and partner staff to discuss their shared experiences with 
researching and taking decisions on new interventions. Facilitated break-out groups 
used a semi-structured guide to identify what processes and data would be needed to 
take a decision to adopt, or not, a malaria vaccine, and when these processes and data 
would be needed. Plenary discussions were used to reach consensus on which processes 
and data points were critical, and which merely helpful. Draft meeting reports were 
circulated back to all participants for input prior to finalization. Meeting materials and 
reports were systematically posted to a public website [203].  
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FIGURE 12. TIMELINE FOR DMF GUIDE DEVELOPMENT PROCESS. 
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Meeting outcomes were analyzed to identify consistent findings across two or more 
countries. Outliers were considered according to their merit relative to published and 
grey literature. Resulting processes and data points were put into a regional decision-
making framework guide which was validated through consultations with countries. The 
process was independently evaluated through an online survey using qualitative and 
quantitative methods [204].  
RESULTS 
AFRICA REGIONAL GUIDE TO A MALARIA VACCINE DECISION-MAKING FRAMEWORK 
The validated regional guide contains 25 processes identified as critical, and six 
identified as helpful to have. The guide identifies 43 data points as critical and a further 
10 as helpful to have. The processes and data are also categorized by accountability for 
action—whether countries see them as largely being done by an international (e.g.  
global or regional-level) entity with data extrapolated to an individual country, or in an 
individual country with local data.  
Both processes and data points are presented according to a timeline related to product 
development, from as many as 5 years pre-licensure and  availability of critical phase 3 
data on safety and efficacy, to licensure and decision on use, to as many as 5 years post-
licensure if introduced. The processes are presented in two rows, reflecting either 
international or national responsibility (Figure 13). The data are presented in seven rows 
based upon WHO guidelines on new vaccine introduction (Figure 14) [189]. Only 
“critical” processes and data are presented in the figures. Full guides can be found 
online. (www.malvacdecision.net) 
An initial step identified by countries for national-level processes was to establish 
technical working groups (i.e. local expert groups) on malaria vaccines prior to 
availability of the phase 3 data. They then suggested that, when the vaccine is licensed 
and a decision taken, such groups would issue advice to inform the government’s policy 
decision. The guide leaves it up to each country to determine the specific remit and 
membership of such groups where they are established. Examples of the activities of 
such groups to date are discussed later.   
Initial global processes called for by countries included the importance of integrating 
country requirements into product development plans to ensure the programmatic 
suitability of a vaccine. Countries also called for global advocacy to fundraise for malaria 
vaccines starting prior to licensure, and identified WHO policy recommendations and 
guidelines on use as critical. 
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FIGURE 13. REGIONAL MALARIA VACCINE DECISION MAKING FRAMEWORK: CRITICAL PROCESSES 
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FIGURE 14. REGIONAL MALARIA VACCINE DECISION MAKING FRAMEWORK: CRITICAL DATA 
 
Legend: White boxes reflect country data; Shaded boxes reflect global data. 
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Countries indicated that they would want data on other malaria interventions from 
within their own countries as well as from international organizations prior to the 
availability of a malaria vaccine. The local data included coverage and impact of 
existing interventions. Countries would also want international data on the impact and 
cost-effectiveness of the range of available malaria-control interventions. The 
international data could come from WHO, the Roll Back Malaria Partnership (RBM), 
modeling, published literature and other sources. If a vaccine is introduced, they 
would then want to have local data on the changes in impact and cost-effectiveness of 
other interventions. Countries indicated that they would want national estimates of 
the affordability of a malaria vaccine at the same time as phase 3 data, with a 
sustainable national commitment in place after licensure but prior to an introduction 
decision. 
Countries indicated it was critical that the global community estimate the vaccine price 
for public use and provide information on donor subsidies at the same time as phase 3 
data, when countries would evaluate national affordability. Countries also indicated 
that data on the vaccine supply would be critical at the same time as phase 3, with 
additional evidence of supply security provided in the post-licensure period. 
SUMMARY FINDINGS OF THE EXTERNAL EVALUATION 
Participants gave the DMF guide development process high marks, with 96% indicating 
that they would recommend it to a colleague. More specifically, 90% indicated that 
the guide will be extremely or very useful for the preparation process prior to vaccine 
licensure, while 88% indicated it would be extremely or very useful for making 
decisions after a vaccine is licensed. In addition, 77% indicated it would be extremely 
or very useful when considering the decision-making process for other vaccines, 79% 
felt that the meeting facilitators were neutral (neither promoting nor discouraging 
introduction of a malaria vaccine), and an equal percentage felt that facilitators did 
not promote any specific vaccine under development.  
Interestingly, 70% indicated that the timing of the DMF guide preparation was about 
right, 5% indicated it was already too late, and 25% felt it was too early. The 
recommendations received form participants called for similar meetings to support 
technical development and central coordination of the information identified in the 
DMF guide. Such a process was seen as valuable to build the foundation of rapport, 
awareness, and coordination among high-level decision-makers, given that many had 
divergent expertise (e.g. malaria and immunization; research and program 
implementation).  
DISCUSSION 
The research described above demonstrates that it is possible to plan for national 
decision-making for a new intervention and that African health officials value this 
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process. The research also shows that developers, partners, and countries should 
begin to consider what will be needed by countries at least three to five years before 
an intervention is anticipated to be approved by the appropriate regulatory 
authorities. The actual timing of a decision relative to licensure, as well as the ultimate 
process, will vary among countries and interventions. A guide developed jointly with 
countries to establish the decision framework should increase the likelihood of 
evidence-based and timely decisions within that variability, but would not guarantee 
such an outcome.  
After the Africa regional guide was validated in 2008 as a common resource, MVI 
engaged a number of malaria and immunization program managers within African 
health ministries in a discussion on if, and if so, how, to start working on the 
requirements that will guide a decision on a possible first-generation malaria vaccine. 
Burkina Faso, Ghana, Tanzania and Uganda organized technical working groups to 
coordinate the process. The focus of the working groups is to assemble the evidence 
needed for a policy formulation and ensure systems are in place for a smooth decision-
making process. Under the guidance of each group’s chair, they develop annual or bi-
annual workplans, and members may choose to carry out the planned activities (e.g. if 
their institution conducts studies that can provide the information needed) or they 
may seek services elsewhere (such as for the conduct of a desk review pertaining to 
particular data needs). Composition and their modes of operating vary, but common 
features include: 1) They are linked to an existing group within the malaria control or 
immunization programs; 2) Members are from Ministries of Health (MoHs), research 
institutes and universities, and partner organizations (e.g. WHO country offices); 3) 
They are officially established by the senior management at the MoH; and 4) They 
report to a formal advisory body to the MoH. In Ghana and Burkina Faso, the 
coordination is led by the National Malaria Control Program and WHO. In the two 
other countries, the coordination is led by local, parastatal research institutions. MVI 
also began discussions in 2010 with Nigeria as it has more recently becoming involved 
in malaria vaccine trials. 
The process for the malaria vaccine decision-making framework benefited from a 
commitment to create a guide, building upon existing WHO guidelines, that was 
generic to any malaria vaccine to come and a focus on all vaccines under development 
instead of only one potential product [189]. Only after the guide was validated was 
there discussion of its application to specific products.  
The iterative nature of such a process creates an important forum for those who may 
not normally collaborate for reasons that may include different specialties in public 
health and splits between researchers and implementers, academia and government 
[177,197]. By creating a forum with a shared technical task, each group is able to apply 
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its unique skills to the shared technical challenge, which also strengthens and prepares 
messages informing political processes.  
One valuable outcome of research to plan for decision-making is the voice that 
countries can have. The process provides a structured means for countries to provide 
their input to those developing interventions. By identifying critical processes and data 
and by assigning responsibility to the international level, countries are signaling their 
expectations of developers and international organizations. The process also identifies 
areas, such as the product profile, in which countries would like to explicitly inform the 
work of developers, and it helps countries understand when such contributions are 
possible (i.e. years before an intervention is available.) Identifying the elements for 
which countries feel they should be held accountable informs and strengthens 
national planning capacity and management processes and provides a means for local 
researchers to collaborate and seek complementarities in their research.  
The process of developing the malaria vaccine decision-making framework guide also 
illustrated some of the challenges inherent in planning for decisions on whether or not 
to introduce an intervention that is still under development. The most significant 
challenges relate to the time constraints of national staff in light of current program 
priorities, to risks of interventions failing in late development, and to over-promising 
by developers. LMIC health system managers are typically pulled in multiple directions, 
responding to the immense challenges faced every day. It is essential to find an 
appropriate balance, not asking for too much time but keeping future interventions 
within view when looking to the future. Because of the many time constraints, 
concrete planning activities will generally require a local organization or part of the 
government to fill a secretariat and coordination role. This was described in the 
previous section. Secondly, this kind of planning also means helping those involved 
understand that a new intervention, particularly a novel one, could fail at any time. For 
example, a safety concern might arise during late clinical trials or efficacy may not be 
seen in certain populations. Lastly, development timelines, and to a lesser extent final 
intervention characteristics, are notoriously difficult to predict. Countries need to 
understand that timelines are rarely shortened, and that they are more typically 
lengthened by years. These three aspects can be mitigated by transparency, 
education, and care in not letting activities get ahead of accumulated scientific 
evidence. Taken together, these three aspects necessitate a cautious, carefully 
planned approach when discussing future health interventions with national decision-
makers.  
Another challenge is to properly contextualize discussions on a new health 
intervention relative to existing health interventions targeting the same disease, to 
other interventions of the same modality (e.g. drugs, vaccines), and to priorities within 
the wider health system [187,189]. A novel intervention like a malaria vaccine will 
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enter a complex arena of existing malaria control measures, an environment of 
multiple new vaccines being considered by countries, and a series of established 
health system priorities. In some cases, interventions may replace existing ones (e.g. 
an improved medication), although perhaps it is more cautious to assume a new 
intervention will co-exist for at least some time with others. For this reason, those 
supporting early planning should not be seen to be pushing a single product onto 
countries to the exclusion of other approaches.  
The basic processes and lessons described above are relevant for novel health 
interventions under development. Second-generation or follow-on interventions may 
not require the same level of research over multiple years. Precedents and advisory 
bodies may already exist [179]. Data may already have been collected on many 
essential aspects. However, a structured approach to confirm the processes and data 
needed, the pieces already in place, those that should be generated, and the relevant 
timelines, remains a valuable step during the development period of an intervention. 
Such exercises do not guarantee that policy decisions will be based only on evidence 
and all countries will go through a predictable process. Political decisions in some 
situations will triumph other factors [174]. Or there can be a last-minute scramble to 
agree on the evidence needed to support the decision and collect it.  
A structured approach provides clear insights into what data countries will need for a 
decision [177]. The process can help governments, researchers, community activists, 
and others to reach consensus on the type of evidence to base the decision on and 
have realistic expectations on what to expect from new interventions, the relevant 
timeframes, as well as funding requirements. It informs the work of those developing 
an intervention, allowing the clinical activities to respond to questions for public 
health/policy as well regulatory requirements. It is a capacity building and health 
systems strengthening exercise creating a pool of expertise to inform government 
decisions after the intervention is available, while allowing greater clarity on roles and 
responsibilities for different stakeholders and parts of government.  
When anticipating a decision-making process, those providing support must 
understand that their efforts may lead a country to decide to adopt an intervention, to 
decide not to adopt it, or to call for further studies. Countries with timely “no” 
decisions help international funding bodies, procurement agencies and manufacturers 
as they do their own long-term planning. Countries that are undecided can be the 
most challenging for these bodies. 
CONCLUSION 
This paper argues for the importance of early planning for country decisions on new 
health interventions. Malaria vaccines provide one example of an approach and 
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multiple lessons, identified above, should be considered for other new interventions. 
With any new intervention, the balance will remain between working “at risk” to 
anticipate an intervention versus the more traditional path of waiting until after 
licensure. The priority for health systems is to address health challenges, which means 
first using available tools. In addition, a small amount of time invested early on new 
interventions has the promise to pay off immensely down the road in terms of 
addressing those same health challenges. 
While there is always a risk that an intervention under development will fail as it gets 
into late development, the chances get slimmer and slimmer. One means of managing 
the development risk is for countries to do nothing until an intervention is approved. A 
second, preferred alternative is to determine which planning steps are appropriate 
and minimally invasive to take prior to intervention availability. One guaranteed 
outcome of the former, historical approach is that effective new interventions sit 
unused after development. This paper argues that the latter approach leads to better 
public health decisions and greater public health impact through accelerated decisions 
on whether or not to use a new intervention once available. 
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ABSTRACT 
INTRODUCTION 
Efforts to develop malaria vaccines show promise. Model-based estimates can be used 
to inform decisions by vaccine developers and policymakers on the use of malaria 
vaccines as complements to existing interventions. However, the complexity of such 
models often makes them inaccessible to non-specialists. This paper reports on a 
Malaria Vaccine Model (MVM) tailored to the needs of developers and policymakers. 
METHODS 
The MVM has three modules: supply and demand forecasting; public health impact; 
and implementation cost and financing requirements. These modules include pre-
entered reference data and also allow for user-defined inputs. The model includes an 
integrated sensitivity analysis function. Model functionality was demonstrated by 
estimating the public health impact of a pre-erythrocytic malaria vaccine with 85% 
efficacy against uncomplicated disease and a half-life of efficacy of four years, similar 
to internationally-established targets for 2025. Demand was estimated by adjusting 
historical vaccine implementation rates for routine infant immunization in 40 sub-
Saharan African countries over a 10-year period. Assumed purchase price was $5 and 
injection equipment and delivery costs were $0.40 per dose. 
RESULTS 
The model projects the number of doses needed, uncomplicated and severe cases 
averted, deaths and disability-adjusted life years (DALYs) averted, and cost to avert 
each. In the demonstration scenario, based on a projected demand of 532 million 
doses, the MVM estimated that 150 million uncomplicated cases of malaria and 1.1 
million deaths would be averted over 10 years. This is equivalent to 943 
uncomplicated cases and 7 deaths averted per 1,000 vaccinees. In discounted 2011 US 
dollars, this represents $11 per uncomplicated case averted and $1,482 per death 
averted. If vaccine efficacy were reduced to 75%, the estimated uncomplicated cases 
and deaths averted over 10 years would decrease by 14% and 19%, respectively.  
DISCUSSION/CONCLUSIONS 
The MVM can provide valuable information to assist decision-making by vaccine 
developers and policymakers.  
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INTRODUCTION 
Modeling can provide key input into public health decisions to use, or not use, new 
health technologies in the developing world [205,206]. Models provide data on a given 
intervention’s impact, cost-effectiveness, and/or financing requirement estimates. 
Models can help inform responses to critical public health questions that are not 
addressed in field trials. They allow analysis of situations that are difficult or 
impossible to replicate in real life, such as the absolute impact of a new malaria 
control intervention in the absence of any existing interventions. They can help 
determine which parameters, and their ranges, are the most important. They provide 
insight into complex questions by analyzing different scenarios and identifying the 
ones most likely to occur [207]. It is imperative that modeling estimates be made 
available to support evidence-based decision-making. This paper describes a new 
model for vaccines against malaria, a disease that caused almost 800,000 deaths in 
2009, mostly of children in sub-Saharan Africa [208]. The Malaria Vaccine Model 
(MVM) was designed to assist vaccine developers and policymakers in developing 
countries and at global organizations to make informed public health decisions. 
Given the expense of research and development (R&D), those developing new public 
health interventions for use in poor countries must invest in interventions with the 
appropriate attributes (e.g., level of efficacy, costs, mode of delivery) to realize desired 
health impacts. As new, often more expensive, interventions become available, the 
pressure for global, regional, and country policymakers to make evidence-based 
decisions is likely to increase. Such decisions will need to be supported by modeled 
estimates, such as potential impact and financial requirements. The GAVI Alliance 
(GAVI) has invested close to $100 million since 2000 into activities related to 
Haemophilus influenzae type B (Hib), pneumococcal conjugate, and rotavirus vaccines. 
Establishing the value of these vaccines through the generation of impact estimates 
was one of GAVI’s three key investment activities. GAVI’s investment in these activities 
arose from the recognition that multi-year delays occurred in the introduction of Hib 
vaccine by countries, partly because of the lack of data on the burden of disease and 
potential impact from vaccines [209]. If the needs of intervention developers and 
policymakers are not anticipated far in advance, developers may waste investments, 
and policy and financing bodies will not be able to make timely decisions--a situation 
that could lead to delays in getting new interventions to those in need. 
A number of models have recently focused on interventions worldwide. Some have 
focused on individual interventions, such as human papilloma virus, HIV, and rotavirus 
vaccines, in an effort to inform global policies [210–212]. By contrast, the Lives Saved 
Tool (LiST) estimates the impact of up to dozens of child survival interventions 
(including malaria interventions) across 42 low- and middle-income countries 
worldwide. This model, which was intended to help global policymakers prioritize 
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interventions, is being extended for use in individual countries [181]. Another tool, 
which is web-based, builds on modeled data to assist African policymakers in making 
local decisions on the use of intermittent preventive treatment of malaria in infants, 
and the ProVac Initiative in the Americas includes a model to support country 
decision-making on the use of new vaccines [213,214].  
These examples reflect the importance of being clear about a model’s purpose and 
target audiences, and of taking into account the impact of multiple interventions 
against diseases. A malaria vaccine model needs to inform vaccine developers as well 
as policy and financing decision-makers at global, regional, and country levels. Among 
other requirements, it needs to reflect the changing epidemiology in each country and 
allow for the consideration of malaria vaccines in the context of other malaria 
interventions available to countries.  
Two dynamic models, recently published, estimate the potential impact of malaria 
vaccines. One model has been under development since 2003 at the Swiss Tropical 
and Public Health Institute (Swiss TPH) [215]. The second, more recent model was 
developed at Imperial College London [216]. Both models consider the dynamics of 
malaria transmission and of natural immunity to Plasmodium falciparum. To do so, 
both models use simulation approaches to reflect the underlying relationship between 
interventions and averted disease. However, these approaches can be difficult for non-
specialists and policymakers to utilize. To obtain predictions of likely malaria vaccine 
impact in countries where malaria is an important public health problem or to obtain 
regional estimates across sub-Saharan Africa, such models need to be linked to data 
on geographical variation in transmission. In addition, published economic analyses of 
malaria vaccination based on these models [217] so far have not considered supply-
side considerations, such as manufacturing capacity, which influence implementation 
and ultimately impact. 
With global efforts to develop malaria vaccines showing promise, the PATH Malaria 
Vaccine Initiative (MVI) worked with the Boston Consulting Group and Swiss TPH to 
build on the Swiss TPH model and to increase access to the model’s simulations by 
vaccine developers and policy audiences. An initial version of the Malaria Vaccine 
Model (MVM version 1.0) was developed and utilized between 2005 and 2007. It 
extended the Swiss TPH model, allowing for supply-side considerations and country-
specific estimates, and it contributed to the MVI and Swiss TPH experience in 
generating predictions. For example, MVI and its collaborators used this version to 
inform discussions regarding the establishment of an Advance Market Commitment 
for malaria vaccines [218].  
Version 2.0 of the Malaria Vaccine Model (MVM) was completed between 2008 and 
2010. MVI led the project, collaborating with Swiss TPH and a private consulting 
company, Applied Strategies (AS).The first intended purpose of MVM version 2.0 was 
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to inform understanding at the country level of the potential impact of malaria 
vaccines as complements to existing health interventions. The model’s second purpose 
was to inform global and regional policymakers of the potential impact, eventual 
delivery strategies, and financing needs for malaria vaccines. Thirdly, it was intended 
to inform R&D decisions by public-sector organizations working on vaccine 
development.  
This paper describes the major design features, critical parameters, and outputs of 
MVM 2.0. A demonstration scenario was created that is used to illustrate the model 
utility. This demonstration scenario draws on targets for the development of a malaria 
vaccine set by the international community in 2006 through the Malaria Vaccine 
Technology Roadmap [219]. The Roadmap calls for the development and licensure of a 
first-generation malaria vaccine by 2015, with 50% protective efficacy lasting longer 
than one year against severe disease and death. The Roadmap also calls for the 
development, by 2025, of a vaccine with protective efficacy of more than 80%, against 
clinical disease and lasting longer than four years. This paper concludes with lessons 
from developing the MVM, and implications for others developing models that target 
vaccine developers and policymakers. 
METHODS 
OVERVIEW OF MODEL STRUCTURE 
The MVM is composed of three distinct modules (Figure 15). The first module, focused 
on vaccine supply and demand, was developed by MVI and AS. The second module, 
based on Swiss TPH’s model simulations, describes the public health impact expected 
from different malaria vaccines deployed in varying populations through several 
modes of delivery. The third module uses data from the first two modules and adds 
vaccine price and cost of delivery to estimate the total investment that would be 
required to achieve the potential public health gains and costs per event averted. Each 
module includes a built-in sensitivity analysis function for some key parameters. 
One demonstration scenario was selected to illustrate the model’s functionality. 
Descriptions of each module are provided below, followed by descriptions of the input 
values used in the demonstration scenario. 
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FIGURE 15. STRUCTURE OF THE MALARIA VACCINE MODEL (MVM).  
 
Legend: This figure depicts the MVM structure. The central box contains the three modules within the 
MVM: supply and demand forecast, public health impact estimates, and financial analysis. Above and 
below the MVM modules box are two rectangles describing the underlying reference data accessed by 
the modules. Arrows represent the interaction between reference data and user inputs and modules 
within the MVM, as well as between modules of the MVM. 
SOFTWARE AND INTERFACE 
MVM was built as a Microsoft® Windows desktop application using the Microsoft® 
.NET framework (version 3.5). The criteria considered in the software selection 
process, drawing on experience from the first model, were ease of use by non-experts, 
familiarity (similar to Microsoft Windows), ability to interface well with large datasets 
containing elements from the Swiss TPH model, and ease of updating new reference 
datasets. Microsoft Excel was considered but not selected as it would have been 
challenging to efficiently manage the complex data underpinning the model, and it 
would have been less user-friendly.  
Model inputs are either selected from drop-down menus or entered as numbers. The 
outputs include graphics displayed on the screen, with an option to export data into 
Excel for customized reports. 
SUPPLY AND DEMAND FORECAST  
Based on user inputs and reference data, the supply and demand forecast module 
predicts the quantity of vaccines that will be available at a given time and the number 
of doses that are in demand by countries (Table 21 and Table 22).  
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TABLE 21. SUPPLY AND DEMAND MODULE: USER INPUTS FOR SUPPLY PARAMETERS. 
Parameter name Definition Input values 
Manufacturing 
capacity 
Describes current known or estimated capacity, 
and timelines of new facilities. 
Number of 
doses and 
year 
available 
Year of vaccine 
approval 
The user determines the year of approval by a 
national regulatory authority (NRA) and World 
Health Organization (WHO) prequalification, which 
are assurances of vaccine quality as a prerequisite 
for availability. The user then selects whether NRA 
approval or WHO prequalification is required by 
each country. 
Year 
 
All countries with an annual average birth cohort estimate and projection from the 
Population Division of the Department of Economic and Social Affairs of the United 
Nations (UN) as of 2008 were included in the MVM. Users may create classifications 
and/or groupings of these countries to help facilitate and focus a particular analysis. 
For example, users could select only those countries that are GAVI-funding eligible, 
they may focus on 40 high malaria disease burden countries in sub-Saharan Africa, or 
they may generate estimates for a single country. 
REFERENCE DATA 
Population: Data on the population of each country were drawn from the UN 
Population Division [220]. Users may select the age range of the target population 
consistent with the expected vaccination strategies of potential malaria vaccines 
(Table 22). 
Vaccine coverage: The MVM included historical and projected vaccine coverage for 
Bacille Calmette-Guerin (BCG); first, second, and third doses of diphtheria-tetanus-
pertussis (DTP1, DTP2, DTP3); and measles-containing vaccine (MCV) for each country. 
Users may set the maximum vaccine coverage for each country equal to historical data 
for any of the above vaccines, or they may set maximum vaccine coverage at any level 
from 0–100%. Data on the 2005–2007 coverage rates were obtained from the World 
Health Organization (WHO) and United Nations Children’s Fund (UNICEF) [221]. Future 
coverage levels were based on projections from WHO (Lara Wolfson, WHO ICE-T v4.0, 
Oct 2007, unpublished data). 
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TABLE 22. SUPPLY AND DEMAND MODULE: USER INPUTS FOR DEMAND PARAMETERS. 
Parameter 
name 
Definition Input values 
Manufacturing 
capacity 
Describes current known or estimated capacity, and timelines of 
new facilities. 
Number of 
doses and 
year available 
Year of vaccine 
approval 
The user determines the year of approval by a national regulatory 
authority (NRA) and World Health Organization (WHO) 
prequalification, which are assurances of vaccine quality as a 
prerequisite for availability. The user then selects whether NRA 
approval or WHO pre-qualification is required by each country. 
Year 
Years between 
vaccine 
approval and 
country 
adoption 
Identifies time between the first year that a vaccine is available and 
the year that each country implements a vaccine.  
 
Number of 
years 
Maximum 
coverage 
Describes the largest percent of the target population reached in 
each country. 
% 
Years for each 
country to 
reach 
maximum 
coverage 
Describes the number of years between implementation and 
achievement of maximum coverage. 
Number of 
years 
Number of 
doses per 
regimen 
Describes the number of doses required to fully vaccinate each 
person at efficacy levels described under the public health impact 
module. 
3,4 
Vaccine 
wastage 
Describes the proportion of doses that will not be administered. 
Vaccine wastage is a percentage set by the user, but suggestions are 
provided in the MVM based on the number of doses per vial, 
according to WHO projected vaccine wastage (available at: 
http://www.who.int/immunization_delivery/systems_policy/logistic
s_projected_wastage/en/index.html; accessed: 2011 Apr 28). The 
model does not take buffer stock (a one-time 25% increase of 
vaccine doses distributed in a logistics system in the first year of 
implementation) into account. 
% 
Target 
population 
The age group in which the vaccine is used: infants (represented by 
the annual birth cohort for each country), 5-17 month olds, 1 year 
olds (yos), 0-4 yos, 1-4 yos, 1-39 yos, 5-39 yos, or the total 
population 
Age range 
Product 
preference 
In the case of multiple available vaccines, the user may model 
scenarios in which particular countries prefer one vaccine over 
another. 
Product 
name 
Maximum 
acceptable 
price  
The maximum price a country is willing to pay for a vaccine. Dollars 
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MODULE SUMMARY AND DEMONSTRATION SCENARIO 
Supply estimates are based on user inputs describing each manufacturer’s anticipated 
capacity, timing of expected increases in capacity, and year of vaccine availability, 
assuming development success and regulatory approval. Demand estimates in the 
form of total doses required per year are based on the size of the target population in 
each country, the maximum level of coverage and time taken to reach this level, and 
the number of doses in a regimen. Along with the above inputs and reference data, 
the model outputs include the year the vaccine is available for use in each country 
(from both supply and approval perspectives), the number of doses demanded, and 
the number of doses available to meet demand in any given year.  
For the demonstration scenario, it was assumed that supply would not be constrained 
by manufacturing capacity and that all countries would require vaccine 
prequalification by WHO. Forty countries in sub-Saharan Africa that experienced a 
malaria disease burden in 2006 of 100 deaths per year or greater, or that experienced 
a malaria mortality rate of 10 deaths per 100,000 per year or greater, were included. 
The criteria were intended to allow inclusion of large countries with many cases at a 
relatively low rate, and small countries with few absolute cases but which have a 
significant rate relative to the population size. The time horizon modeled in the 
demonstration scenario was 10 years of vaccine use. 
Demand in the demonstration scenario assumed a vaccine regimen of three doses 
delivered to a target population of infants and a wastage rate of 10%. No product 
preference or maximum acceptable price was modeled. Year of country adoption of 
the modeled malaria vaccine, maximum coverage, and the time to reach maximum 
coverage were benchmarked from historical data, based on the uptake of Hib vaccine 
from 2001 to 2010 (either on its own, in the form of a tetravalent vaccine with DTP, or 
as a pentavalent vaccine with DTP and hepatitis B). WHO data on Hib coverage served 
as a reference point for the number of years post vaccine availability that each country 
began implementation, each country’s maximum coverage (DTP3 coverage was 
selected to represent maximum), and the time it took for Hib3 to match DTP3 levels 
(available at: 
http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/i
ndex4.html; accessed November 2010) (Figure 16. Estimated number of malaria 
vaccine doses delivered per year over a 10-year period.). Malaria is a much better 
recognized health threat than Hib, and countries have gained experience in vaccine 
implementation since Hib introduction began. Therefore, all countries that did not 
adopt Hib in the first two years of its availability were modeled as adopting a malaria 
vaccine two years earlier than they adopted Hib. Time to maximum coverage was not 
adjusted.  
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FIGURE 16. ESTIMATED NUMBER OF MALARIA VACCINE DOSES DELIVERED PER YEAR 
OVER A 10-YEAR PERIOD. 
Legend 
Numbers of doses delivered are based upon reports of the use of Hib vaccine to WHO between 2001 
and 2010 from 40 countries in sub-Saharan African with significant malaria burden. 
 
If countries did not introduce Hib by 2010, they were excluded from the 
demonstration scenario. The exception was Nigeria, which appears to be moving more 
quickly to adopt more recent vaccines than it did with Hib [222]. Nigeria was assumed 
to adopt the malaria vaccine midway through the time horizon analyzed, and reach 
maximum coverage in two years.  
PUBLIC HEALTH IMPACT ESTIMATES 
The natural history and epidemiology of P. falciparum were modeled using a stochastic 
simulation model developed at Swiss TPH and described in detail in previous 
publications [223–228]. The age structure of the simulated human populations was 
based on Ifakara, Tanzania [229]. Model parameters were estimated by fitting the 
model to field data from a variety of settings across sub-Saharan Africa [230]. Pre-
vaccination transmission intensity was scaled to give the different required values of 
the initial exposures (e.g. 1, 10, or 100 ibpa as described below). Pathogenesis and 
case management (including hospitalization of severe cases) was also simulated as 
described in previous publications [225,228,231]. Thus, any changes in transmission 
intensity induced by a vaccination program (due to herd immunity or other indirect 
effects) were captured, but the vectorial capacity followed the identical periodic 
pattern as in the absence of vaccine. The MVM allowed the Swiss TPH outputs to be 
estimated for key parameters found in the first MVM to be of interest to developers 
and policymakers—for example, specific populations in specific transmission settings 
and utilization of particular modes of delivery (Table 23). 
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TABLE 23. PUBLIC HEALTH MODULE USER INPUTS. 
Parameter 
name 
Definition Input 
values 
Type of 
vaccine 
Describes the antigens targeted. Options include pre-erythrocytic 
(PE), blood-stage (BS), or a combination of these plus a vaccine 
component targeting sexual, sporogonic, and/or mosquito (SSM) 
antigens to interrupt transmission from an infected person to the 
next. 
PE, BS, PE + 
BS, PE + 
SSM, BS + 
SSM, PE + 
BS + SSM  
Vaccine 
efficacy 
Describes the efficacy of the vaccine immediately after 
completing the full regimen. For a pre-erythrocytic vaccine, 
efficacy is defined as the proportional reduction in incidence of 
blood-stage infection. For a blood-stage vaccine, efficacy is 
defined as the proportional reduction in blood-stage parasite 
density. For a vaccine targeting the SSM antigens, efficacy is 
defined as the proportion by which the probability that a 
mosquito is infected during one bite is reduced [232]. 
35%, 50%, 
60%, 75%, 
85% 
Half-life of 
efficacy 
Describes the point at which the efficacy (as described above) has 
fallen to half of its initial value. Half-life of efficacy assumes an 
exponential decay of efficacy. 
2, 4, 10 
years 
Future 
malaria 
transmission 
Transmission is described as the percent of the population of the 
country of interest residing in each of five categories of 
entomological inoculation rate (EIR), which is a measure of how 
many infectious bites a person receives per year (ibpa) in a given 
setting. The starting transmission level for each country is derived 
from the reference data described below. The user can choose to 
keep transmission fixed at this level throughout the time period 
under consideration, or can enter scenarios of future 
transmission, for example, specific to an individual country. 
See 
Supplement 
A 
Mode of 
vaccine 
delivery 
Describes the means by which the vaccine is delivered to its 
target population. The options include routine vaccination via a 
country’s immunization system and campaign delivery. 
See  
Table 24 
Booster 
compliance 
rate 
Percentage of population originally vaccinated who receive a 
single booster dose. 
50%, 80%, 
95% 
 
REFERENCE DATA 
Disease burden: Morbidity and mortality rates were obtained from the WHO for both 
the entire population and the population under 5 years of age [233]. In situations 
where no data specific to the under-5 population were available, the total population’s 
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malaria morbidity and mortality rates were applied. Projections of future disease 
burden were based on each country’s current morbidity rate or current mortality rate 
multiplied by the country’s population forecast for the selected population. Options 
for changing the future disease burden, such as from implementation of other 
interventions, are described below. 
Malaria transmission: In the MVM, transmission is represented by the entomological 
inoculation rate (EIR). EIR, a measure of the intensity of malaria parasite transmission, 
is the product of the human biting rate of mosquitoes and the proportion of 
mosquitoes infected with sporozoite-stage malaria parasites. EIR is measured in the 
number of infective bites per person per annum (ibpa). Two sources of data on 
transmission were incorporated into the MVM, allowing the user to choose between 
them. Data from WHO were in the form of the percentage of each country’s 
population at high or low risk for malaria infection [233]. Alternatively, the Malaria 
Atlas Project (MAP) data were in the form of P. falciparum parasite prevalence [234]. 
Neither the WHO nor the MAP source data were provided in the form of EIR, requiring 
the data to be converted using methodology endorsed by both MAP and an external 
expert panel (see Supplement A for details). The MVM calculates the percentage of 
each country’s population that falls into each of five EIR levels (0, 0.1, 1, 10, and 100 
ibpa). The user is also free to input future changes in levels of transmission for 
countries. 
VACCINE IMPACT ON DISEASE BURDEN 
Pre-erythrocytic vaccination was simulated as described in previous publications 
[232,235], assuming that vaccination leads to both a reduction in the proportion of 
inoculations from the bites of infected mosquitoes and resulting blood-stage infection 
(an estimate of efficacy which is substantially higher than the proportion of clinical 
episodes prevented by such a vaccine [236]). Blood-stage vaccination was simulated by 
assuming that the vaccine reduced blood-stage parasite densities [232]. Vaccination 
scenarios were paired with non-vaccination comparator simulations to provide impact 
estimates of the outcomes found to be of greatest interest from the first MVM: the 
numbers of cases (uncomplicated and severe), deaths, and disability-adjusted life 
years (DALYs) averted through vaccine use over time periods of interest. 
MVI, AS, and Swiss TPH agreed on possible combinations of input parameters 
anticipated to be of interest to vaccine developers and policymakers, resulting in over 
100,000 scenarios to be simulated (Table 24). Each scenario was run multiple times, 
and mean frequencies of events were computed in order to reduce stochastic 
variability in the estimates of health effects. The results of these simulations are 
stored in look-up tables as reference data in the MVM, drawn upon as necessary 
according to the particular combinations of inputs for specific populations in the 
scenario chosen by the user. 
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MODULE SUMMARY AND DEMONSTRATION SCENARIO 
Estimates of the public health impact of a vaccine are generated based on the type of 
vaccine, initial efficacy and half-life of efficacy, mode of vaccine delivery, and 
transmission setting. The model outputs from this module are the total number of 
uncomplicated cases, severe cases, deaths, and DALYs averted through use of the 
vaccine. The model also provides the number of each of these events averted per 
1,000 vaccinees. 
For the demonstration scenario, a pre-erythrocytic vaccine with an efficacy of 85% 
against uncomplicated malaria cases was assumed. The half-life of efficacy was four 
years, meaning that four years after receiving the third dose, vaccine efficacy would be 
42.5%. These values of efficacy and half-life were selected for the demonstration 
scenario as they were expected to be broadly consistent with targets set by the 
international community [237]. Routine infant immunization (via the Expanded 
Program on Immunization) was selected as the mode of delivery. As described above, 
the user enters the projected country EIR into the MVM. Three different projections 
were created to reflect decreases in transmission from current levels, due to 
implementation of existing interventions. The projection applied to the demonstration 
scenario used the MAP-derived EIR distribution across countries, shifting one-quarter 
of the population at each EIR level (0, 0.1, 1, 10, and 100 ibpa) into the next lower 
category (e.g., from EIR of 10 down to 1). The other two scenarios shifted either one-
half or three-quarters of the population at each level to the next lower level of EIR. It 
was assumed that the percentage of the population residing in each EIR level 
decreased in a linear fashion to the next lowest level over a period of five years, and 
remained constant for the remaining five years modeled. 
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TABLE 24. VACCINATION STRATEGIES AND NUMBER OF SIMULATIONS OF EACH 
SCENARIO GENERATED BY SWISS TPH. 
Strategy # Strategy name Scenarios Replications of 
each strategy 
0 No vaccination 5 2,500 
1 Routine infants with a boost 2 years 
later 
6,480 55,232 
2 Routine infants (no boost) 2,160 18,492 
3–4 Routine infants with a boost 2 years 
later PLUS a catch-up of 5–17 month 
olds (no boost) 
19,440 166,869 
5–6 Routine infants (no boost) PLUS a catch-
up of 5–17 month olds (no boost) 
6,480 55,634 
7–8 Routine infants with a boost 2 years 
later PLUS a catch-up of 1–5 year olds 
(no boost) 
19,440 168,160 
9–10 Routine infants (no boost) PLUS a catch-
up of 1–5 year olds (no boost) 
6,480 55,685 
11–12 Routine infants with a boost 2 years 
later PLUS a catch-up of 1–39 year olds 
(no boost) 
19,440 166,318 
13–14 Routine infants (no boost) PLUS a catch-
up of 1–39 year olds (no boost) 
6,480 55,408 
15 Routine 5–17 month olds with a boost 2 
years later 
6,480 55,143 
16 Routine 5–17 month olds (no boost) 2,160 18,787 
17–18 Periodic 1–5 year olds every 5 years (no 
boost) PLUS a catch-up of 6–39 year olds 
(no boost) 
6,480 55,684 
Legend: Strategies reflect different implementation approaches and target population. Scenarios are 
the variations of each strategy to cover potential user-selected transmission settings and vaccine 
characteristics such as efficacy and half-life. “Infants” mean children approximately six weeks of age at 
first vaccination. “Routine” vaccination means that it is happening continuously as individuals reach the 
target age. “Catch-up” campaign means a one-time, mass vaccination targeting the indicated age range. 
“Periodic” campaign means regular mass vaccinations targeting the indicated age range, at the 
indicated frequency. 
IMPLEMENTATION COST AND FINANCING REQUIREMENTS 
The implementation cost and financing requirements module estimates the total 
investment that would be required to purchase and deliver the vaccine simulated in 
PLANNING FOR NEW HEALTH INTERVENTIONS   
Modeling the impact of malaria vaccines 136 
the public health impact module, and the cost of each event averted in US dollars. 
User inputs are presented in Table 25.  
TABLE 25. FINANCIAL MODULE USER INPUTS. 
Parameter name Definition Input 
values 
Vaccine price The cost of the vaccine in dollars as set by the 
manufacturer, including insurance and delivery to the 
airport of a country specified by the consignee. 
$ 
Cost of injection 
equipment and 
disposal 
The cost of the syringes and waste disposal 
equipment. 
$ 
Cost of vaccine 
delivery 
Different costs can be entered for each country, 
allowing customized estimates that take into account 
factors such as the cold-chain capacity and transport 
needs of each. 
$ 
Discount rate A distinct discount rate can be entered for the 
supplier and the donor, reflecting the cost of capital 
of each. 
% 
Financing 
scenario 
Users select the financing start and end dates, and 
the level of country co-pay to complement support 
from donor organizations. Users can create various 
financing scenarios. 
Dates; 
dollars 
 
REFERENCE DATA 
This module does not include pre-entered reference data.  
MODULE SUMMARY AND DEMONSTRATION SCENARIO 
Based on the user inputs of vaccine price and implementation costs, the module 
generates the total investment required to achieve the public health gains estimated 
in the public health impact module. Depending on the assumed financing scenario, for 
example, if donors support a portion of the purchase and implementation costs, the 
model provides a break-down by donor and country contributions for each year of 
vaccine use—a breakdown that was found to be of significant interest to those using 
the original MVM. A discount rate can be used to calculate the present values of the 
total investments, and can be summed to estimate the net present value.  
The demonstration scenario assumed a vaccine price remaining constant at $5/dose, 
including insurance and delivery to the airport of a country as specified by the 
consignee. Inflation was not included. This price is broadly consistent with the 
assumed cost of other new vaccines for low-income countries, such as pneumococcal 
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conjugate and human papilloma virus vaccines. In addition to the vaccine price, the 
implementation cost modeled was $0.33/dose and injection equipment costs were 
$0.07/dose, totaling $1.20/fully immunized child (FIC). Costs were based upon a 
simulation study of the cost of introducing a malaria vaccine into the routine 
immunization system in Tanzania [238], and were also consistent with results from a 
similar study following the introduction of a pentavalent DTP-hepatitis B-Hib vaccine in 
Ethiopia [239]. 
SENSITIVITY ANALYSIS  
The MVM allows the user to perform sensitivity analyses to determine the magnitude 
of the impact of select factors on the model outputs. Sensitivity-analysis outputs can 
be generated for any given year, or over the entire period modeled. Sensitivity-
analysis results indicate the impact of the adjusted parameter(s) on the public health 
and financial estimates. The following model inputs can be increased or decreased by 
a percent of the value set by the user: country willingness to pay (maximum price); 
discount rate; price of vaccine or injection equipment; and percentage of product 
wastage. Country adoption and product availability inputs can be increased or 
decreased by a number of years relative to a baseline. Alternatively, for those 
parameters not included in the formal sensitivity analysis, such as vaccine efficacy, 
half-life of efficacy, transmission, or the use of a booster dose, model outputs from 
several scenarios can be saved and compared. 
RESULTS 
The demonstration scenario was run to illustrate the functionality of the MVM. The 
inputs selected for this scenario were described above in the Methods section. The 
outputs of the demonstration scenario are presented below. 
SUPPLY AND DEMAND MODULE 
Based on the historical data from Hib, adapted as described above, in its first two 
years of use, over 16 million (M) doses of malaria vaccine were required to meet 
demand, plateauing at 93 M between years 7 and 10 (Figure 16). Over the course of 10 
years of vaccine use, the MVM outputs from the demonstration scenario indicated 
that a total of 532 M doses would be used in the 40 African countries in the analysis. 
PUBLIC HEALTH IMPACT MODULE 
The output from the supply and demand module on the number of doses of vaccine 
required directly contributed to the calculation of public health impact. While the 
underlying calculations were made for each country, the results were presented at an 
aggregate level to give a sense of impact across all of sub-Saharan Africa. 
Based on the demonstration scenario inputs, an estimated 150.4 M uncomplicated 
cases of malaria would be averted over 10 years of vaccine use (Table 26), with 44.3 M 
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averted in year 10 alone (Figure 17). Over this same period, 5.1 M severe cases of 
malaria would be averted, along with 1.1 M deaths and 28.4 M DALYs. The number of 
severe cases, deaths, and DALYs averted annually increased over the whole time 
period, with the largest number seen in the final year: 1.3 M, 258,000, and 6.9 M, 
respectively (Figure 17). MVM provides these data as ratios of the number of events 
averted per 1,000 vaccine recipients, as well. Averaged over the 10-year time period, 
the inputs for the demonstration scenario led to 943 uncomplicated cases 
averted/1,000 vaccinees, 32 severe cases averted/1,000 vaccinees, 7 deaths 
averted/1,000 vaccinees, and 178 DALYs averted/1,000 vaccinees (Table 26). 
TABLE 26. CUMULATIVE NUMBER AND RATIO OF MALARIA EVENTS AVERTED, AND 
COST PER EVENT AVERTED. 
 Total events 
averted over 
10 years 
Events 
averted/1,000 
vaccinees 
$/event averted 
(undiscounted) 
$/event 
averted 
(discounted) 
Uncomplicated 
malaria 
150,394,000 943 19 11 
Severe malaria 5,114,000 32 561 309 
Death 1,067,000 7 2,690 1,482 
DALY 28,394,000 178 101 56 
 
IMPLEMENTATION COST AND FINANCING MODULE 
The cost per event averted was calculated in the MVM for each year of the analysis 
using the non-discounted total investment (vaccine price plus injection equipment plus 
delivery costs). It could also be informative to consider the present value (PV) of the 
investments, calculating the cost per event averted with a discounted number. These 
data are presented in Table 26 as the aggregate over the entire period. In the 
demonstration scenario, the undiscounted cost was $19 per uncomplicated malaria 
case averted, $561 for each severe case averted, $2,690 for each death averted, and 
$101 for each DALY averted. After discounting the total investments at 5% to a net 
present value, the costs were $11, $309, $1,482, and $56, respectively. 
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FIGURE 17. ANNUAL MALARIA EVENTS AVERTED IN 40 HIGH-BURDEN AFRICAN 
COUNTRIES BY THE SIMULATED VACCINE. 
Legend 
MVM projections of the number of A) uncomplicated cases; B) severe cases; C) deaths; D) DALYs 
averted by use of an 85% efficacious PE vaccine with an efficacy half-life of 4 years over 10 years in sub-
Saharan Africa. 
SENSITIVITY ANALYSIS 
Lower vaccine efficacy and a larger decrease in malaria transmission were considered 
(Figure 18). If efficacy was set to 75% instead of the demonstration scenario level of 
85%, the estimated uncomplicated cases averted over 10 years would decrease by 
14%, from 150.4 M to 130 M. Similarly, the total number of severe cases, deaths, and 
DALYs averted were predicted to decrease by 14%, 19%, and 18%, respectively (data 
not shown). While the total investment would remain the same, fewer events would 
be prevented, increasing the undiscounted (and discounted) cost/event averted from 
$19 ($11) per uncomplicated case to $22 ($12). The cost per severe case averted 
would increase to $652 ($359), per death averted to $3,340 ($1,840), and per DALY 
averted to $124 ($68). 
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FIGURE 18. IMPLICATIONS OF CHANGING VACCINE EFFICACY OR TRANSMISSION 
INTENSITY ON IMPACT.  
Legend 
The impact of vaccine efficacy and transmission setting on the potential number of uncomplicated 
malaria cases averted annually over a 10-year period of vaccine use. The demonstration scenario of 85% 
efficacy at one-quarter step reduction in transmission averted the most cases (●), followed by 85% 
efficacy at one-half step reduction in transmission (▲), 75% efficacy at one-quarter step reduction in 
transmission (■), and 75% efficacy at one-half step reduction in transmission (×).  
 
Great progress has been made over the past decade in scaling up the current malaria 
control interventions [208]. While our demonstration scenario shifted one-quarter of 
the population in each EIR category to the next lower level of risk, it is possible that 
national malaria control programs and their partners will achieve greater success in 
lowering transmission. To understand the potential public health gains that could be 
attributed to the vaccine in a setting with lower transmission, and therefore many 
fewer cases to avert, we also modeled the scenario described in the Methods section 
in which one-half of the population in each EIR category is shifted to the next lower 
level of risk. MVM outputs indicated that such a shift would lead to approximately 21% 
fewer events averted across all categories over the 10-year period, relative to the 
demonstration scenario.   
DISCUSSION 
This paper describes a collaborative effort to develop a malaria vaccine model of 
supply, demand, public health impact, and costs that is sufficiently robust to generate 
reliable outputs, yet simple enough to allow application to diverse audiences at 
country, regional, and global levels. The functionality of the model was demonstrated 
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by estimating the impact and implementation costs associated with a vaccine broadly 
consistent with international targets. The estimates suggest that such a malaria 
vaccine could have an important public health impact.  
The model is intended to have the flexibility to include real-life data in order to 
generate outputs. For example, implementation in the demonstration scenario took 
place over 10 years according to historical data from Hib, which means 
implementation and impact did not smoothly increase year to year, but increased in 
rate particularly as large countries began implementing.  
In the future, the model will also be applied to other types of malaria vaccines that are 
being considered or that are in R&D currently—for example, vaccines that have 
different efficacy levels, delivery strategies, and costs. Data from studies of the most 
advanced malaria vaccine, RTS,S, indicate that it may cut episodes of clinical malaria in 
young children by about half [240]. Additional modeling will need to be done to inform 
planning for such a vaccine. The MVM also allows for the generation of estimates if 
multiple vaccines were to be available. 
MODEL DESIGN 
The balancing of a comprehensive approach with simplicity can lead to models that 
attempt to include all considerations and field data, yet lose their usability and 
interpretability. On the other hand, a complex, vector-borne, parasitic disease, like 
malaria, is not well-reflected by overly simplified assumptions. Collaborators settled 
on a compromise to integrate the strengths of a comprehensive and computationally 
intensive model associating epidemiological patterns and vaccine characteristics with 
impact from Swiss TPH with simpler, specially designed, component modules for less 
computationally intensive elements such as the number of individuals that might be 
immunized. The MVM integrates pre-defined inputs from Swiss TPH with the other 
models through a tailor-made user interface, providing a seamless means of inputting 
data and generating outputs. The design of the second MVM reflects the 
understanding gained about underlying model design and software, parameters, 
potential uses, and associated outputs. 
The first MVM was developed in Microsoft Excel. However, the large amount of data 
and the complexity of the model made this a less user-friendly option. The second 
MVM moved to the Microsoft .NET framework. It greatly improved the usability of the 
model. One negative consideration of the second MVM’s software is that it is 
proprietary (although granted with an unrestricted license for use in the MVM). This 
may make it more challenging for others wanting to extend the MVM interface for 
other uses. Secondly, the program requires 2.98 gigabytes of storage space. The 
majority (about 90%) of the required space is needed to hold the Swiss TPH simulation 
reference data. 
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USES AND OUTPUTS 
The MVM and outputs are intended to be freely available to public and not-for-profit 
organizations. The interface is intended to provide an accessible means for users to 
enter data and generate results. The outputs of the MVM are intended to address 
questions arising from three distinct audiences: country policymakers, regional and 
global policymakers, and vaccine developers. Each of these audiences could seek 
different but interrelated information from the MVM.  
While misinterpretation of results is a consideration for any model, the MVM is 
designed to decrease this likelihood, in part by emphasizing relatively straightforward 
outputs. The authors anticipate that guidance and interpretation will be required to 
allow other groups to properly use and interpret the results of the MVM.  
The MVM can provide country policymakers with estimates of impact and costs of 
malaria vaccines tailored to their local transmission setting, and based on local 
assumptions about implementation, such as delivery strategy, coverage, and cost. For 
regional and global policymakers it can provide multi-country estimates that may 
support the setting of standards on the use of a malaria vaccine. The types of outputs 
generated by the MVM are relevant to policymakers seeking information on the role 
of malaria vaccines as complements to other strategies to address malaria. 
Information can be made available to countries through pre-formatted two-page or 
customized reports, or countries may choose to run scenarios themselves. Similar pre-
formatted or customized reports can be generated for individual countries or 
aggregated across multiple countries for regional and global-level policymakers. 
For malaria vaccine developers and global organizations, the MVM can help inform 
trade-offs between various product characteristics, delivery options, impact, and 
costs, as well as supply and demand considerations. Reports generated by the MVM 
can be customized to address questions arising from vaccine candidates being 
considered for development.  
PARAMETERS 
The MVM includes pre-entered reference parameters where possible, while allowing 
users the flexibility to enter a wide range of scenario-specific parameters when 
desired. The number of parameters and associated ranges led to more than 100,000 
scenarios from Swiss TPH. A number of the parameters and associated assumptions in 
the MVM merit specific discussion.  
There is no universally agreed-upon means for converting malaria transmission data 
from WHO and the Malaria Atlas Project into EIR for each country. Furthermore, there 
is no standard for projecting how transmission may change for each country. MVI 
sought the participation and validation of expert collaborators and arrived at an 
approach, as described in Supplement A, which transparently translates existing data 
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into EIR-equivalents. Users are able to customize assumptions of underlying and 
changing transmission. Perhaps in the future there will be greater standardization on 
one means of measuring the prevalence and transmission of malaria. 
One of the strengths brought by building upon the Swiss TPH model is that it is 
parameterized with extensive field data on malaria. A challenge is that the current 
standard for mathematical models of malaria (Swiss TPH and Imperial College London) 
is to assume that efficacy decays according to an exponential decay with a certain half-
life. The demonstration scenario assumed a four-year half-life. However, the 
relationship between the half-life of efficacy and vaccine duration for malaria vaccines 
is not yet fully clear.  
The purpose of the demonstration scenario presented in this paper was not to 
forecast when individual countries might adopt a malaria vaccine. Rather, the purpose 
was to demonstrate the functionality of the model. That said, the timing of 
implementation by countries, and time to maximum coverage, are important drivers 
of impact. Large country adoption can influence estimates due to their size, as the 
model is built upon estimates for individual countries. 
CONCLUSION 
The field of malaria is rapidly changing, with malaria transmission decreasing, partly 
due to other effective interventions, and the potential for an efficacious vaccine on the 
horizon.  These changes are important to those developing malaria vaccines as well as 
those who make policy decisions on the use and financing of vaccines. This paper 
presents the iterative work undertaken towards developing a robust and user-friendly 
model on supply, demand, public health impact, and costs, to inform this changing 
field. Not-for profit partnerships invest millions of dollars each year on the 
development of malaria vaccines. The current MVM, future iterations, and other 
models like it can provide additional reassurance that those investments are well-
targeted. Policymakers at national, regional, and global levels must make decisions on 
the optimal means to prevent the millions of malaria cases each year and, more 
broadly, on the means to address diseases and health problems prevalent in 
developing countries. The MVM can help inform these critical public health decisions. 
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ABSTRACT 
Background: The RTS,S/AS01 pre-erythrocytic malaria vaccine is in phase III clinical 
trials. It is critical to anticipate where and how this new intervention should be 
implemented if trials are successful. Such planning may be complicated by changing 
malaria levels, as existing interventions are scaled-up.  
Methods and results: Computer simulations were used to examine RTS,S/AS01 impact, 
using a vaccine profile based on phase II trial results, and assuming that protection 
decays only slowly. Settings were simulated in which baseline transmission (in the 
absence of vaccine) was fixed or varied between 2 and 20 infectious mosquito bites 
per person per annum (ibpa) over ten years. Four delivery strategies were studied: 
routine infant immunization (EPI), EPI plus infant catch-up, EPI plus school-based 
campaigns, and EPI plus mass campaigns. Impacts in changing transmission settings 
were similar to those in fixed settings. At 2 ibpa, the vaccine averted approximately 5 – 
7 deaths per 1000 doses of vaccine when delivered via mass campaigns, but decreased 
rapidly at higher transmission levels. EPI, catch-up and school-based strategies averted 
2 – 3 deaths per 1000 doses in settings with 2 ibpa. In settings where transmission was 
decreasing, naturally increasing or increasing after a sudden breakdown of malaria 
control EPI, catch-up and school-based strategies averted approximately 3 – 4 deaths 
per 1000 doses.  
Discussion and conclusion: For situations with changing malaria transmission levels, it 
appears to be sufficient to consider simulations of pre-erythrocytic malaria vaccine 
impact at a range of initial transmission levels. At 2 ibpa, mass campaigns could avert 
the most deaths and reduce transmission, but this requires further verification and 
study. If delivered via established EPI systems, RTS,S/AS01 could avert approximately 6 
– 11 deaths per 1000 vaccinees in all examined settings. This ratio is similar to that of 
approximately 7 per 1000 vaccinees estimated for pneumococcal conjugate vaccine in 
African infants. These results support implementation of RTS,S/AS01 via EPI in 
contexts where vector control interventions are already in place, providing that the 
phase III trials provide support for our assumptions about efficacy. 
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INTRODUCTION 
RTS,S/AS01 (RTS,S) is the most advanced malaria vaccine under development. Work 
started in the 1980’s, and the phase III, or final trial prior to seeking regulatory 
approval, began in 2009 in Africa [241]. If all goes as planned, the trial could be 
completed around 2015. Meanwhile, malaria continues to kill close to 800,000 people 
each year, almost entirely among children under five years of age living in Sub Saharan 
Africa [242]. Nevertheless, the epidemiology of malaria is changing across Africa. This 
is primarily due to the growing use of control interventions, most importantly long 
lasting insecticide treated bednets (LLINs), indoor residual spraying (IRS), and 
improved medicines for treating malaria [243]. A malaria vaccine could be a valuable, 
additional tool to prevent malaria mortality and morbidity.  
Two major mathematical models of malaria and pre-erythrocytic malaria vaccines, 
such as RTS,S, have been published in the past ten years [244,245]. Both models run 
probabilistic micro-simulations in populations of thousands of people. The models are 
systematically fitted to an extensive library of field data from varying transmission 
settings. The transmission in an area is reflected by the entomological inoculation rate 
(EIR), which is a direct measure of the number of infectious mosquito bites per person 
per annum (ibpa). In the published model studies, the EIR is modeled at fixed levels of 
2, 5, 11, 20, 42, 84, and 168 infectious bites per annum (ibpa) [232,235,246] or 3, 43, 
46 81, 586, and 675 ibpa [244].  
The model studies estimate that RTS,S is likely to have an important and varying public 
health impact, primarily according to assumed transmission in an area and delivery 
strategy [232,235,244,246]. Impact is quantified in terms of reduced transmission 
and/or cases and deaths averted. The decision to use RTS,S will partially depend on if 
the impact sought, apart from saving lives, includes transmission reduction. For 
transmission reduction, the initial transmission level and the feasibility of the delivery 
strategy are critical considerations. At low EIRs, such as 2 ibpa and below, transmission 
becomes more focal and less stable. 
Model studies quantifying impact in terms of malaria transmission suggest that RTS,S 
will reduce transmission primarily in areas where it is already low (e.g. 3 ibpa) [244], 
and when delivered through mass campaigns, reaching 50% [246] or more [244] of the 
entire population. These studies also suggest that RTS,S will save lives and avert cases 
in all but the highest transmission settings in Africa when implemented through the 
Expanded Programme on Immunization (EPI) [232,235].  
EPI programs have delivered infant vaccines in developing countries for decades. 
Among African infants in 2009, 73% were immunized with three doses of Diphtheria-
Tetanus-Pertussis (DTP3) vaccine scheduled at approximately 6, 10 and 14 weeks of 
age [247]. This is the same initial schedule as is being anticipated for RTS,S. The current 
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clinical trials of RTS,S and regulatory plans include children aged six weeks through 17 
months at first RTS,S vaccination. EPI and catch-up strategies, targeting this age range, 
thus represent the near-term options for implementing RTS,S. When delivered 
through EPI, RTS,S is likely to have greatest efficacy and impact in low to medium 
transmission settings [232,235], and to be most cost-effective in areas with EIR from 2 
– 20 ibpa [248]. This suggests that the value of RTS,S, as a complementary intervention 
to save lives and prevent morbidity, is likely to grow in importance with anticipated 
decreasing transmission trends resulting from the scaling up of malaria interventions 
across Africa. Impact through EPI is questionable in very high transmission settings 
(e.g. 168 ipba), where a large proportion of disease episodes prevented early in life 
may simply be experienced with a delay and are thus not fully prevented.  
Vaccine delivery strategies other than EPI, such as school-based and population-wide 
mass campaigns, target incrementally wider age ranges and greater numbers of 
people. Mass campaigns are estimated to have relatively little impact on mortality and 
morbidity at a transmission above an EIR of 5 ibpa [232]. School-based and mass 
campaign strategies for delivering RTS,S may require additional multi-year clinical 
studies and regulatory decisions, beyond those currently anticipated. They may also 
require large, specialized initiatives for which there is limited precedent, suggesting 
feasibility studies would be needed.  
The recognition that RTS,S may have varying efficacy and associated impact in 
different transmission settings has been considered in the design of its phase III trial: 
the trial includes 11 sites spread across Burkina Faso, Gabon, Ghana, Kenya, Malawi, 
Mozambique, and Tanzania, intended to reflect the wide range of transmission levels 
seen in Africa [241]. While possible to select sites over a range of transmission levels, it 
was not possible to select sites according to changing transmission dynamics. 
RTS,S is, however, likely to be implemented in environments where baseline malaria 
transmission levels are changing. In some countries still scaling up interventions, 
transmission will likely be decreasing. Other countries, after initial successes, may be 
struggling to maintain suppressed malaria transmission levels and may see malaria 
transmission increase. Predictions of the potential impact of RTS,S, to be used by 
policy-makers at global and country levels [249,250], will need to consider such 
contexts of changing transmission. It is unclear if the findings of models using fixed 
annual transmission levels hold where annual transmission is changing.  
This paper uses simulations to examine how, depending on the delivery strategy, the 
expected impact of RTS,S may be affected when implemented in the context of 
increasing or decreasing malaria transmission trends.  
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METHODS 
SIMULATION MODEL 
The study made use of the same ensemble of 14 inter-related models as in our recent 
study of RTS,S in settings with vectorial capacities oscillating seasonally around fixed 
values [246]. The base model [215], comprising a computer representation of the 
acquisition of P. falciparum infections [251], regulation of parasite densities [223], 
morbidity [228], mortality [225] and case management [231], was thus complemented 
by other models, capturing different assumptions about decay of immunity, 
heterogeneities in exposure, case management, susceptibility and comorbidity.  
Each model run was a stochastic simulation of a stable population of 100,000 people, 
run with five day time steps for an observation period of 10 years. The simulated 
populations had approximately stationary age-distribution typical of rural Tanzania, 
achieved by adjusting birth and out-migration rates to the required values [223].  
The models were programmed in C++ as part of the open source software platform 
OpenMalaria (http://code.google.com/p/openmalaria/). SAS GPLOT was used to 
generate the figures (SAS Institute Inc., Cary, NC, USA, version 9.2 for Windows).  
TRANSMISSION SETTINGS 
In the absence of vaccination, baseline transmission was modeled to follow the 
seasonal patterns observed in Namawala, Tanzania, as in previous studies [235,246], 
but with the EIR scaled to be in the range of 2 ibpa to 20 ibpa. Although transmission 
becomes less stable at the lower end of this range, a consistent cycle of transmission 
was assumed for the purposes of the modeling, unless changed as described below. In 
this range, comparable to EIRs achievable with existing interventions in most of rural 
Africa, the previous modeling studies suggest that RTS,S will be highly effective. In 
each case, the initial immune status of the simulated humans was set to that of a 
population recurrently exposed to an EIR of 20 ibpa. Simulations of vector control 
programs were then implemented so that in the absence of vaccination, the profile of 
transmission during the period of the vaccination program followed one of the 
following seven patterns (Figure 19): 
a) EIR = 11 ibpa, approximately, throughout the ten year observation period. 
b) EIR = 2 ibpa, approximately, throughout the ten year observation period. 
c) Decreasing: EIR decreasing linearly from 20 down to 2 ibpa over a ten year period. 
d) Increasing after brief suppression: EIR initially reduced to 2 ibpa, then increasing 
linearly to 20 ibpa over the ten year observation period. 
e) Increasing after ten years suppression: EIR which had been brought from 20 down 
to 2 ibpa and maintained there for ten years, increasing again up to 20 ibpa over 
the ten year observation period due to decreased use of IRS. 
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f) Suppressed: EIR decreased rapidly from 20 down to 2 ibpa, and subsequently 
maintained at 2 ibpa during the ten year observation period. 
g) EIR = 20 ibpa, approximately, throughout the ten year observation period. 
FIGURE 19. SIMULATED TRANSMISSION SETTINGS. 
Legend: a (dashed purple line): EIR=11 ibpa; b (dashed black line): EIR=2 ibpa; c (solid black line): EIR 
decreasing from 20 down to 2 ibpa over 10 years; d (solid green line): EIR increasing after brief 
suppression from 2 to 20 ibpa over 10 years; e (solid orange line): EIR increasing from 2 to 20 ibpa after 
being suppressed for 10 years; f (solid purple line): EIR suppressed from 20 down to 2 ibpa, and 
subsequently maintained at 2 ibpa; g (dashed orange line): EIR=20 ibpa. 
 
Settings a, b, and g correspond to settings with stable transmission. In these cases, the 
populations were simulated as having been exposed to these EIRs for a warm-up 
period corresponding to a full lifetime, before the start of the observation period 
during which vaccines were introduced. 
Settings c, d, e, and f had changing baseline levels of transmission. The simulated 
populations were exposed to an annual EIR of 20 ibpa during the ‘warm-up’ period but 
then changes in the transmission, and hence the EIR during the observation period 
were induced by simulating IRS programs carried out in parallel with the simulated 
vaccination programs. The simulated coverage and effectiveness of the IRS programs 
were adjusted to achieve approximately linear trends in EIR in the absence of 
vaccination.  
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VACCINE DELIVERY STRATEGY 
Four delivery strategies were considered:  
 (i) EPI. Coverage of 89%, based upon Tanzania’s DTP3 coverage in 2002. 95% of 
subjects received one dose, 93% two doses, and 89% all three doses.  
 (ii) EPI plus catch-up. In addition to delivery through EPI (i above), children up to 18 
months of age were vaccinated at monthly campaigns with three doses at program 
initiation only. Coverage of children through campaigns was 80% selecting randomly 
for each dose, thus 51% of children up to 18 months of age received all three doses.  
 (iii) EPI plus vaccination of school children. In addition to delivery through EPI (i 
above), primary school age children (aged 6 to 11 years) were vaccinated in monthly 
campaigns with three doses at program initiation only. Coverage of children through 
campaigns was 80% selecting randomly for each dose, thus 51% of children 6 – 11 
years of age received all three doses. Each subsequent year, only new students were 
vaccinated. Children who were initially vaccinated as infants received a single 
(booster) dose upon entry into the school system, also at 80% coverage. 
 (iv) Mass vaccination. People from all ages were vaccinated in an initial campaign for 
three doses at one month intervals. Coverage through campaigns was 80% selecting 
randomly for each dose, thus 51% of people of all ages receive all three doses. 
Subsequent campaigns delivered a single booster to 80% of the population every five 
years. 
VACCINE EFFICACY AND HALF LIFE  
RTS,S was modeled to have an efficacy of 60% against the force of infection from the 
time of completing the full, three dose vaccination course. Efficacy after a single dose 
and two doses was modeled as 40% and 50%, respectively. The same moderate level 
of heterogeneity among individuals in the level of protection was assumed as in 
previous simulations [236,246]. Efficacy against clinical disease in these models is 
lower than efficacy against force of infection [236,246], as is the efficacy against 
severe disease found in a clinical trial. Field studies have not yet associated efficacy 
against clinical disease with efficacy against deaths. Vaccine efficacy against force of 
infection was modeled to decay exponentially with a half-life of ten years. Past 
modeling has suggested that vaccine impact is not particularly sensitive to the length 
of the half-life in the 4 – 10 year range [235], but that if half-life is shorter than this it 
will narrow the settings in which the vaccine may be useful. In these models, clinical 
efficacy wanes more rapidly than efficacy against the force of infection [246]. 
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RESULTS 
NUMBER OF DOSES REQUIRED 
Figure 20 shows the cumulative number of doses per capita (in the all age population) 
required for each delivery strategy over a ten year period. EPI (strategy i), vaccinating 
infants from six weeks of age, required the fewest doses, ranging from 0.67/capita 
over five years to 1.50/capita over ten years. For a population of 100,000 this is 
equivalent to 67,000 doses over five years and 150,000 over ten years. An EPI plus 
catch-up strategy (ii), which involves a single campaign in the first year, targeting the 
cohort of children up to 18 months of age, required an additional 0.10 doses/capita. 
The EPI plus school-based strategy (iii), which assumed 51% of kids fully vaccinated, 
required 1.14 doses/capita over five years and 2.12/capita over ten years. The mass 
campaign (strategy iv), which assumed 51% of the population fully vaccinated, 
progressed in a stepped fashion. The year-one campaign required 2.37 doses/capita, 
or 237,000 for a population of 100,000. A total of 3.38 doses/capita was required after 
the booster in year five.  
FIGURE 20. CUMULATIVE DOSES PER CAPITA, BY DELIVERY STRATEGY, IN A DYNAMIC 
POPULATION. 
 
Legend: Black = EPI; Yellow = EPI plus catch-up of children up to 18 months of age; Brown = EPI plus 
school-based immunization of children 6-11 years of age; Green = Mass campaigns in entire population. 
The per capita estimates assume a dynamic population, modeled upon the age distribution in rural 
Tanzania. 
  
IMPACT OF DELIVERY STRATEGY ON TRANSMISSION 
Figure 21 presents the impact of RTS,S, delivered through EPI or mass vaccination, on 
malaria transmission over a ten year period, in each transmission setting except EPI 
plus catch-up and EPI plus school-based strategies. These were similar to those with 
EPI alone. Also, results for EIR = 20 ibpa, similar to those of EIR = 11 ibpa, are not 
shown.  
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FIGURE 21A – F. MODIFICATION OF TRANSMISSION TRENDS, BY DELIVERY STRATEGY, 
OVER TEN YEARS. 
Legend: The first column corresponds to no vaccine, the second corresponds to vaccine delivered 
through EPI and the third corresponds to vaccination through mass campaigns to all ages of the 
population. The vertical axis for each panel is EIR on a log scale measured in infectious bites per person 
per night. The horizontal axis for each panel is time in years. The blue line corresponds to the median 
transmission of the 14 models, while the grey shading reflects the range of medians from each of the 
models. 
Panel A: EIR=11 ibpa; B: EIR=2 ibpa; C: EIR decreasing from 20 down to 2 ibpa over 10 years; D: EIR 
increasing after brief suppression from 2 to 20 ibpa over 10 years; E: EIR increasing from 2 to 20 ibpa 
after being suppressed for 10 years; F: EIR suppressed from 20 down to 2 ibpa, and subsequently 
maintained at 2 ibpa.  
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The annual patterns were a result of seasonality of vector abundance and the timing of 
the IRS rounds, if implemented. Consistent with past analyses using a fixed level of 
transmission [232,244], RTS,S did generally not have much impact on transmission in 
the higher EIR ranges modeled. At EIR = 2 ibpa, whether naturally occurring, or 
suppressed to that level through use of IRS, the vaccine lowered transmission initially 
when delivered through mass campaigns but the effect leveled off after seven years. 
IMPACT ON UNCOMPLICATED MALARIA CASES 
Table 27 presents the number of uncomplicated malaria cases experienced in each 
setting and the percentage of those cases which could be averted by RTS,S, depending 
on the delivery strategy. 
TABLE 27. UNCOMPLICATED CASES AVERTED WITH RTS,S BY TRANSMISSION SETTING 
AND DELIVERY STRATEGY. 
 
Cases/Person-
year (without 
vaccine) 
Percentage of cases averted 
(Range) 
Transmission 
setting 
 EPI 
Catch-up 
(plus EPI) 
School-
based  
(plus EPI) 
Mass 
campaign 
a) EIR = 11 1.63 6.0 
(4.8-7.0) 
7.1 
(5.6-8.4) 
12.0 
(8.6-13.1) 
24.5 
(20.2-30.6) 
b) EIR = 2 1.38 5.2 
(4.1-6.0) 
6.6 
(5.4-7.3) 
17.6 
(15.0-21.7) 
73.0 
(70.4-76.5) 
c) Decreasing  
(EIR 20 to 2) 
1.35 7.1 
(5.5-8.0) 
8.6 
(6.6-9.7) 
14.0 
(10.0-16.4) 
30.0 
(25.4-37.9) 
d) Increasing after 
brief suppression 
(EIR 2 to 20) 
1.96 5.1 
(3.7-6.8) 
5.2 
(3.7-7.0) 
11.9 
(7.8-20.5) 
32.1 
(26.4-59.7) 
e) Increasing after 
10 year suppression 
(EIR 2 to 20)  
2.97 3.4 
(2.5-4.5) 
4.1 
(3.0-5.8) 
8.3 
(5.2-12.6) 
20.7 
(16.7-50.2) 
f) Suppressed  
(EIR = 2)  
1.46 5.1 
(3.0-6.1) 
6.6 
(4.6-7.8) 
15.3 
(9.9-17.8) 
48.5 
(20.2-50.1) 
g) EIR = 20 1.53 6.0 
(4.1-7.1) 
7.0 
(4.4-8.2) 
10.0 
(5.4-11.6) 
15.5 
(6.6-20.7) 
Legend: The first column presents transmission settings. The second column presents the total 
estimated cases in the population of 100,000 people per person-year in the absence of vaccination. The 
remaining columns present the percentage of cases averted by each delivery strategy, as the median 
and (range) estimated from 14 models.   
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All-age rates of uncomplicated disease in simulated stable settings were rather 
insensitive to the average level of EIR, corresponding to the data used to fit the models 
[228,252], where the effect of varying transmission is to shift the age-pattern, rather 
than the overall incidence of uncomplicated disease. However, changes in EIR, and in 
particular an increase in transmission has a substantial effect on simulated incidence. 
In the absence of vaccination, each person was estimated to have between 1.35 cases 
per year (in a decreasing transmission setting) and 2.97 cases (setting where control 
was lost).  
EPI averted 3.4 – 6.0% of malaria cases depending on the transmission, while EPI plus 
catch-up averted 4.1 – 8.6% of cases. EPI plus school-based strategies averted 8.3 – 
17.6% of cases, depending on transmission, while mass campaigns averted 15.5 – 
73.0% of cases. The range of estimates was widest for the mass campaign strategies 
and most narrow for EPI strategies.  
Figure 22 presents the ratio of uncomplicated cases averted to 1000 doses 
administered. This standardized measure allows comparison of the efficiency of 
different delivery strategies across transmission settings.  
Across all settings, the cumulative number of cases averted per1000 doses was highest 
with mass campaigns, followed by EPI plus school, EPI plus catch-up, and EPI alone. 
After ten years, EPI and EPI plus catch-up averted 500 – 700 cases per 1000 doses 
across all settings. An EPI plus school-based strategy averted 800 – 1100 cases per 
1000 doses across all settings. Results from mass campaigns were more variable. In 
settings with EIR = 11 ibpa (Panel A), decreasing EIR (Panel C), and increasing EIR after 
a brief suppression (Panel D), RTS,S averted 1100 – 1300 cases per 1000 doses. In a 
setting with EIR increasing after ten years suppression (Panel E), it averted 
approximately 2000 cases per 1000 doses from year eight onwards but the effect 
appeared to be plateauing. In a setting with EIR suppressed to 2 ibpa (Panel F), it 
averted a similar ratio of cases over the ten year period, but the curve suggested 
increasing efficiency beyond year ten. The highest efficiency was seen in EIR = 2 ibpa 
where the models predicted that RTS,S could avert more than 2000 cases per 1000 
doses after 5 – 8 years.  
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FIGURE 22A – F. UNCOMPLICATED CASES AVERTED PER 1000 DOSES ADMINISTERED, 
BY DELIVERY STRATEGY AND TRANSMISSION SETTING, OVER TEN YEARS.  
Legend: Vertical axis for each panel is 
number of cumulative uncomplicated cases 
averted per 1000 doses administered. 
Horizontal axis is years. Vaccination is 
assumed to begin at year one with the 
vaccination schedule completed three 
months later for the first subjects. 
Black = EPI; Purple = EPI plus catch-up of 
children up to 18 months of age; Brown = 
EPI plus school-based immunization of 
children 6-11 years of age; Green = Mass 
campaigns in entire population.  
Panel A: EIR=11 ibpa; B: EIR=2 ibpa; C: EIR 
decreasing from 20 down to 2 ibpa over 10 
years; D: EIR increasing after brief 
suppression from 2 to 20 ibpa over 10 
years; E: EIR increasing from 2 to 20 ibpa 
after being suppressed for 10 years; F: EIR 
suppressed from 20 down to 2 ibpa, and 
subsequently maintained at 2 ibpa.  
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IMPACT ON MALARIA DEATHS 
Table 28 presents the number of malaria deaths, per 1000 person-years, occurring in 
each transmission setting, and the percentage of deaths which simulations suggested 
could be averted by RTS,S. Figure 23 complements this data, presenting the 
cumulative deaths averted per 1000 persons over 10 years for each of the 14 models.  
TABLE 28. DEATHS AVERTED WITH RTS,S BY TRANSMISSION SETTING AND DELIVERY 
STRATEGY. 
 
Deaths/1000 
person-years 
(without 
vaccine) 
Percentage of deaths averted 
(Range) 
Transmission 
setting 
 
EPI 
Catch-up 
(plus EPI) 
School-
based 
(plus EPI) 
Mass 
campaign 
a) EIR = 11 3.8 13.7 
(10.3-16.2) 
14.8 
(11.9-16.7) 
15.9 
(10.3-20.9) 
18.8 
(7.1-25.7) 
b) EIR = 2 3.7 10.2 
(7.2-14.3) 
11.9 
(9.0-16.7) 
22.4 
(14.5-26.0) 
68.1 
(65.5-72.2) 
c) Decreasing 
(EIR 20 to 2) 
3.3 15.5 
(11.3-17.7) 
17.2 
(14.1-20.9) 
19.0 
(12.4-20.7) 
25.2 
(13.1-32.8) 
d) Increasing 
after brief 
suppression 
(EIR 2 to 20) 
5.0 10.3 
(8.0-11.5) 
9.8 
(7.3-11.4) 
14.9 
(9.0-20.1) 
28.3 
(13.8-58.5) 
e) Increasing 
after 10 year 
suppression  
(EIR 2 to 20)  
7.8 6.8 
(3.1-8.3) 
7.2 
(4.9-9.0) 
9.4 
(3.7-12.1) 
14.2 
(1.8-42.5) 
f) Suppressed 
(EIR = 2)  
3.7 10.5 
(5.6-12.7) 
11.7 
(4.4-14.7) 
18.7 
(10.8-21.1) 
45.4 
(21.0-47.5) 
g) EIR = 20 3.8 13.3 
(9.6-15.7) 
14.0 
(9.7-17.8) 
13.6 
(8.1-18.8) 
9.9 
(1.6-15.7) 
Legend: The first column presents transmission settings. The second column presents the total 
estimated malaria deaths in the population of 100,000 people per person-year in the absence of 
vaccination. The remaining columns present the percentage of deaths averted by each delivery strategy, 
as the median and (range) estimated from 14 models. 
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FIGURE 23A – F. DEATHS AVERTED PER 1000 POPULATION, BY TRANSMISSION 
SETTING, OVER TEN YEARS.  
Legend: The first column 
corresponds to vaccine delivered 
through EPI and the second 
corresponds to vaccination 
through mass campaigns to all 
ages of the population. The 
vertical axis for each panel is 
number of cumulative deaths 
averted per 1000 population. The 
horizontal axis for each panel is 
years. The black lines correspond 
to the median effect estimated by 
each of the 14 models, while the 
grey shading reflects the range of 
model medians. Vaccination is 
assumed to begin at year one 
with the vaccination schedule 
completed three months later for 
the first subjects. 
Panel A: EIR=11 ibpa; B: EIR=2 
ibpa; C: EIR decreasing from 20 
down to 2 ibpa over 10 years; D: 
EIR increasing after brief 
suppression from 2 to 20 ibpa 
over 10 years; E: EIR increasing 
from 2 to 20 ibpa after being 
suppressed for 10 years; F: EIR 
suppressed from 20 down to 2 
ibpa, and subsequently 
maintained at 2 ibpa.  
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Delivery through EPI was estimated to avert 6.8 – 15.5% of malaria deaths, depending 
on the transmission, while EPI plus catch-up averted 7.2 – 17.2% of deaths. EPI plus 
school-based strategies averted 13.6 – 22.4% of deaths, depending on transmission, 
while mass campaigns averted 9.9 – 68.1% of deaths. The range of estimates was 
widest for the mass campaign strategies and narrowest for EPI strategies. This is 
illustrated by the variation between model medians shown in Figure 23. The only 
setting where all model medians showed higher impact from mass campaigns than 
from EPI was in settings with EIR = 2 ibpa (Panel B). A high level of uncertainty was 
associated particularly with settings where the EIR was increasing after a brief 
suppression (Panel D), increasing after a ten year suppression (Panel E), or 
continuously suppressed to 2 ibpa (Panel F).  
The efficiency of RTS,S averting deaths is presented as a ratio of the number of deaths 
averted to 1000 doses administered (Figure 24). The results for the setting of EIR = 20 
ibpa is not shown as it was similar to the setting of EIR = 11 ibpa. 
Across all settings, the cumulative number of deaths averted per 1000 doses of RTS,S 
generally leveled off at a maximum of 3 – 4. Such efficiency was realized only after 
approximately seven years in settings with increasing transmission, either after brief or 
ten year suppression (Panels D and E), while it was reached after only two to three 
years in the setting with decreasing transmission (Panel C) with delivery through EPI 
plus catch-up or EPI alone. The highest impact after ten years was approximately 5 – 7 
deaths averted per 1000 doses with mass campaigns (reaching 51% of people with 
three doses) in settings where the EIR was naturally at or suppressed to 2 ibpa (Panels 
B and F). Note that in these settings, RTS,S not only protected those vaccinated, but 
also reduced transmission (Figure 21). 
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FIGURE 24A – F. DEATHS AVERTED PER 1000 DOSES ADMINISTERED, BY DELIVERY 
STRATEGY AND TRANSMISSION SETTING, OVER TEN YEARS. 
Legend: Vertical axis for each panel is 
number of cumulative deaths averted per 
1000 doses administered. Horizontal axis is 
years. Vaccination is assumed to begin at 
year one with the vaccination schedule 
completed three months later for the first 
subjects. 
Black = EPI; Purple = EPI plus catch-up of 
children up to 18 months of age; Brown = 
EPI plus school-based immunization of 
children 6-11 years of age; Green = Mass 
campaigns in entire population.  
Panel A: EIR=11 ibpa; B: EIR=2 ibpa; C: EIR 
decreasing from 20 down to 2 ibpa over 10 
years; D: EIR increasing after brief 
suppression from 2 to 20 ibpa over 10 
years; E: EIR increasing from 2 to 20 ibpa 
after being suppressed for 10 years; F: EIR 
suppressed from 20 down to 2 ibpa, and 
subsequently maintained at 2 ibpa. 
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DISCUSSION 
Modeled estimates of the effect of the RTS,S vaccine allow for comparisons of 
uncomplicated cases and deaths averted, and the efficiency of different delivery 
strategies to avert those cases and deaths, in a variety of malaria transmission 
settings. 
In most transmission settings studied, an approximately proportional relationship 
between the number of deaths averted and the number of doses administered 
through EPI, EPI plus catch-up and EPI plus school-based campaigns, was observed 
over the ten year period simulated. That is, among the delivery strategies that target a 
portion of the population, the greater the number of doses administered, the greater 
the total number of lives that can be saved.  
The EPI strategy immunized the fewest people over ten years, and consequently 
averted the fewest deaths, but with a relatively high efficiency per 1000 doses 
administered across transmission settings. EPI has demonstrated its feasibility and is 
compatible with current clinical trial and regulatory plans. The opportunity to make 
use of the thus far successful EPI infrastructure is a strong argument to use this 
strategy in (all) transmission settings where it is likely to be cost-effective to deliver 
RTS,S this way.  
Supplementing EPI delivery with a one-time catch-up vaccination reaching children 
below 18 months may be particularly appealing in an environment with decreasing 
transmission (setting c). The catch-up delivery round would require additional 
investment and planning beyond that seen for EPI, although most likely less than 
required for repeated school-based or mass campaigns.  
School-based delivery strategies did not increase efficiency in any of the transmission 
settings studied, so its main benefits are in reaching a greater number of people. A 
recent pilot of school-based strategies for delivering human papilloma-virus (HPV) 
vaccine could be part of the momentum to strengthen and expand school-based 
strategies over time [253].  
The findings for mass campaigns were more complex. Mass campaigns reached many 
times more people than EPI alone, and simulations suggested this delivery strategy 
could be expected to avert more cases and deaths in some situations. Highest 
efficiency was seen in very low transmission settings (e.g. EIR of 2 ibpa), whether 
naturally occurring or achieved by other interventions (settings b and f). Efficiency 
decreased as transmission increased, making mass campaigns much less efficient than 
EPI at EIRs above 2 ibpa.  
The impact of mass campaigns varied the most between different transmission 
settings, and there were wide ranges in the model predictions. The expected benefits 
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of mass vaccination were highly sensitive to model assumptions about transmission 
heterogeneity and immunity. There is a clear need to improve the evidence base for 
parameterizing these aspects of the models. Part of the uncertainty about impact of 
mass-vaccination (also reaching adults) arose because relatively sparse data about 
disease incidence in older people were available when the models were fitted 
[225,228]. In our models, the main effect of reducing transmission on disease is to shift 
morbidity to older ages. It is not clear how important this shift is in settings where 
transmission is currently reducing. If this shift is less important, independently of the 
effects of the vaccine, we might have expected to see larger effects of reducing 
transmission on morbidity and mortality rates. In contrast to most field datasets, the 
presented rates are calculated over the entire population and simulated events in 
adults dilute the effects on children. Thus, caution is advised when interpreting model 
results of mass campaigns until further data is available. 
Mass vaccination also appears the most distant potential RTS,S delivery strategy. New 
clinical trials, in older age groups potentially with different safety questions and 
needing different doses, may be necessary. Regulatory, cost-effectiveness and 
feasibility considerations related to mass campaigns may also need to be addressed. 
The findings suggest that further work is needed to more clearly understand the 
impact and feasibility of mass campaigns, potentially when partnered with other 
interventions to rapidly decrease transmission. The potential for significant impact in 
some settings may make it worth beginning to anticipate such work. 
Estimates of efficiency in this paper are expressed using the ratio of deaths averted 
per 1000 doses of vaccine. This can be converted to deaths averted per 1000 
vaccinees, a ratio used by the GAVI Alliance (GAVI) when considering the impact of 
various vaccines it supports financially [254]. The ratio of deaths averted by 
pneumococcal conjugate vaccine in African infants is estimated from trial data to be 7 
per 1000 vaccinees (59 deaths averted in 8000 vaccinees) [255]. Immunizing 1000 
infants with RTS,S via EPI, given the coverage assumptions stated earlier, equates to 
delivering approximately 2770 doses of vaccine. Given the ratios under transmission 
settings above, simulations suggest RTS,S in EPI would avert 2 – 4 deaths per 1000 
doses, equivalent to 6 – 11 deaths per 1000 vaccinees. These ratios compare favorably 
with the pneumococcal vaccine, for which implementation planning is progressing 
rapidly in Africa and some $3 billion in financing have been committed [184]. 
The findings across the different settings suggest that for understanding the potential 
impact of pre erythrocytic vaccines, it is probably sufficient to use fixed transmission 
settings in modeling efforts, even for situations where the underlying baseline 
transmission is believed to be decreasing or increasing. The simulations used in this 
paper used IRS to create trends in transmission. Effects would have been slower if the 
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transmission changes were induced by LLIN use, but there is no reason to assume that 
the relative impact of the delivery strategies would be different.  
The effect for RTS,S was expected to be at maximum in the transmission range studied 
in these simulations (2 – 20 ibpa). It is reasonable to expect that EPI, EPI plus catch-up 
and EPI plus school-based strategies will have comparable effects to those seen in this 
paper at somewhat higher transmission settings than studied. Although cost-
effectiveness estimates for EPI are available [248], the other impact estimates could be 
further informed by cost and cost-effectiveness analyses which were beyond the 
scope of this paper 
CONCLUSION 
The development of the RTS,S malaria vaccine is progressing. If the vaccine is shown to 
be safe and efficacious in the current phase III trial, as has been shown in earlier trials, 
and it is made available to countries in Africa, there will be a complex decision-making 
process to determine how and where it should be used. In order to help this process, 
the authors studied the potential impact and efficiency of RTS,S delivered through 
various strategies and under changing levels of malaria transmission patterns, 
although findings suggest that it is probably sufficient for future simulations to 
consider constant EIR levels. The type of impact sought, whether on mortality and 
morbidity, or on transmission as well, together with assumptions about feasibility of 
different delivery strategies, may lead to different conclusions about the role of RTS,S.  
Findings support further investigation of RTS,S to determine its potential contribution 
to malaria transmission reduction through high coverage of an all age population in 
low transmission settings. At 2 ibpa, mass campaigns could avert the most deaths and 
decrease transmission; however, a lot of uncertainty was associated with these 
findings. Also, the feasibility of mass campaigns delivering a multi-dose immunization 
requires assessment. Further consideration of the regulatory implications, clinical 
studies required to address questions of the extent of the benefit, and other product 
development activities will be important to anticipate, prior to RTS,S being used in 
mass campaigns. Such considerations would benefit from early planning due to their 
lengthy nature.  
The findings also support going forward with EPI delivery as an initial strategy for 
RTS,S. If delivered via established EPI systems, RTS,S could avert approximately 6 – 11 
deaths per 1000 vaccinees in all examined settings, an efficiency consistent with or 
superior to other new vaccines being implemented across Africa. However, it would 
have little effect on transmission when delivered via EPI. The number of events 
averted increases somewhat with the EPI plus catch-up and the EPI plus school-based 
strategies. The increase is essentially proportional to the larger population covered, 
and because that larger population coverage is modest, it is not an enormous added 
PLANNING FOR NEW HEALTH INTERVENTIONS   
RTS,S impact in changing malaria transmission  164 
benefit. These results, combined with those of other modeling studies, should provide 
information to help policy-makers at international and country-levels to take evidence-
based decisions on optimal strategies to avert malaria cases and deaths in Africa. 
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CHAPTER 9. SYNTHESIS, FUTURE RESEARCH AND CONCLUSIONS 
INTRODUCTION 
This thesis proposes a novel approach for transitioning health interventions from 
research and development (R&D) to decisions on use and implementation through 
health systems in developing countries. It is about accelerating access to interventions 
for those most in need. It is built upon a hypothesis that there have been re-occurring 
delays in implementing interventions, and that the causes of those delays can be 
foreseen and minimized by beginning to address them during R&D. It details elements 
of a strategy to address the delays, building upon the access framework created by 
Frost and Reich (2008), and research and practical examples from work relating to 
malaria vaccines and other interventions. It intertwines the implications and lessons 
for new health interventions into each chapter. Only through a new approach can the 
decade plus of delays between development and implementation of most 
interventions be decreased. Such a decrease holds the promise of saving millions of 
lives.  
Chapter one establishes the context of the thesis, highlighting that a growing number 
of new interventions are under development and being approved by regulatory bodies 
for use in developing countries. Chapter two addresses how long it has typically taken 
for interventions to be implemented, determining that over the past decade the pace 
of implementation appears to have remained largely unchanged from that in the 
1980s. The chapter introduces the major themes found in the remainder of the thesis 
and proposes modifications to Frost and Reich’s access framework, identifying key 
activity milestones which can be anticipated and worked towards during R&D in order 
to accelerate later access. Chapter three considers the importance of strategies for 
ensuring that as products become available they are aligned with the needs of and 
acceptable to health systems and health system users. Chapter four analyses the roles 
and decisions of international organizations, such as setting policies, making 
recommendations, and issuing guidelines, which impact adoption decisions by 
countries. Chapter five reviews the support provided by product development 
partnerships (PDPs) for decision-making in developing countries (DCs), while chapter 
six reports on research related to national decision-making on malaria vaccines more 
specifically. Chapters seven and eight provide examples of two complementary 
modeling approaches which support R&D and adoption decisions.  
NEW STRATEGY TO ACCELERATE ACCESS 
Frost and Reich’s access framework focuses primarily on the implementation period, 
after interventions have been approved by regulators. Yet the activities in the 
framework are impacted by decisions and activities undertaken during the R&D 
period. This realization led to the modified access framework in this thesis (Figure 25). 
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The modified access framework identifies activities to be undertaken during R&D, 
prior to regulatory approval, as a new strategy to accelerate access. The framework, 
elaborated upon in chapter two, summarizes major themes which are considered in 
subsequent chapters. Briefly, it consists of activities related to: 1) establishment of an 
architecture coordinating the activities related to an intervention; 2) availability of the 
intervention; 3) affordability; and 4) decisions on adoption at international, national, 
and individual levels. Activities occur in the context of and in coordination with 
regulatory oversight, and pre-clinical, clinical, and effectiveness studies. Epidemiologic, 
economic and impact data inform adoption decisions, implementation and access but 
may have far wider relevance than a single intervention, represented by their position 
in parallel to other activities but also considered by the same overall coordinating 
architecture.  
The framework represents a strategy which should be relevant to most new health 
interventions targeting the developing world, but should not be seen as fixed or one-
size-fits-all. Activities in the framework will need to be tailored to the context of each 
intervention. As noted in chapter two, the activities impact and are impacted by each 
other. The interrelationships are likely to vary, such that the framework is a starting 
point to tailor activities specific to each interventions’ needs, as seen in the individual 
chapters. Subsequent sections will reflect on how the individual chapters relate to the 
access framework. 
ACCESS ARCHITECTURE (COORDINATOR) 
A coordinating architecture during the R&D period ensures that plans for and activities 
addressing availability, affordability, and adoption are undertaken. It serves as “glue.” 
It also anticipates what needs to occur during the decision and implementation period 
so that access activities smoothly transition after regulatory approval. The coordinator 
helps to see that access activities integrate well with complementary R&D work, for 
example that clinical studies address the needs of policy-makers (Chapters 3-6) and 
that burden of disease studies are generating timely, relevant data (Chapters 7 and 8). 
The coordinator should understand and foresee the needs of health systems and 
individuals, and play a critical role helping to balance those needs with R&D and 
manufacturing decisions, such as during the establishment of target product profiles 
(TPPs) (Chapter 3). The coordinator should be deeply familiar with the timing of R&D 
decisions and data in order to be sure that access planning does not fall behind R&D 
activities. On the other hand it should also be cautious to not get ahead of R&D 
findings and risk overpromising. The not-for profit partner in a product development 
partnership (PDP), a university, WHO, or a similar group may be well positioned to act 
as the coordinator. 
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FIGURE 25. PROPOSED ACCESS FRAMEWORK INCORPORATING R&D AND 
IMPLEMENTATION PERIODS. 
 
Legend: The area in grey reflects Frost and Reich’s (2008) original access framework. Other areas are 
new to the framework. Actions that take place during the R&D period are described in the space above 
the black strip, “Regulatory Approval, while actions carried out in the decision and implementation 
period are described in the space below. Area in grey is reproduced under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License. 
 
AVAILABILITY 
Availability reflects the importance of, and strategies to ensure that, an intervention 
approved by regulators will be produced in sufficient quantities for developing 
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countries. Forecasting and manufacturing planning are important to ensuring that 
sufficient product will be available for demand in the developing world, and at an 
affordable price. Available interventions should also be designed and have 
characteristics aligned with the needs of relatively fragile developing world health 
systems and acceptable to health system users.  
Chapter three considers target product profiles (TPPs) and research into the design of 
interventions. For example, an available intervention should have characteristics which 
minimize its implementation costs, impacting affordability, such as avoiding special 
handling requirements by distributors and health workers. The alignment of an 
intervention with developing country needs arises in chapter four regarding 
international organizations, as one factor determining if WHO will pre-qualify an 
intervention and provide a recommendation on use. Countries also indicate in chapter 
six that they want to give input into intervention characteristics. Modeling plays a key 
role, as reflected in chapters seven and eight, estimating the impact of various 
intervention characteristics and delivery strategies in order to inform R&D and policy 
decisions.  
AFFORDABILITY 
Affordability activities seek to ensure that purchase price and implementation costs 
will not prevent developing countries from using an intervention. They include 
planning for financial subsidies from international organizations as well as ways to 
minimize capital and recurrent implementation costs. Specific studies to further 
address or complement affordability considerations could target the willingness and 
ability of donors, countries, and individuals to pay (e.g. budget impact analyses), 
financial sustainability, and/or determining if an intervention is a wise use of funds 
such as through cost-effectiveness analyses.  
As noted above and in chapter three, planning for the characteristics of an 
intervention should include their impact on affordability. Chapter four considers the 
importance and timing of policy decisions by international financing organizations, 
particularly GFATM and GAVI, to subsidize procurement and implementation of new 
interventions. It notes that these organizations tend to rely upon WHO 
recommendations regarding adoption and use when deciding to commit funds. 
Chapter five considers the ways PDPs are supporting countries to address affordability. 
Chapter six finds that affordability, financial sustainability of national and donor 
commitments, and cost-effectiveness are important considerations in DC decision-
making. Chapter seven reports on modeling work which includes estimates of the 
costs and financing requirements of averting events (e.g. uncomplicated malaria cases; 
deaths) for different malaria vaccines in different epidemiological settings and using 
different delivery strategies. Chapter eight raises trade-offs between delivery 
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strategies, such as mass campaigns, that may provide more public health impact than 
infant immunization, but which may not be financially or technically feasible.  
ADOPTION 
Activities during the R&D period need to address the data required by international 
organizations to set policies, make recommendations and issue guidelines on the use 
of an intervention. Activities should also address research questions specific to and 
anticipated from developing country governments, and ensure that interventions will 
be acceptable to users of health systems. As much data as reasonably possible for 
international and country-level decision-makers should be available at the time of 
regulatory approval. Otherwise, years of additional work may be required to generate 
data informing adoption decisions, while a licensed intervention sits waiting. 
Chapter three considers the importance of clinical trials addressing the questions and 
populations specific to use of an intervention in DCs.  Chapter four highlights the role 
of early collaboration of developers with WHO and other international organizations 
to anticipate their requirements, as much as feasible, in study designs. Chapters five 
and six focus on activities in support of country processes to decide on the adoption, 
or not, of interventions into national health systems, including the importance of 
having an intervention that is acceptable to health system users. Chapters seven and 
eight present modeling approaches intended to inform adoption decisions by 
international and national policy-makers. 
REGULATORY OVERSIGHT/REGULATORY MONITORING 
The work of regulatory agencies, or in some cases WHO or others playing a regulatory-
like role for interventions, is not part of Frost and Reich’s original access framework. 
As noted in chapter two, regulation was added to the modified framework as it 
directly impacts access activities. During the R&D period, regulatory agencies impact 
decisions on intervention and trial design (Chapter 3.) The determination by a 
regulatory agency that an intervention is of assured safety and quality, and is 
efficacious, then monitoring to assure quality and safety do not change, is a critical 
input to WHO and other policy-making groups, as well as DCs (Chapters 4-6).  
PRE-CLINICAL AND CLINICAL STUDIES; PHASE FOUR/COMMUNITY EFFECTIVENESS AND 
SYSTEM EFFECTIVENESS STUDIES 
Clinical, phase four, and community effectiveness studies are also not part of Frost and 
Reich’s original framework. They impact, and are impacted by, TPP decisions as 
described in chapter three. They are critical to decisions of international organizations 
(Chapter 4) as well as countries (Chapters 5-6). Modeling (Chapters 7-8) helps translate 
data from such studies into estimates for policy-makers to inform adoption decisions. 
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BURDEN OF DISEASE, ECONOMICS, AND GENERATING EVIDENCE OF IMPACT 
The range of studies necessary to complement access activities depends greatly on the 
disease and intervention. For example, recent interventions like rotavirus and 
pneumococcal vaccines became available while DCs remained unfamiliar with their 
underlying burdens of disease from these pathogens. In contrast, a new intervention 
targeting P. falciparum malaria in Africa does not need to be accompanied by new 
data seeking to determine if malaria is a problem, but instead by data regarding the 
role the intervention may play relative to existing interventions. The coordinating 
architecture must ensure that the critical studies are in place to support the other 
access activities at the appropriate times.  
Chapters seven and eight describe models intended to help understand the roles of 
interventions in the context of changing disease burden and use of other 
interventions, and to generate impact and economic estimates. Chapter three 
highlights that the TPP should be consistent with the intended impact, a consistency 
that is likely explored through models. Chapter four recognizes the importance of data 
arising from studies for international organizations to take decisions. Chapter five 
reviews how PDPs are supporting such studies. Chapter six addresses the need for 
such studies from a country perspective, and if such studies need to be done in each 
country or whether the decision-makers felt that data extrapolated from other 
countries or models was sufficient. 
TAKING ACTION: OPERATIONALIZING THE STRATEGY 
The chapters in this thesis cover a wide range of activities, many developed or 
researched over multiple years. Incorporating access planning into the R&D period of a 
new intervention is not a small or simple undertaking. However, such an undertaking 
should be seen in the context of investments to develop and license a new 
intervention which can take a decade or more, costing tens or hundreds of millions of 
dollars. The experience from malaria vaccines, and interventions more generally, 
suggest a number of lessons for those seeking to incorporate access planning into the 
R&D period. The lessons reflect the conclusions of the author only, and in no way 
reflect those of any individual organizations. 
RECRUIT THE APPROPRIATE SKILL SETS  
The R&D team working on an intervention should be complemented by individuals 
deeply familiar with developing countries and health systems, and able to bring those 
insights to R&D discussions when needed. While it may be sufficient to draw upon 
such skill sets on an ad hoc, consultancy basis if interventions are only in early 
development, a dedicated unit may be needed as products move towards late 
development. An organization should consider how accountabilities may shift as R&D 
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progresses, for example with the staff focused on access having regular roles in R&D 
decisions as an intervention moves into late development. 
AGREE WHO FILLS THE COORDINATING ROLE 
There may be many organizations that could provide the coordinating architecture for 
an intervention. Perhaps the most likely is whichever is most deeply involved in R&D. 
PDPs, universities, research institutes, and WHO have all filled the coordinating role. 
The organization could be from the developed or developing world. The role requires 
investment in terms of staff, collaboration with partner organizations, and support for 
access-related research. 
TAILOR THE STRATEGY TO THE INTERVENTION AND WIDER CONTEXT 
Those responsible for the access strategy during R&D need to begin with an 
understanding of the context of the disease in developing countries, and the most 
likely means of implementation. From this understanding, one can create a timeline 
backwards from the envisioned access to the current phase of development. The 
framework and chapters in this thesis provide conceptual as well as practical ideas 
about what may need to be addressed and when. It may be helpful to structure the 
timeline and activities to be addressed according to critical time points in the R&D 
process (e.g. transition from phase I to II, or phase II to III of clinical trials; regulatory 
decisions.)  
SET EXPECTATIONS FOR A LONG-TERM VIEW AND LONG-TERM PROCESS  
As with intervention development, addressing access-related issues is a multi-year 
process. Consideration of access-related issues should begin early in the R&D process, 
as part of establishing TPPs. The work intensifies as interventions move into late 
development. Expectations need to be set not only within the coordinating 
organization or with those leading the R&D, but also with funders and with groups like 
WHO which may be challenged to foresee their data needs years in advance.  
AGREE ON MANDATE WITH FUNDERS 
Planning for access may be seen as tangential to core R&D activities. It is important to 
explicitly agree with funding agencies supporting an organization on roles and discrete 
support for activities related to access during R&D. 
WHO COLLABORATION 
WHO plays a unique role in relation to health systems in developing countries. It also 
plays a key policy-setting role that is relied on by other organizations. It is important to 
work with WHO as early as possible to find the appropriate level and timing of 
collaboration relative to key R&D time-points, as detailed in chapter four, and 
discussed in chapters three, five, and six.  
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FUTURE RESEARCH 
This thesis raises a number of future research questions. The perspective of the thesis 
is largely that of not-for profit organizations working on interventions intended for use 
through national health systems in DCs. It could be valuable to explore the access 
framework and findings of the individual chapters through the perspectives of for-
profit partners, such as pharmaceutical companies, or private health practitioners in 
developing countries. Regulatory agencies may also have unique perspectives on the 
issues raised in this thesis. 
The work focused most on interventions targeting malaria, vaccines, and malaria 
vaccines, while attempting to generalize findings to other interventions. Malaria and 
vaccines reflect a broad range of intervention types and diseases, addressing some of 
the most important causes of mortality and morbidity in the developing world. 
However the fields of malaria and vaccines are among the highest-profile, with wide 
support at international, country, and community levels. It could be valuable to apply 
this access strategy to a relatively neglected disease and/or type of intervention. 
As a growing number of interventions specifically intended to address diseases of 
developing countries are approved by regulators, it will become feasible to conduct a 
comparative evaluation of access activities undertaken during and after R&D relative 
to the level of access achieved by an intervention. In the meantime, individual 
activities are strengthened by incorporating validation steps and evaluations. 
Examples include surveys of African immunization specialists to validate modeling 
findings as described in chapter three; validation of findings with international 
organizations described in chapter four; validation steps with African immunization 
experts, malaria experts and national policy-makers, as well as an independent 
external evaluation, described in chapter six; and parameterizing models such as 
described in chapters seven and eight to historical data (e.g. on uptake of a new 
intervention) or findings from clinical studies.  
Affordability is touched on in each chapter of the thesis. However, there remains room 
for additional work by the international community to try and standardize reasonable 
country co-financing expectations for a new intervention. GFATM and GAVI have each 
set co-financing requirements which they expect countries to meet. Clarity of 
expectations could inform target product profile characteristics, and other 
assumptions about a new intervention. 
If progress continues as anticipated for the first generation malaria vaccine, the full set 
of access activities described in this thesis in support of malaria vaccines could be 
evaluated sometime after approximately 2016. Among the opportunities in such an 
evaluation would be to try and associate the time and resource commitments to 
access planning during R&D, with any years saved in implementation relative to other 
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interventions. An evaluation could also look historically to consider which access 
activities started too early relative to R&D progress and which started too late. Such an 
evaluation would need to be qualified by recognition of the risk that an intervention 
under development could always fail, although the risk decreases as the intervention 
progresses through late development.  
CONCLUSION  
New interventions hold the promise of decreasing the divergence in health between 
developed and developing countries. Growing international political and financial 
commitments to develop interventions and support their implementation, such as 
through the GFATM and GAVI, create room for hope. However promise and hope are 
insufficient for interventions to rapidly realize their potential of impacting public 
health throughout the developing world. Interventions need to be created not only 
with an ethereal vision that they will be used in developing countries, but with the 
unique needs and perspectives of an intervention intended for developing countries 
integrated into and complementing R&D activities from the earliest days. The strategy 
proposed in this thesis, summarized by the modified access framework, identifies 
concrete activities to transition promise and hope into a reality. Only by such actions 
can new interventions avoid the decade plus of delay seen traditionally, but instead 
realize their potential of preventing disease and saving lives as rapidly as possible.
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SUPPLEMENTARY MATERIAL 
SUPPLEMENT A: CHAPTER 7. MODELING THE PUBLIC HEALTH IMPACT OF 
MALARIA VACCINES FOR DEVELOPERS AND POLICY-MAKERS 
 
In order to provide public health impact estimates, the Swiss Tropical and Public 
Health Institute (Swiss TPH) model requires malaria transmission data in entomologic 
inoculation rate (EIR) format. As such, the PATH Malaria Vaccine Initiative (MVI) 
created the following five EIR buckets (or categories) for grouping data: 
 A: intended to approximate an EIR of 0 
 B: intended to approximate an EIR of 0.1 
 C: intended to approximate an EIR of 1.0 
 D: intended to approximate an EIR of 10.0 
 E: intended to approximate an EIR of 100 
 
Neither the World Health Organization (WHO) nor the Malaria Atlas Project (MAP) 
currently provides their transmission data in EIR format. The need then, is to create a 
distribution of each country’s population across these five EIR buckets, such as 
depicted here. The goal is to find the best representation of transmission risk—in EIR 
format—for each country. 
 
WHO-BASED TRANSMISSION SCENARIO 
For the WHO-based transmission scenario, MVI elected to create distributions such 
that simulated (i.e. modeled) disease burden approximates WHO disease burden, as 
shown below. 
 
EIR 0.0 EIR 0.1 EIR 1.0 EIR 10 EIR 100 
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In the WHO World Malaria Report 2008 (WMR), WHO expresses transmission risk as 
the percentage of population in each country at: 
 high risk of transmission  
 low risk of transmission  
For some countries, the total percentage reported does not amount to 100%. In these 
cases, it is assumed that the missing percentage is not endemic for malaria. WHO data 
also includes the %P. falciparum (Pf) in each country (as opposed to P. vivax (Pv)).  
  
 
 
 
 
WHO-BASED TRANSMISSION SCENARIO METHODOLOGY 
High and low transmission percentages for each country were multiplied by the Pf 
percentage to arrive at the high and low transmission that is specific for Pf for each 
country. This assumes that Pf and Pv are similarly distributed in each country—an 
assumption made for lack of information to the contrary. 
 
 
 
 
 
 
E.g. Tanzania 
 High transmission:  75% 
 Low transmission:   25% 
    (assume 0% is non-endemic for malaria) 
 %Pf:    100% 
 
 
E.g. Tanzania 
 High transmission:  75% x 100% = 75% 
 Low transmission:  25% x 100% = 25% 
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Countries were then ranked by the total cases per 100,000 people (as provided in the 
WMR) and divided into the following 13 categories:  
 0 – 400 cases/100,000 
 400 – 900 cases/100,000 
 900 – 1500 cases/100,000 
 1500 – 2000 cases/100,000 
 2000 – 5000 cases/100,000 
 5000 – 10000 cases/100,000 
 10000 – 16000 cases/100,000 
 16000 – 25000 cases/100,000 
 25000 – 30000 cases/100,000 
 30000 – 34000 cases/100,000 
 34000 – 38000 cases/100,000 
 38000 – 41000 cases/100,000 
 41000+ cases/100,000 
 
Within each of the 13 categories, each country’s population was distributed across 
each of the five EIR buckets for the two levels of transmission risk (high and low). As a 
reminder, the goal was to determine the distribution that best approximates WHO 
disease burden. Through trial and error, distributions were set for each of the 13 
categories.  
 
 
 
 
 
 
 
Note: The EIR 0.0 category is not actually assigned, rather it receives the 
unassigned distribution. In other words, it is presumed to be the difference 
between 100% and the sum of the four other buckets (i.e. EIR 0.0 = (100 – (EIR 
0.1 +  EIR 1.0 + EIR 10.0 + EIR 100.0)). 
 
E.g. 25,000-30,000 
All countries falling into this category were ascribed the same 
distribution for low and high transmission. 
 
High 
transmission  
Low 
transmission  
EIR 0.0 47.5%  52.0% 
EIR 0.1 25.0% 25.0% 
EIR 1.0 20.0% 20.0% 
EIR 10 6.0% 3.0% 
EIR 100 1.5% 0.0% 
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For example, according to WHO, Tanzania has a disease burden of 29,245 cases per 
100,000 population. As a result, Tanzania falls into the 25,000 – 30,000 cases/100,000 
category, as defined above. 
For each EIR bucket, the distributions were weighted by the high and low transmission 
risk percentages for that country, and then summed across the high and low 
transmission settings. 
 
 
 
 
 
 
 
 
 
 
 
 
The WHO-based transmission scenario holds the transmission risk constant over time. 
However, users are free to create scenarios in which transmission risk varies over time 
or in which views about transmission risk varies across countries. Applying the 
country’s population to the distribution in the transmission scenario provides the 
modeled disease burden over time. This modeled disease burden may then be 
compared to the expectation of the WHO disease burden, as shown here for Tanzania, 
in a screen shot from the Malaria Vaccine Model. 
E.g. Tanzania   
 
High 
transmission  
Low 
transmission  
Sum 
EIR 0.0 47.5% * 75% 52.0% * 25% 35.6 + 13.0 = 48.6% 
EIR 0.1 25.0% * 75% 25.0% * 25% 18.8 + 6.3 = 25% 
EIR 1.0 20.0% * 75% 20.0% * 25% 15.0 + 5.0 = 20.0% 
EIR 10 6.0% * 75% 3.0% * 25% 4.5 + .8 = 5.3% 
EIR 100 1.5% * 75% 0.0% * 25% 1.1 + 0.0 = 1.1% 
% of 
Population 
in EIR = 0 
% of 
Population in 
EIR = 0.1 
% of 
Population in 
EIR = 1.0 
% of 
Population in 
EIR = 10 
% of 
Population 
in EIR = 100 
49%       25%    20% 5.3% 1.1% 
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It is important to note that this WHO-based transmission scenario is but one 
representation of how low and high transmission risk may be translated to EIR. Users 
are free—and encouraged—to create their own transmission scenarios. 
Note: Transmission scenarios require significant computer memory. The user is 
advised to keep this in mind when creating multiple scenarios. 
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MAP-BASED TRANSMISSION SCENARIO 
For the MAP-based transmission scenario, MVI relied on the opinion of MAP experts to 
translate their population at risk assessment to an EIR distribution.  
MAP expresses transmission risk in the following Pf population at risk categories, 
according to the P.f. parasite rate (PfPR)  
 % of Total Population Living in No Malaria 
 % of Total Population Living in Unstable Malaria 
 % of Total Population Living in 0% < P.f. PR <= 5% 
 % of Total Population Living in 5% < P.f. PR <= 40% 
 % of Total Population Living in 40% < P.f. PR <= 100% 
 
As an example, MAP reported the following PfPR distribution to MVI for Tanzania. 
  
 
 
 
 
 
MAP-BASED TRANSMISSION SCENARIO METHODOLOGY 
In working with MAP experts, MVI arrived at the following methodology for translating 
MAP’s Pf parasite rate estimates to EIR: 
 EIR 0.0 = (% of Total Population living in No Malaria + % of Total Population 
living in Unstable Malaria + 1/4 * % of Total  Population living in 0%< Pf PR<= 
5%) 
 EIR 0.1 = (3/4 * % of Total Population living in 0%< Pf PR<= 5% + 1/2 * (% of 
Total  Population living in 5% < Pf PR <= 40%) 
 EIR 1.0 = 1/2 * (% of Total Population living in 5%< Pf PR<=40%) + 7/10 * (% of 
Total  Population living in 40% < Pf PR <= 100%) 
 EIR 10.0 = 2/10 * (% of Total Population living in 40% < Pf PR <= 100%) 
 EIR 100.0 = 1/10 * (% of Total Population living in 40% < Pf PR <= 100%) 
E.g. Tanzania 
 % of Total Population Living in No Malaria:     5% 
 % of Total Population Living in Unstable Malaria:    0% 
 % of Total Population Living in 0% < P.f. PR <= 5%:  13% 
 % of Total Population Living in 5% < P.f. PR <= 40%: 70% 
 % of Total Population living in 40% < P.f. PR <= 100%: 12% 
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This methodology results in the graphic below, as shown for Tanzania. 
 
The MAP-based transmission scenario holds the transmission risk constant over time. 
However, users are free to create scenarios in which transmission risk varies over time, 
or in which views about transmission risk varies across countries.  
It is important to note that this MAP-based transmission scenario is but one 
representation for translating PfPR to EIR. Users are free—and encouraged—to create 
their own transmission scenarios. 
 Note: Transmission scenarios require significant computer memory. The user is 
advised to keep this in mind when creating multiple scenarios. 
 
 
 
 
EIR 0.0 EIR 0.1 EIR 1.0 EIR 10.0 EIR 100.0 
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CURRICULUM VITAE 
CAREER SUMMARY________________________________________________________ 
I have a rich experience base and proven leadership and management expertise from 
approximately 15 years as a professional, working primarily on public health in the 
developing world. My experience spans: working on targeted public health issues and 
developing strategies behind global initiatives; developing and implementing new health 
interventions and strengthening health systems; and using existing health resources 
more efficiently and establishing innovative financing mechanisms. I have worked within 
countries and at the international level, and with not-for profit organizations and with 
the private sector.  
 
My management experience includes leading small teams and leading large, multi-
organization collaborations; hiring staff and removing staff; and making grants and 
writing successful proposals seeking grants. In each aspect of my career I have sought to 
improve the lives of vulnerable populations. 
 
PROFESSIONAL EXPERIENCE_________________________________________________ 
PATH, Ferney-Voltaire, France, 2001 to 2010 
Director, Policy & Access Unit, Malaria Vaccine Initiative (MVI), 5/2007-9/2010 
 Ensured malaria vaccines in research and development were aligned with the 
needs of developing countries and able to be integrated into existing health 
systems.  
 Led MVI’s strategic and technical collaborations at global and regional levels with 
WHO, UNICEF, GAVI, GFATM, and UNICEF.  
 Managed MVI’s collaborations with governments, public health and bilateral 
partners in African countries. 
 Led the development of the research plan for post-approval studies in Africa for 
the anticipated first generation vaccine. 
 Collaborated regularly with other PATH projects in such areas as health system 
strengthening, reproductive health, and logistics. 
 Co-managed collaboration with large pharmaceutical organization as member of 
small decision-making team on $180 million project.  
 Developed and oversaw implementation of multi-year unit strategy, including 
metrics, administration, staffing, financing and staff professional development. 
 Managed international team of 3.5 staff 
 Member of the Leadership Team of MVI’s Directors, overseeing organizational 
strategy and development, including development and implementation of a 
matrixed management structure, and donor relations and reporting. 
 Raised funds as one of the lead authors on successful grants to PATH of almost 
$300 million. 
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Senior Program Officer, Malaria Vaccine Initiative, 2/2005 to 4/2007 
 Led the design and establishment of MVI’s policy and access unit and strategy. 
Accountable for implementing this strategy through annual work plans, budgets 
and management of 3 staff based in the US, Europe, and Africa. 
 Collaborated in the planning and management of MVI research and development 
activities, contributing policy-related considerations and planning as appropriate. 
 Managed operational research to create and validate a framework of processes 
and data sought by African countries in order to take eventual decisions on use 
of malaria vaccines. In partnership with WHO, implemented 7 country 
consultations, each with up to 50 participants, over a 12 month period.  
 Led analyses of factors important to global and regional policy-makers for the 
uptake of new vaccines and health interventions in the developing world. 
 Managed modeling activities to predict the impact, cost-effectiveness, and 
financing requirements of malaria vaccines. 
 Analyzed innovative financing mechanisms, including a critical role determining 
the feasibility of creating a multi-billion dollar advance market commitment for 
vaccines. 
 Co-created and rotating chair of formal standing collaboration mechanism with 
large pharmaceutical company. 
 Chaired or member of the Leadership Team which oversaw organizational 
strategy, development, donor relations and reporting. 
 Co-created and implemented a multi-program management and administration 
structure for the PATH office in France. 
 Raised funds as one of the lead authors on successful grants to PATH of over 
$100 million. 
 
Senior Program Officer, Children’s Vaccine Program (CVP), 9/2001 to 1/2005 
 Led PATH activities, and managed multi-million dollar investments, to improve 
the financial sustainability of immunization programs and wider health systems. 
Served as a core member of GAVI’s Financing Task Force.  
 Managed developing country programs and supported PATH country staff 
working on health system and immunization strengthening, adoption of new 
vaccines, and/or financial sustainability, such as in Cambodia, India and 
Indonesia. 
 Led PATH’s collaboration and contributed to GAVI’s work establishing innovative 
financing mechanisms, such as the International Financing Facility for 
immunization which is anticipated to raise $4 billion over 10 years. 
 Catalyzed collaboration across PATH programs, particularly those working on 
vaccine-related issues, as well as reproductive health.  
 Developed jointly with staff in Seattle, an innovative distance learning module, 
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particularly contributing to issues relating to new vaccine decision-making, 
financing and economics, and supply and procurement. 
 Managed the analysis of group procurement mechanisms for vaccines in order to 
evaluate potential cost savings for countries in Eastern Europe and the Newly 
Independent States. 
 Represented PATH to immunization partners and countries as member of the 
Eastern and Southern Africa sub-Regional Working Group. 
 
PATH, Seattle, USA, 6/1999 to 8/2001 
Program Officer, CVP 
 Provided core analytic and strategic input to the establishment of the Global 
Alliance for Vaccines and Immunization and Global Fund for Children’s Vaccines 
(now called the GAVI Alliance). Analyzed and provided projections of impact, 
financing, and demand implications of strategic decisions for GAVI on behalf of 
its Secretariat and Board. Co-developed original country application mechanism. 
 Evaluated opportunities for new country projects. 
 Established and managed a grant-making system, including application and 
review.  
 Provided technical assistance to developing country health programs and 
supported PATH country staff working on immunization strengthening and/or 
adoption of new vaccines. 
 Managed epidemiological studies in developing countries. Managed, with the 
Thai government, a burden of disease study of bacterial pneumonia, meningitis, 
and sepsis with over 100,000 children under surveillance. 
 
PATH, Bangkok, Thailand, Feb-May, 1999 
Consultant, Bill & Melinda Gates Children’s Vaccine Program 
 Posted to the Ministry of Public Health, Thailand.  
 Early design and planning for a burden of disease study for invasive bacterial 
disease. 
 
London School of Hygiene and Tropical Medicine, Infectious Disease Epidemiology Unit 
and Children’s Vaccine Initiative, London, Geneva, and Seattle, 10/1998 to 2/1999 
Consultant  
 Studied new vaccine adoption in developing countries.  
 
Washington State Reformatory, Department of Corrections, Monroe, WA, 10/1994 to 
8/1997 
Registered Nurse II  
 Facilitated health promotion and disease prevention for inmates in maximum-
PLANNING FOR NEW HEALTH INTERVENTIONS   
Curriculum vitae  205 
security prison; managed acute and chronic illnesses 
 HIV-Test Counselor  
 Infectious Disease Trainer - Designed and taught communicable disease and 
safety curricula to prison staff 
 
Western State Psychiatric Hospital, Legal Offender Unit, Ft. Steilacoom, WA, 1994 
Nursing Student 
 
Ministry of Public Health/National School of Nursing, Quito, Ecuador, 1993 
Nurse Intern 
 
University of Washington, Department of Psychology, Seattle, WA, 1992 to 1993 
Research Assistant to Kristin Rytter, PhC 
 
 
EDUCATION______________________________________________________________ 
 PhD Candidate, Epidemiology and Public Health, Thesis title: Planning for new 
health interventions in Africa: An integrated strategy to prepare for malaria 
vaccines and lessons for future interventions, Swiss Tropical and Public Health 
Institute/University of Basel, Oral exam October 28 2011, Anticipated completion 
November 2011 
 MSc, Public Health “Control of Infectious Diseases”, London School of Hygiene 
and Tropical Medicine, UK, 1998 
 Bachelor of Science, Nursing, Summa Cum Laude, University of Washington, 
Seattle, 1994 
 Additional education: 
o Multiple courses in leadership and working with the media. 
o Advanced Methods in Cost-Effectiveness Analysis (short-course), Oxford, 
July 2005 
 
 
COUNTRY EXPERIENCE_____________________________________________________ 
 Managed projects and/or worked in all regions outside of the Middle East 
 
 
HONORS/AWARDS________________________________________________________ 
 Best PhD Student’s Presentation - Swiss Society of Tropical Medicine and 
Parasitology, Student’s Conference, 2010 
 Fulbright Grant—postgraduate study, London School of Hygiene and Tropical 
Medicine, 1997-1998 
 Outstanding Service Award—University of Washington School of Nursing Alumni 
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Association, 1994 
 Outstanding Humanitarian Award—University of Washington School of Nursing, 
1994 
 Dean’s Club Special Scholar—Grant to support health care work in South 
America, 1993 
 Fuld Fellow—National award and scholarship to attend International Council of 
Nurses Conference in Madrid, Spain, 1993 
 
 
EXAMPLES OF VOLUNTEER ACTIVITIES________________________________________ 
 President, Board of Directors, United Nations Association, Seattle Metropolitan 
Chapter, 1995-1997 
 Member, Board of Directors, United Nations Association, Seattle Metropolitan 
Chapter, 1992-1995 
 United Nations Elections Observer, international expatriates voting in USA; South 
Africa-1994, Eritrea-1993 
 State Conference Organizer, State of Washington, Associated Nursing Students, 
1993-1994 
 Hospital Fray Guillermoe, Guatemala, part-time volunteer, 1991 
 
 
SELECTED PROFESSIONAL ACTIVITIES AND PRESENTATIONS_______________________ 
 Chairman, WHO Standing Committee on Programmatic Suitability of Vaccines for 
Pre-Qualification, From September 2011. 
 Founding Co-Chair, Product-Development Partnership (PDP) Access Steering 
Committee. Led a collaboration across 11 PDPs sharing strategies by different 
organizations to ensure that developing countries have access to newly 
developed health interventions. 2009 to 2010. 
 PATH Representative to Eastern and Southern Africa sub-Regional Working 
Group (Immunization). 2001 to 2010. 
 Brooks A. Planning ahead for the first malaria vaccine: The path from 
development to impacting health. Presented at the Multilateral Initiative on 
Malaria (MIM); November, 2009. 
 Brooks A. Investment case for malaria vaccines. Roundtable presentation at the 
Global Health Council annual conference. May 2006. 
 PATH Representative to GAVI Financing Task Force. 2000 to 2004. 
 Chairperson. WHO Meeting on post-introduction evaluations of hepatitis B and 
Hib vaccine introduction in developing countries. June 2003. WHO/HQ, Geneva. 
 Lydon P. Brooks A. and Simpson J. Microsoft excel e-learning course for 
developing country senior managers. 2002. 
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 Brooks A and Masambichaka K (co-authors), Mutabaruka E. Planning 
immunization activities at the national, provincial, and district levels. Curriculum 
for WHO AFRO Mid-Level EPI Managers Training. Namibia. June, 2002. 
 Brooks A. Vaccine preventable diseases: The changing landscape. Workshop 
presentation. American Public Health Association annual conference. Atlanta. 
October 2001. 
 Brooks A (Session Organizer.) New directions for immunization in developing 
countries: The Global Alliance for Vaccines and Immunizations (GAVI) and the 
Vaccine Fund. American Public Health Association annual conference. Atlanta. 
October 2001.  
 Brooks A. Protecting children of all nations and of all socioeconomic levels 
against vaccine-preventable diseases. Plenary presentation. US National 
Immunization Program Annual Conference. Washington DC. July 2000.  
 Brooks A. (Workshop organizer.)  Global Alliance for Vaccines and Immunizations. 
US National Immunization Program Annual Conference. Washington DC. July  
2000. 
 Founding Co-Chair. GAVI Hepatitis B and Hib Vaccine Demand Forecasting Group. 
1999-2000. 
 
PUBLICATIONS AND REPORTS_______________________________________________ 
Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, Brooks A, Penny M, and Tanner 
M. Ensemble modeling of the likely public health impact of the RTS,S malaria 
vaccine. PLoS Medicine (in press). 
Leach A, et al. Design of a phase III multicenter trial to evaluate the efficacy of the 
RTS,S/AS01 malaria vaccine in children across diverse transmission settings in 
Africa. Malaria Journal 2011, 10:224. 
Milstien J, Cardenas V, Cheyne J, and Brooks A. Analysis of WHO Policy Development 
Processes for a New Vaccine: Malaria Vaccine. Malaria Journal 2010, 9:182. 
Brooks AD and Wells WA (co-authors), McLean TD, Khanna R, Coghlan R, Mertenskoetter 
T, Privor-Dumm LA, Krattiger A and Mahoney RT. Ensuring that Developing Countries 
have Access to New Healthcare Products: The Role of Product Development 
Partnerships. Innovation Strategy Today. 2010; 3:1-5. 
www.biodevelopments.org/innovation/index.htm 
Garnett A., Brooks A, and Biellik R. Public-sector preferences for RTS,S/AS01 malaria 
vaccine formulation, presentation, and packaging. Report from the PATH Malaria 
Vaccine Initiative. October, 2008. 
Garnett A., Biellik R., and Brooks A. Vaccine presentation for pneumococcal vaccines: 
WHO consultation for the development of a target product profile for 
pneumococcal vaccines. Report to the GAVI Alliance from PATH. October, 2007. 
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Soeung SC, Grundy J, Maynard J, Brooks A, Boreland M, Sarak D, Jenkinson K, and Biggs 
BA. Financial sustainability planning for immunization services in Cambodia. Health 
Policy Plan. 2006 Jul;21(4):302-9.  
Soeung SC, Grundy BM, Ly CK, Samnang C, Boreland M, Brooks A, Maynard J, and Biggs 
BA. Improving immunization coverage through budgeted microplans and sub-
national performance agreements: early experience from Cambodia. Asia Pac J 
Public Health. 2006;18(1):29-38. 
DeRoeck D, Bawazir SA, Carrasco P, Kaddar M, Brooks A, Fitzsimmons J, and Andrus J. 
Regional group purchasing of vaccines: review of the Pan American Health 
Organization EPI revolving fund and the Gulf Cooperation Council group purchasing 
program. Int J Health Plann Manage. 2006 Jan-Mar;21(1):23-43.  
Roberts P, Brooks A. Advanced market commitment for malaria vaccines. Feb 2006. 
Report to Italian Ministry of Finance, Global Alliance for Vaccines and Immunizations, 
and the World Bank. 
Rerks-Ngarm S, Treleaven SC, Chunsuttiwat S, Muangchana C, Jolley D, Brooks A, 
Dejsirilert S, Warintrawat S, Guiver M, Kunasol P, Maynard JE, Biggs BA, and Steinhoff 
M. Prospective population-based incidence of Haemophilus influenzae type b 
meningitis in Thailand. Vaccine. 2004 Feb 25;22(8):975-83.  
DeRoeck D, Brooks A, McArthur A, and Mort M. Comprehensive e-learning curriculum 
on the global vaccine market and immunization financing, for senior managers in 
developing countries. Web published. 2003. 
Kane MA and Brooks A. New immunization initiatives and progress toward the global 
control of hepatitis B. Curr Opin Infect Dis. 2002 Oct;15(5):465-9. 
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into national immunization programs of developing countries. Children’s Vaccine 
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